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Abstract 
RIG-I and MDA5 are the major intracellular sensors for the induction of IFN-β, by 
dsRNA, in Huh7 cells. It was found that the expression of RIG-I, MDA5 and the 
signalling mediators TRIF, MAVS and MyD88 were upregulated in Huh7 HCV RNA 
replicon cells. Similar findings were obtained in Huh7 cells infected with JFH-1 
HCV. When replicon and HCV infected cells were further stimulated by dsRNA the 
induction of these genes were reduced compare to control cells. The expression of 
NS3 and NS3/4A proteins, using adenovirus vectors, reduced RIG-I, MDA5, MAVS 
and MyD88 expression levels in response to dsRNA stimulation. Ablation of MDA5, 
MAVS, MyD88 and TRIF in HCV infected Huh7.5 cells, using siRNAs, increased 
virus replication demonstrating their importance in inhibiting HCV infection. These 
results show that HCV inhibits the induction of interferon in response to dsRNA and 
that NS3 plays an important role in this inhibition. 
Analysis of gene expression during HCV infection showed significant changes in the 
expression of genes involved in the innate immune response, interferon, apoptosis and 
cell cycle regulation pathways. These include SOCS1, 2 and 3, OAS3, MXA1, IRF9, 
IRF1, IFNAR2 and STAT1.  SOCS3 knockdown by siRNAs reduced HCV 
replication indicating an additional mechanism of IFN inhibition by HCV. 
Infection with HCV also caused cell cycle arrest leading to DNA fragmentation and 
apoptosis. A decrease in cyclin B1 and an increase in GADD45-β expression during 
HCV infection indicates that they may play an important role in HCV induced 
alterations to the cell cycle. 
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CHAPTER ONE: 
1. INTRODUCTION: 
1.1. History of Hepatitis C Virus 
Hepatitis C virus (HCV) is a major cause of liver disease and is also considered to be 
one of the leading causes of liver disease. It was identified as the causative agent for 
most post-transfusion and sporadic non-A, non-B hepatitis cases in 1989.  
During the 1960`s blood screening measures were developed, to detect Post 
Transfusion Hepatitis (PTH) using serological tests to detect hepatitis B virus (HBV) 
and hepatitis A virus (HAV) antigens. In a study of 30 episodes of acute viral 
hepatitis, 53% of these were not attributable to HAV or HBV (1). During the 1970s, 
7-10% of patients from blood transfusions developed viral hepatitis and serological 
tests failed to identify the agent as Hepatitis A or B and thus the condition was termed 
Non A non B Hepatitis (2). When plasma or serum from 4 patients with non-A, non-B 
(NANB) PTH and from a blood-donor implicated in two cases of PTH was inoculated 
into chimpanzees (3) it gave rise to hepatitis in the animals. This indicated that there 
may be an additional hepatitis agent (or agents) in addition to HAV and HBV 
Attempts were made to identify the causative agent or agents of NANB hepatitis by 
using standard immunological techniques but these were not successful. In 1989, a 
random-primed cDNA library was constructed from plasma containing the 
uncharacterized NANBH agent and screened with serum from a patient diagnosed 
with NANBH. One cDNA clone was shown to encode an antigen associated 
specifically with NANBH infections (4). This cDNA clone was then shown to 
correspond to part of an agent that consisted of at least 10,000 nucleotides that was 
positive-stranded and was similar in structure to members of the Flaviviridae (4). 
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Later, an assay was developed to detect antibodies specific to the antigen encoded by 
this cDNA clone. It found that 88% of NANB hepatitis cases tested had antibodies 
against this antigen and the agent was then called Hepatitis C Virus (HCV) (5). By 
1990, HCV was identified as the main cause of post transfusion associated NANB 
hepatitis and a universal donor screening programme was developed and the detection 
of anti-HCV antibodies using an ELISA assay became the standard test for blood 
transfusion and blood products. Introduction of this assay resulted in a 70% decrease 
in transfusion associated hepatitis in first generation of assay (6). A second generation 
(PCR based) assay developed in 1992 together with the ELISA assay has nearly 
eliminated HCV transmission (6) through blood transfusions and blood products. 
 
1.2. The Flaviviridae 
Flaviviruses comprise a family of greater than 70 enveloped, positive sense RNA 
viruses (7). The classification of the Flaviviridae, based on the study of virus genes, 
virus replication cycles and virus structure has divided then into three distinct 
evolutionary sub-groups namely, (1) the flavivirus, (2) the pestivirus and (3) the 
hepacivirus genera (7). 
HCV is the main member of the hepacivirus genus. Based on comparison of genome 
organization and sequence homologies, GBV-B/HGV is the most closely related virus 
to HCV, and it is a second member of the hepacivirus genus. Other members of the 
Flavivirus family that can infect humans are usually transmitted by infected arthropod 
vectors such as mosquitoes or ticks. These include yellow fever virus (YFV), dengue 
virus (DENV), Japanese encephalitis virus (JEV), tick-borne encephalitis virus 
(TBEV) Murray valley encephalitis virus (MVEV), Saint Louis encephalitis virus 
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(SLEV) and West Nile virus (WNV). Animal viruses within the Pestivirus genus, 
including classical swine fever virus (CSFV) and bovine viral diarrhoea virus 
(BVDV), are more closely related to the GB viruses (which also included GBV-B and 
GBV-A) and HCV (7, 8). The phylogenetic relationships between these flaviviruses 
are shown in (figure 1.1). 
The members of the Flaviviridae have diverse biological properties and they show 
little serological cross-reactivity, however they have common features in terms of 
genome organisation, RNA replication strategy and possibly virion morphology. For 
example they have similar genome sizes, they have a lipid envelope which contains 
virally encoded glycoproteins and their genomes are translated to produce a single 
polyprotein which is cleaved by both virus encoded and host cell proteases. They also 
express an RNA dependant RNA polymerase required for virus genome replication 
(7). Viruses within the flaviviruses genus have capped genome (5‟ type I cap, 
m7GpppAmpN2), which its translation is cap dependent. In contrast, the hepacivirus 
and pestivirus genomes are not capped and have an IRES in the 5‟ nontranslated 
region (7). 
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Figure 1.1: Phylogenetic tree based on analysis of amino acid sequences of flavivirus 
genomes. The flavivirus family are more distantly related to HCV and include tick-borne 
encephalitis virus (TBEV); yellow fever virus (YFV); West Nile virus (WNV); dengue 
virus (DEN), than the pestiviruses: bovine viral diarrhoea virus (BVDV). The 
hepaciviruses include, HCV (genotypes la, lb, 2a, 2b, and 3a) and the most closely related 
viruses to HCV, GBV-A, GBV-B (HGV) and GBV-C. Figure adapted from  Polgreen et 
al, 2003 (8). 
 
1.3. Epidemiology 
According to WHO, it is estimated that around 170 million people, representing about 
3% of the world population, are infected with HCV and 3 to 4 million people are 
newly infected each year. HCV genotypes and subtypes have different geographical 
distributions around the world. 
There is a large degree of geographic variability in the distribution of HCV, with rates 
of infection ranging from 1% to more than 10%. Countries with the highest reported 
prevalence rates are located in Africa and Asia. China has a reported seroprevalence 
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of 3.2% (9). In India rate of HCV infection is 0.9% (10). In a few countries such as 
Egypt, HCV prevalence is between 10-20 % of the population. In Egypt, a national 
campaign to treat schistosomiasis infection is suspected to be the major cause of the 
increase in HCV prevalence (11). Most developed countries have prevalence rates of 
less than 2.5%, although it varies among different countries. In USA 4.1 million 
(1.6%) Americans have been infected with HCV, of whom 80% are chronically 
infected (12). The prevalence in the United Kingdom has been estimated to be 0.5% 
and 1.3% in France (13). 
 
1.4. HCV transmission: 
In the majority of cases, infections are spread through exposure to the blood of 
chronically infected individuals. However, the serological tests for anti-HCV 
antibodies that were introduced for blood screening has reduced transfusion-related 
HCV infection and infection from blood products. 
Many studies have been carried out to identify the prevalence rates of HCV within 
certain areas or age groups and also with race, economic and marital status, sex, and 
education.  For instance, HCV infection through perinatal transmission is estimated to 
occur in 5% of infants born to HCV infected mothers, and a higher proportion of 
infants born to HIV/HCV coinfected mothers (14). Transmission of HCV occurs only 
when serum HCV RNA is detectable (about 10
6
 copies or more per ml) and co-
infection with HIV increases the rate of transmission 4–5 fold (15).  
Illegal drug use has been found to be the factor most strongly correlated with HCV 
infections e.g. in people who use cocaine, particularly with intranasal administration, 
using shared equipment. The Hepatitis C European Network for C-operative Research 
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(HENCORE) group also reported a prevalence of hepatitis C of 80% among 
intravenous drug users (IVDU) (16). 
People with high-risk sexual behaviour, multiple partners, and sexually transmitted 
diseases are also at risk of HCV transmission (17). Sexual practices have not 
correlated significantly with HCV seroprevalence in IVDUs. However, those infected 
with both HCV and HIV are much more likely to transmit HCV to sexual partners 
(18). Transmission of HCV has been reported among HIV-infected men who have sex 
with men (MSM). However, this increase in prevalence is controversial; a study in the 
Netherland has reported a high and increasing HCV prevalence in HIV-infected 
MSM. Two of 532 (0.4%) HIV-negative MSM and 28 of 157 (17.8%) HIV-positive 
MSM were infected with HCV. Over the study period, HCV prevalence among HIV-
infected MSM increased from 14.6% to 20.9%. Seven of 28 (25.0%) HIV/HCV 
coinfected MSM had acute HCV infection (18). By contrast, study in the UK showed 
that over 6 months, 3365 MSM attended for STI screening. Of 2309 MSM who 
agreed to be screened for HCV (69%) the prevalence of HCV was 0.65%. This is 
similar to the prevalence of HCV in the general population within the UK (19). 
 
1.5.  Hepatitis C Virus (HCV) Biology: 
HCV is a small, enveloped virus containing a positive sense single-stranded RNA. 
The HCV genome is approximately 9.6 kilobases in length and contains a single open 
reading frame (ORF), which encodes a single polyprotein that is ≈ 3000 aa in length. 
This polyprotein is co and post-translationally processed by a combination of host and 
viral proteases to produce at least ten different proteins in the following order; core, 
envelope proteins E1, E2 and p7, and non-structural proteins NS2, NS3, NS4A, 
NS4B, NS5A and NS5B (figure 1.2). The ORF is flanked by 5‟ and 3‟ nontranslated 
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regions (NTRs). These NTRs contain cis-acting RNA elements (CREs), which 
regulate major steps of the viral life cycle. 
HCV isolates show substantial divergence in their genomic sequences. This is because 
of the high rate of virus replication and its high mutation rate. HCV has an estimated 
virion half-life (t1/2) of 2.7 hours and a clearance rate of around 10
10
 to 10
12
 virions 
per day in an infected patient (20, 21). The HCV RNA–dependent RNA-polymerase 
(NS5B) has poor fidelity and lacks proof reading activity. This leads to viral variants 
being produced continuously during infection. Its estimated that the error rate is 
approximately 10
-3
 to 10
-5
 mutations per nucleotide per genomic replication (22). 
These different variants, which are present in an infected patient, are called a viral 
quasispecies. On the basis of these variations, the phylogenetic evolution of HCV 
isolates has been classified into seven genotypes (numbered 1-7) with nucleotide 
sequence divergence of as much as 31% to 33%. Genotypes are further classified into 
subtypes, such as 1a and 1b with a difference of 20% to 25% between their genomes 
(23-25). Thus, the development of HCV therapies is challenged by the presence of 
different genotypes and subtypes of virus in different patients and also the variation in 
viral quasispecies in each patient. These heterogeneities in viral sequence mean that 
not all antiviral drugs will be equally effective for all HCV genotypes, subtypes, and 
isolates.  
 
1.5.1. Non translated regions (NTRs) 
1.5.1.1.           5’ NTR 
The highly conserved 5‟ NTR is 341-344 nucleotides long and contains a highly 
structured internal ribosome entry site (IRES) in the HCV 5‟ NTR. The 5′ NTR has 
two independent functions that are necessary for the virus life cycle. The recognition 
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of a short 5‟ NTR sequence by microRNA122 (miR122), which is highly expressed in 
the liver, enhances replication and it allows protein synthesis to occur in a cap-
independent manner (26).  
Three dimensional structures of the 5' NTR have been elucidated by a combination of 
biochemical analysis and computer modelling (27). This revealed four distinct RNA 
domains in the HCV 5' NTR. The short
 
stem-loop 1 is formed by residues 5 to 20 and 
it is not required
 
for IRES activity. The HCV IRES is composed of three main 
structural domains comprising 340 nucleotides (27), stem loop II (SLII), 5′ SLIII, and 
5′ SLIV (27, 28). SLIII is the core of the IRES and it has the highest degree of 
structural conservation and participates in the formation of
 
an RNA pseudoknot that is 
essential for IRES activity. Domain IV contains a small stem loop which in turn 
contains the polyprotein start codon at nucleotide position 342, it also forms a 
pseudoknot by base pairing with a loop within domain III (29). The IRES also 
requires sequence elements downstream of the AUG in the core protein coding region 
to function correctly (see figure 1.2).  
1.5.1.2.          3′ NTR 
The 3` NCR which follows the ORF stop codon, consists of a short variable (VR) 
region of about 40 nucleotides within which substantial sequence diversity
 
is evident 
between different genotypes of HCV, this region is followed by a stretch of 
polyuridines, a polypyrimidine poly(U)-poly (UC) [poly(U/UC)] tract, and a highly 
conserved 98 nucleotide sequence termed the 3′ X tail which forms three stem-loop 
structures
 
(designated SL1, SL2, and SL3) (27, 28). The 3′ RNA structures have 
important roles in RNA replication and polyprotein expression, in particular for minus 
RNA strand synthesis (30) (figure 1.2). 
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Figure 1.2: Structure and processing of the hepatitis C virus (HCV) genome: (a) The 
single-stranded RNA genome encodes a long open reading frame (ORF) flanked by 2 
NTRs, which contain signals for viral protein and RNA synthesis and the 
coordination of both processes. Translation is initiated through an internal ribosomal 
entry site (IRES) in the 5‟ NTR. (b) The structural proteins are processed by cellular 
signal peptidases from the N-terminal region of the polyprotein: core, E1, E2, and p7. 
Non-structural proteins are processed by virally encoded proteases from the C-
terminal region of the polyprotein: NS2, NS3, NS4A, NS4B, NS5A, and NS5B. (c) 
Functions of the resulting 10 structural and nonstructural proteins. A frameshift (F) 
protein is translated from a short alternate reading frame (ARF).  Figure adapted from 
Rehermann B, 2009 (31). 
 
1.5.2. The structural proteins: 
The structural proteins include the core protein, which forms the viral nucleocapsid, 
and the envelope glycoproteins E1 and E2 and p7 (figure 1.2).  
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1.5.2.1.         Core (C) protein: 
The HCV core protein is an RNA-binding protein, 191 aa in length, highly basic and 
it associates with HCV genomic RNA to form the viral nucleocapsid. It is released 
from the viral polyprotein by nascent proteolytic cleavage at amino acid 191 by 
cellular proteases (32). It consists of three distinct domains: an N-terminal hydrophilic 
domain 1 (D1) formed by the first 117 aa; a hydrophobic D2 directly after the C-
terminal of D1 with 169 aa; and a highly hydrophobic domain 3 (D3) spanning the C-
terminal 20 aa, which serves as the signal peptide of the C-terminal E1 protein (33). 
This immature form of core protein (p23) generated by the primary cleavage at the C 
terminus by signal peptidase (SP) undergoes additional C-terminal processing leading 
to the removal of most or all of the D3 by the intramembrane-cleaving protease signal 
peptide peptidase (SPP). This cleavage produces mature p21 core, that contains D1 
and D2, which forms a dimeric, α-helical protein exhibiting features that are 
consistent with those of a membrane protein (34). D2 associates with lipid droplets 
(LDs) and endoplasmic reticulum (ER) membranes.  This interaction between HCV 
core and LDs is vital for viral replication and production of infectious virus particles. 
The binding strength of the D2 domain of core for LDs is crucial in determining the 
efficiency of virus assembly (35). 
Core protein has several additional functions. Nucleolar localization of core may be 
caused by its ability to bind to ribosomes assembled in the nucleus (36). It has been 
shown that expression of the core protein affects mitochondrial function
 
and lipid 
metabolism. The core protein increases the cellular
 
production of reactive oxygen 
species with subsequent increases
 
in lipid peroxidation (37). The core protein also 
colocalizes
 
with human apolipoprotein AII leading to an increase in the capacity to 
influence metabolic events involving
 
lipid storage. Analysis of the triglyceride 
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populations within the cell revealed that core protein expression stimulates a change 
in cellular metabolism of triglycerides (38). In addition, the core protein
 
reduces 
microsomal triglyceride transfer, leading to defects
 
in very low density lipoprotein 
assembly and secretion (39). Also liver steatosis, which is considered a characteristic 
of HCV infection, may be a result of the direct effect of the core protein on lipid 
metabolism. 
In addition to its function as a nucleocapsid component, the core protein has been 
incorporated in several cellular processes which contribute to alterations of host cell 
functions upon HCV infection. For instance, core can specifically suppress 
programmed cell death and interact with the cytoplasmic tail of the lymphotoxin-α 
receptor, a member of the tumour necrosis factor family, suggesting a possible 
immunomodulatory function and a critical role in the establishment of persistence and 
disease pathogenesis (40). 
 
1.5.2.2.           Envelope (E) proteins: 
The major viral structural envelope proteins are the glycoproteins, E1 and E2, with 
molecular weight 31 and 70 kDa, respectively. They interact with each other to form a 
heterodimer (41). These proteins are released from the viral polyprotein by the action 
of host-cell signal peptidases. Both proteins contain hydrophobic domains in their C-
terminal portions. These domains presumably act as membrane anchors (41). 
E2 contains hypervariable regions, called HVR 1 (amino acids 390-410) and HVR 2 
(amino acids 474-480). It is believed that E2 may elicit production of virus-
neutralizing antibodies (42, 43). These antibodies against E2 have been shown to have 
the ability to protect against HCV infection in cell culture (44) and in chimpanzees 
(45). Despite the protective capacity of these antibodies, the virus can escape from 
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neutralizing antibodies produced in the host. This is caused by random mutation and 
selection of mutations in HVR-1 which occur during the course of HCV infection in 
individual patients. The importance of the selective pressure of the host immune 
system on the HVR region is shown by the escape of HCV from neutralization 
because of its extreme variability and because this variability was not observed in a 
patient with agammaglobulinemia (46). Although the development of HCV 
neutralizing antibodies occurs, the extremely high degree of variability tolerated by 
the virus in the HVRs enables the selection and immune escape of viruses that may 
initially represent only a small fraction of the viral population. As a result the 
development of a prophylactic vaccine which targets the E2 protein remains doubtful. 
E2 also has a significant role in evading the innate immune response during HCV 
replication. The HCV E2 protein contains a sequence identical to phosphorylation 
sites of the interferon (IFN)-inducible protein kinase (PKR), and the translation 
initiation factor eIF2, a target of PKR, leads to inhibition of PKR activation (47). 
Additionally, E2 protein interacts with and inhibits PKR-like ER resident kinase 
(PERK) as well (48). These interactions of E2 help to promote the persistence of 
HCV infection by suppressing the antiviral effect of interferon. 
HCV E2 has been shown to bind to CD81 (49), a cellular protein expressed on the 
surface of membranes of mammalian cells that is essential for the entry of HCV into 
the hepatocytes and B lymphocyte (50). CD81 is a member of the tetraspanin family 
and is required to mediate HCV cell entry in combination with other co-receptors. The 
low density lipoprotein receptor (LDLR) (51) and scavenger receptor class B type I 
(SR-BI) (52) have also been proposed as components of the HCV receptor complex. 
Lipoproteins have also shown to play an important role for cell entry, (53, 54) in 
studies on HCV pseudotypes. The association with high density lipoprotein (HDL) 
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seems to enhance SR-BI guided cell entry and protect viral particles from neutralizing 
antibodies (55).  
 
1.5.2.3.         P7 protein: 
This 63-amino acid protein is located at the junction between the structural and 
nonstructural region. It is unknown whether p7 is packaged into viral particles. It is 
composed of two transmembrane domains and is mainly located in the ER, 
mitochondrial and plasma membranes (56, 57). Different reports have shown that p7 
can form hexamers that have ion channel activity (58, 59). It is believed that p7 could 
be important for viral assembly because the corresponding protein of the related 
bovine viral diarrhoea virus (BVDV) is essential for the production of infectious 
progeny virus but not for RNA replication (60). Recent work using HCV cell culture 
showed that p7 could facilitate virus assembly and release (61, 62). Other work, 
showed that p7 functions mainly at the late stage of virus propagation and that, 
iminosugars coupled to long alkyl chains like N-nonyl deoxygalactonojirimycin (NN-
DGJ) not only interfere with ion channel activity but also repress the release of 
infectious particles from transfected Huh7 cells (62). Beside ion channel activity, p7 
harbours a signal-like sequence in its C-terminal domain that directs the insertion of 
the N terminus of NS2 into the lumen of the ER (56).  Brohm et al, developed a trans-
complementation assay permitting the analysis of p7 outside of the HCV polyprotein 
to analyse the role of the native signal sequence of p7 and p7-containing precursor. 
They found that p7 is absolutely essential for the production of infectious HCV 
particles and can operate independently of an upstream signal sequence and that the 
cleavage of an E2- p7- NS2 intermediate, and tyrosine residue close to the conserved 
dibasic motif of p7 are important for optimal virus production. Mutation of the 
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tyrosine residue led to defects in HCV morphogenesis. In contrast, neither influenza A 
virus M2 nor HIV-1 vpu compensated for defective p7 in HCV morphogenesis (63). 
 
1.5.3. Non structural proteins (NS): 
1.5.3.1.            NS2: 
NS2 is 23 kDa transmembrane protein which has cysteine protease activity. The N-
terminus of this protein is separated from the E2/p7 polypeptide by cleavage by host 
peptidases, whereas cleavage at the NS2/NS3 junction is mediated by HCV NS2-3 
proteinase which is comprised of NS2 and the serine proteinase domain of NS3 (64-
66). The HCV NS2-NS3 proteinase was originally thought to be a metalloprotease 
based on the observation that its enzymatic activity was stimulated by zinc and 
inhibited by metal chelators. Site directed mutagenesis studies have shown that amino 
acids His-952 and Cys-993 are important for proteolytic activity (67). Using HCV 
JFH-1 to assess the NS2-3 protease, with selected NS2-3 point mutants, demonstrate 
that these active site mutations do not solely affect the cleavage activity of the HCV 
NS2-3 protease but significantly affect the integrity of the global protein fold (68).  
Recent work has shown that NS2 plays an important role in the production of 
infectious HCV particles. Cell culture adaptation mutations in NS2 led to an increased  
titre of either inefficient HCV chimeras or the JFH-1 as major contributors to 
assembly (69). Moreover, analyzing a set of NS2 mutants provides evidence that NS2 
appears to play an essential role in HCV particle production (61, 70). HCV assembly 
defects caused by mutations in NS2 can also be rescued by trans-complementation 
(70).  
Although the precise role of NS2 during virus production is unclear, genetic evidence 
suggests it may interact with viral structural proteins or other NS protein. Schregel et 
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al, defines NS2 as a bona fide protease, NS3 act as its regulatory cofactor, and the 
functional subdomains in NS3 that cooperate in NS2 protease activation (66). Besides 
this, NS2 also interacts with cellular factors. It has been noted that the function of 
NS2 relies on cyclophilin A, which via its cis-trans prolyl isomerise activity, may 
modulate NS2 protein folding (71).  
 
1.5.3.2.              NS3: 
NS3 protein is a 70-kDa non-structural protein. The N-terminal 180 aa of NS3 has 
serine protease activity, while the C-terminal portion encodes helicase and nucleoside 
triphosphatase activities (NTPase). NS3 is multifunctional protein involved in 
polyprotein processing and virus replication and is therefore, an attractive target for 
antiviral drug development. The N-terminal serine protease requires NS4A, a 54-
residue viral protein, co-factor required for efficient proteolytic processing for 
cleavage at the NS3/NS4A, NS4A/4B and NS4B/NS5A sites and it accelerates the 
rate of cleavage at the NS5A/NS5B junction. 
 
The NS3 Protease domain: 
The N-terminal portion of the NS3 protein is a serine protease which is necessary for 
the cleavage of certain regions of the HCV polyprotein. This protease activity cleaves 
most of the polyprotein to form the mature non-structural proteins: NS3, NS4A, 
NS4B, NS5A and NS5B. It rapidly cleaves the NS3/NS4A junction in cis while the 
rest of the junctions are cleaved in trans (72). The catalytic domain of the NS3 
protease has been mapped to the amino-terminal 181 amino acids (amino acids 1027 
to 1207 of the polyprotein), with the minimal protease region being narrowed down to 
amino acids 1059 to 1204. The N-terminal amino acid region contains a characteristic 
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serine protease catalytic triad (His-1083; Asp-1107; Ser-1165) (figure 1.3) (72, 73). 
These residues have been shown to be critical for polyprotein processing, since 
substitution at these positions abolished cleavage at the NS3/4A, NS4A/4B, NS4B/5A 
and NS5A/B junctions but not at the other sites (74, 75).  
NS4A has been shown to be a cofactor for the NS3 protease, which is required for 
efficient proteolytic processing. NS4A had been shown to bind to NS3 and enable the 
protease to cleave peptide substrates more efficiently in particular at the NS4B/NS5A 
(65, 76). 
 
 
Figure 1.3: Three dimensional conformational structure of the HCV NS3 protease 
domain showing the catalytic triad of amino acids forming the active site, the portion 
of NS4A which associates with NS3 is shown in red. Side-chains of active-site 
residues His-1083, Asp-1107 and Ser-1165, as well as the zinc ligands Cys-1123, 
Cys-1125 and Cys-1171 (yellow spheres). The tetrahedrally co-ordinated zinc ion in 
the C-terminal -barrel is coloured blue. Figure from Bartenschlager R. 2002 (73). 
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The RNA Helicase domain: 
The HCV RNA helicase is composed of the C-terminal two-thirds of NS3. X-ray 
crystallography has showed that the helicase region of NS3 forms a three-domain Y-
shaped structure (figure 1.4) (77, 78). Domains 1 and 2 are similar to those seen in 
other helicases, and they contain several conserved motifs characteristic of 
superfamily 2 helicases while domain 3 seems to be novel with no motifs found in 
other helicases. Based on its sequence homology to other RNA helicase domains, 
HCV NS3 RNA helicase is classified as a member of the DEAD-box family of RNA 
helicases. This group of helicases consists of three subfamilies of proteins that contain 
either a DEAD, DEAH or DExH amino acid motif. NS3 contains an Asp-Glu-Cys-His 
(DECH) motif at position 1315-1318 of the polyprotein, and is therefore, a member of 
the DExH subfamily (79).  
It is thought that the main role for HCV RNA helicase is to assist the NS5B RNA-
dependent RNA polymerase with viral replication by resolving RNA secondary 
structures and/or double- stranded replication intermediates. The HCV helicase carries 
out this function by binding and hydrolyzing nucleoside triphosphatase, translocating 
in a 3′-to-5′ direction along the template RNA, separating nucleic acid base pairs, and 
displacing nucleic acid binding proteins. One strand of nucleic acid binds in the cleft 
between domain 3 and the first two domains, and ATP probably binds within the cleft 
separating domains 1 and 2 (80, 81).  
To initiate unwinding, the HCV helicase requires a single-stranded region of RNA 
with a 3′ overhang on which to load, and the energy from ATP hydrolysis is believed 
to fuel both translocation and unwinding. ATPase activity is stimulated up to 100-fold 
by nucleic acids depending on the nucleic acid sequence and whether or not the 
protease region is present (82-84). HCV NS3 alone is a poor helicase on RNA, and 
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helicase  activity on RNA is promoted by cofactor NS4A (84). In contrast, NS3 alone 
is a highly processive helicase on DNA substrates (84), although HCV replication 
does not involve any known DNA intermediate during its replication cycle.  
Besides unwinding viral RNA, the motor action of HCV helicase could also perform 
other cellular functions such as assisting translation, disrupting RNA-protein 
interaction, packaging RNA in viral capsids, and even interacting with cellular DNA 
to alter host gene expression. Mutational analyses of the helicase domain have shown 
that residues of the conserved motifs of DEAD-box helicases are essential for NTPase 
and helicase activities and also that NTPase activity is essential but not sufficient for 
helicase activity (85-88).  
 
 
Figure 1.4: Ribbon diagram of the HCV NS3 helicase domain (3D image) with a 
bound oligonucleotide (yellow).  The helicase domain has three distinct domains; 
Domain 1 (blue), Domain 2 (red) and Domain 3 (green). Figure from Kim et al, 1998 
(89)  
 
Recent research suggests that NS3 may have a role in viral assembly.  Yi and 
colleagues have shown, that a chimeric HCV genome, which is comprised of 
genotype 1a H77c spanning
 
the core to the NS2 region, placed within the 
corresponding
 
region of the genotype 2a JFH-1 genome, did not produce infectious 
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virus despite evidence for
 
robust RNA replication in the transfected cells until 
approximately after 9 days when large amounts of infectious virus
 
began to be 
released from the cells (69). Sequencing revealed that a single amino acid change 
(NS3-Q221L) within the helicase domain
 
of NS3 was responsible for this change in 
the virus production
 
phenotype. Also work with other flavivirus NS3 proteins 
supports these findings. For instance, Kunjin virus (KUN), from genus Flavivirus, 
NS3 protein is involved in assembly in cis but its RNA sequence or secondary 
structure are not essential for efficient RNA packaging (90). Moreover, a defective 
mutation within
 
the NS2A sequence of yellow fever virus (YFV) can be rescued by a 
second-site mutation within the NS3 helicase
 
domain, suggesting that NS3 is involved 
in the production of infectious
 
YFV (91). Additionally, a mutation in NS3, W349A, 
had no effect on viral replication, but caused defects on release of infectious virus 
particles which indicate the role of NS3 in virus assembly (92). However, the precise 
biological roles that the NS3 RNA helicase plays during the replication cycle of the 
virus are still not fully understood.  
 
1.5.3.3.                NS4B 
In last few years more studies have revealed the importance of NS4B for virus 
replication. NS4B is a 261 amino acid, hydrophobic protein with a molecular weight 
of about 30 kDa. It is a highly hydrophobic, integral ER-membrane protein which 
contains four transmembrane domains (TM1-TM4) and is palmitoylated at two C-
terminal cysteine residues (93). In addition, several critical domains within NS4B 
have been identified and genetically validated as essential for HCV genome 
replication. These include: an N-terminal amphipathic helix called 4BAH1 (94). 
Palmitoylation of 4B protein facilitates oligomerization which appears to be essential 
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for HCV replication (95). NS4B induces the formation of a structure termed the 
membranous web which is comprised of small vesicles (80-180 nm in diameter) 
embedded in a membranous matrix and is found closely associated (96) with the 
rough ER. HCV proteins and genomic RNA are associated with the membranous web 
indicating that it is a platform upon which HCV replication occurs (96, 97). This 
protein has also been implicated in interacting with NS5B together with NS3 to form 
a regulatory complex important in RNA replication (98).  
Recently, NS4B has been shown to bind the 3' terminus of the negative RNA strand 
of the viral genome with a dissociation constant (Kd) of 3.4 nM (99, 100). 
Additionally when pairs of highly conserved positively charged arginine rich amino 
acid motifs were mutated to alanine, either partially or completely, NS4B RNA 
binding activity was abrogated. Moreover, introduction of these same mutations into 
HCV replicons resulted in similar partial or complete abrogation of RNA genome 
replication (99, 100). These findings suggest NS4B could be a new potential target for 
antivirals. A clemizole hydrochloride compound was found to inhibit HCV RNA 
replication in cell culture and its activity has been shown to be mediated by its 
suppression of RNA binding by NS4B, with little toxicity for the host cell (99, 100). 
 
1.5.3.4.             NS5A: 
Two phosphorylated variants of NS5A have been described and designated according 
to their molecular masses as 56 kd and 58kd, which correspond to the basal and 
hyperphosphorylated forms. NS5A is composed of three domains. Domain I is 
relatively conserved among HCV genotypes compared
 
to domains II and III. Analysis 
of the crystal structure of
 
the conserved domain I, which immediately follows the 
membrane-anchoring
 α-helix localized at the N terminus revealed a dimeric structure 
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(101). The interface between the dimer is characterized
 
by a large, basic groove, 
which has been proposed as an RNA binding site. Domain II contains a region 
referred to as the interferon
 
sensitivity determining region (ISDR), and this region and 
its C-terminal
 
26 residues have been shown to be essential for interaction
 
with the 
interferon-induced, double-stranded RNA-dependent protein
 
kinase (101).  
NS5A is implicated in multiple interactions with the host cell to support persistent 
infection and is involved in RNA replication. NS5A has an important role in 
resistance against IFN-α induced antiviral response. The IFN sensitivity determining 
region (ISDR) can bind to PKR inhibiting dimerization, resulting in the repression of 
PKR function
 
and inhibition of PKR-mediated eIF-2α phosphorylation (102, 103). 
Moreover, interfering with the activity of PKR, which is responsible for translational 
arrest and the induction of apoptosis, leads to resistance
 
to apoptosis by NS5A (104). 
Alanine substitution for serine residues in the central cluster 1 enhances RNA 
replication but reduces NS5A hyperphosphorylation. This indicates that NS5A might 
be a key regulatory molecule in the HCV replication cycle (105). 
 
1.5.3.5.               NS5B: 
NS5B is a 68 kDa protein with RNA-dependent RNA polymerase (RdRp) which 
contains a GDD motif, at the residues 317-319, which is essential for RNA 
polymerase function and it can synthesize RNA by using various RNAs as templates 
in vitro. As is the case with other polymerases, the three dimensional structure of the 
HCV polymerase resembles a right hand, complete with finger, palm and thumb 
domains (106).  
The full-length HCV NS5B protein contains 591 amino acids, and the catalytic core 
domain consists of the N-terminal 530 amino acids. The final 21 amino acids at the C- 
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terminus of NS5B are hydrophobic and responsible for the anchorage of NS5B to the 
ER membrane. Deletion of this fragment enhanced the RNA synthesis rate up to 50 
fold (107). It has been shown that the C-terminal 21 amino acids not only have a 
membrane-anchoring function but also may perform additional functions for RNA 
synthesis in vivo (108).  
 
1.6. HCV replication Cycle 
HCV RNA has been detected in the livers, peripheral blood mononuclear cells 
(PBMCs) and bone marrow of infected patients, confirming that as well as occurring 
in the liver, virus replication may also occur at extra-hepatic sites including 
hematopoietic cells, dendritic  cells and central nervous system (109-111). HCV 
particles have a density of about 1.15-1.17 g/ml and a spherical morphology with an 
average diameter of about 55 nm (112). HCV is surrounded by a host membrane-
derived envelope containing the virus-encoded glycoproteins, E1 and E2. The E1 and 
E2 interact with specific molecules or receptors on the cell surface that promote the 
attachment and internalisation of particles into the cell (113, 114).  
Until recently the investigation of the HCV life cycle in detail had been hampered by 
the lack of a cell culture system. The first studies for virus life cycles and the 
characterisation of HCV non-structural proteins was based on analogies with flavi- 
and pesti- viruses. The development of in vitro models for HCV RNA replication 
using replicon cell lines has helped to elucidate some of processes involved. Studies 
of HCV replication using replicon cell lines initially showed that the amount of 
replicon RNA in cells was dependent on the degree of cell confluence where the 
highest levels were found in exponentially growing cells, followed by a sharp decline 
in resting cells which indicates that HCV RNA replication or translation is tightly 
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linked to host cell metabolism (115). Point mutations within the NS5A and NS3 
encoding sequences can lead to an increase in the rate of HCV RNA replication. 
Further analysis of replicon cell lines indicated that HCV RNA replication is not 
cytopathic to the cells (116). 
However, in 2005, HCV isolated from fulminant Japanese hepatitis, demonstrated that 
genome-length RNA from a genotype 2a HCV strain JFH-1 could produce infectious 
virus in cell culture (112, 117, 118). This development opened a new era for 
investigating the mechanisms responsible for HCV particle assembly and release. 
Along with JFH-1, studies using chimeric derivatives encoding structural proteins 
from other HCV genotypes established roles for several non-structural proteins in the 
production of infectious virus. HCV from cell culture (HCVcc) has been found to be 
infectious in chimpanzees and mice transplanted with human hepatocytes (117). More 
importantly, isolation of JFH-1 has permitted the analysis of the essential contribution 
of host cell factors to virus production.   
The life cycle of HCV may be summarised as follows (figure 1.5):  
 Attachment to receptors on the cell surface, penetration of host cell and 
liberation of genomic RNA into cytoplasm of cell. 
 Translation of the RNA genome; processing of the polyprotein generated. 
 Synthesis of a minus strand intermediate from the plus strand genomic RNA.  
 Generation of new positive strand molecules which may then be used for 
production of more negative strand molecules or packaging into progeny 
virions. 
 Virion maturation and release of virus from the infected cell. 
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1.5: Model of the HCV replication cycle: Host cell (large rounded rectangle shape- 
blue). (1) Binding of the virus to the cell receptors by interactions with 
glycosylaminoglycans (GAG) and/or the LDLR and then the virions interact with 
entry receptors CD81 and SR-BI, (2) receptor-mediated endocytosis facilitated, by 
translocation of the virus–receptor complex to the tight junctions, where claudin 
(CLDN) and occludin (OCLN) act as cofactors and induce receptor- endocytosis (3) 
virion-membrane fusion and uncoating, (4) translation and polyprotein processing, (5) 
RNA replication at ER membrane where synthesis of (-) strand RNA takes place and 
serves as template for the production of plus strand (genomic RNA), (6) and (7) 
assembly of (+) strand with the interaction of RNA with the structural proteins to 
form virus particles, transport of virus particle via vesicles, and (8) vesicle fusion and 
release of the virus. Figure adapted from Tang & Grise, 2009 (119). 
 
 
1.6.1. Attachment and Entry 
HCV initiates its lifecycle by the attachment of virus particles to a specific host cell. 
Therefore, the interaction between receptors on the cell surface and the attachment 
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proteins on the virus surface is necessary. As has been described earlier, CD81, 
scavenger receptor class B member I (SR-BI) and the tight junction proteins Claudin-
1 (CLDN1) (120) and Occludin (OCLN) (121, 122) are critical factors defining HCV 
entry (figure 1.6). Two additional Claudin family members, CLDN6 and CLDN9, 
have also been reported to confer HCV entry (123).  In addition, it is thought that 
HCV may utilize glycosaminoglycans (GAGs) and low density receptors, low-density 
and very-low-density lipoproteins receptors (LDLR and VLDLR) as initial attachment 
factors (124).  
The major envelope glycoprotein E1 and E2, both are believed to be responsible for 
initiating virus attachment to the host cell. HCV pseudoparticles (HCV pp) have been 
used to study virus entry mechanisms. HCVpp are produced in 293T cells by 
expressing the HCV glycoproteins, retroviral core proteins and a packaging-
competent retrovirus-derived genome containing a reporter gene. During budding, 
HCV envelope glycoproteins are incorporated into the pseudoparticle envelope. As no 
retroviral glycoproteins are present in this system, the cell entry properties of HCVpp 
are determined by HCV glycoproteins. HCVpp entry results in the delivery of the 
retroviral nucleocapsid into the cytosol followed by reverse transcription and 
integration of the retroviral-derived genome into the cellular genome. Retroviral 
pseudoparticles (HCVpp) bearing HCV E1E2 gps infect hepatocytes and hepatoma 
derived cell lines suggest that virus-receptor interactions may in part define HCV 
tropism for the liver (125). Also E2-specific antisera prevent attachment of HCV to 
mammalian cells (126).  HCV-like particles (HCV-LPs) have also been isolated from 
insect cells, infected with recombinant baculovirus expressing HCV structural 
proteins (Core, E1 and E2). Isolated HCV-LPs are composed of all the structural 
proteins (E1, E2 and C). Further analysis of HCV-LPs by cryoelectron microscopy 
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(CryoEM) revealed that they are spherical particles with smooth surfaces. They were 
found to be consistent with the native HCV virions isolated from HCV infected 
patients. HCV-LPs for the first time allowed 3D structural analysis of HCV particles, 
which further allows analysis of the complex mechanisms of HCV assembly and 
maturation (127). 
After attachment, the nucleocapsid of enveloped viruses is released into the cell 
cytoplasm as a result of a fusion process between viral and cellular membranes. 
Fusion is mediated by specialized viral proteins and takes place either directly at the 
plasma membrane or following internalization of the particle into endosomes. The 
entry process is controlled by viral surface glycoproteins that trigger the 
conformational changes required for mediating fusion. At least two different classes 
of fusion proteins (I and II) found in enveloped viruses have been determined and 
shown to be activated by two general mechanisms based upon their requirement for 
low pH. Fusion of pH-independent viruses, such as HIV, is activated by receptor 
binding at the plasma membrane. In contrast, the fusion of pH-dependent viruses, 
such as influenza or alphaviruses/flaviviruses, is triggered by low pH in the endosome 
(128). By analogy, HCV envelope glycoproteins belong to class II fusion proteins 
(129) and enter target cells by receptor-mediated endocytosis and use class II fusion 
proteins (130, 131).  
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Figure 1.6: Host cell molecules involved in HCV entry. Expression and role of host 
tetraspanin CD81, scavenger receptor B I (SR-BI) and tight junction proteins 
Claudin-1 (CLDN1) and Occludin (OCLN). Extracellular loops 1 and 2 (EC1 and 
EC2). Figure adapted from Lemon et al, 2010 (94). 
 
1.6.2. HCV RNA Translation and Proteolytic Processing 
Once the virus is in the cytoplasm, the viral RNA is directly translated in a cap-
independent way mediated by the viral IRES element, which interacts with the host 
cell ribosomes (29, 132). Ribosomes appear to bind in close proximity to the 
polyprotein initiator codon AUG with little or no scanning (133, 134).  
Recent work has identified other factors involved in HCV RNA translation. For 
instance non-coding RNA molecules or microRNAs (miR) are important in the 
control of gene expression and regulation. Transcription of miR-122 stimulates HCV 
RNA translation and virus production via the direct interaction of miR-122 with two 
sites S1 and S2 in the 5‟NTR, whereas its sequestration in liver cell lines strongly 
reduced HCV translation (135). This important role of miR-122 in HCV replication 
has led to it being considered as a potential therapeutic target. Base substitutions in 
both S1 and S2 failed to produce infectious virus in transfected cells, while virus 
production was rescued to near wild-type levels in cells supplemented with a 
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complementary miR-122 mutant and translation of HCV RNA was reduced over 50% 
by mutations in either S1 or S2 (136).  
Another factor involved in RNA translational control is proteasome alpha-subunit 
PSMA7 which has been shown to have important role in regulating HCV IRES 
mediated translation (137). Unlike capped eukaryotic cellular mRNAs, The HCV 
IRES has been shown to bind directly to the 40S ribosomal subunit without the 
requirement for other translation factors, in a way which resembles the function of the 
Shine-Delgarno sequence in prokaryotes (138).  
The polyprotein mediated by IRES translation is targeted to the rough endoplasmic 
reticulum, where the polyprotein is then cleaved co- and post-translationally by host 
cell signal peptidase and the two viral proteases. Polyprotein processing cleavage 
junctions have been deduced by the presence of hydrophobic sequences preceding the 
cleavage sites and the dependence on microsomal membranes. Cleavage at the C-NS2 
region is processed by host cell encoded signal peptidases, with cleavage occurring at 
the following junctions: C/E1; E1/E2; E2/p7; p7/NS2. Cleavage of the signal 
sequence by the host signal peptidase yields the immature form of the core protein 
p23 (139, 140). The signal peptide is further processed by a host signal peptide 
peptidase to yield the mature form of the core protein p21 (139, 140). The host signal 
peptidase also ensures cleavage at the E1-E2 junction in the ER lumen. Additional 
signal peptidase cleavage at the C-terminal end of E2 and between p7 and NS2 gives 
rise to p7. E1 and E2 subsequently undergo several maturation steps, including N-
glycosylation, conformational changes, and assembly of E1E2 heterodimers (140, 
141).  
The zinc-dependent NS2-3 autoprotease ensures cis-cleavage of NS3 from NS2. NS3 
interacts with its cofactor NS4A to catalyze cis-cleavage at the NS3-NS4A junction 
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and trans-cleavage at all downstream junctions including NS4A-NS4B, NS4B-NS5A, 
and NS5A-NS5B (74, 75). The cleavage sites recognized by the NS3/NS4A 
proteinase have a common sequence: Asp/GluXXXXCys/Thr-Ser/Ala, with trans-
cleavages occurring downstream of a cysteine residue and the cis-cleavage occurring 
downstream of a threonine residue (141). 
 
1.6.3. HCV replication complex formation 
Positive-strand RNA viruses, including HCV replicate their genome by inducing 
alterations in cellular membranes and interacting with them to form replication 
complexes. For HCV,  the membrane structure „membranous web‟ has been observed 
in cells expressing mature NS4B protein (96) or the precursor NS4A-B (142) which 
were seen in subgenomic replicon (143), or in HCV JFH-1 infected cells (144).  The 
NS4B induced membranous web contains the HCV replication complex (RC), which 
also contains NS proteins (NS3, NS4A, NS4B, NS5A and NS5B), host factors and 
viral RNA. 
It is not known whether NS4B recruits cellular proteins responsible for vesicle 
formation or induces vesicle formation by itself. Recent work has identified different 
host cellular factors that contribute to the formation of NS4B foci. For example, it is 
reported that the early endosome (EE) protein Rab5 is associated with NS4B foci, 
binds to NS4B and is required for HCV genome replication (145). Additionally, a 
recent report indicates that Rab5 is required for cell culture JFH-1 genome replication 
(146, 147).  
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1.6.4. RNA Replication 
The 5` and 3` nontranslated regions of the HCV genome are presumed to contain the 
signals required for initiation and termination of viral replication, and transcriptional 
initiation occurs in both the 3` and 5` NTRs. The RdRp enzyme (NS5B) initiates 
synthesis of complementary negative-strand RNA using the HCV genome (positive 
polarity) as a template. The negative-strand RNA serves as a template to produce 
numerous strands of positive polarity. Subsequently, these are used for polyprotein 
translation and the synthesis of new intermediates of RNA replication, or packaging 
into new virus particles. Studies on subgenomic replicons cells showed that HCV 
RNA replicons efficiently replicating in cell lines accumulate 50-5,000 copies per cell 
and that negative strands are 5 to 10 fold less abundant than plus strands (148). 
 It is believed that a primer is required for the initiation of RNA replication, either by 
elongation of a primer hybridised to an RNA homopolymer or via a copy back 
mechanism when heteropolymeric templates are used. Sequences at the 3` end would 
fold back intramolecularly and hybridise producing a 3` end which may then be used 
for elongation (141). Evidence for this fold back mechanism in HCV has been shown 
by interaction of the 3′ end of the plus and minus strand to form a G/C-rich stem loop. 
This involves domain I of the 5′NTR,  the 3′NTR, and a cis-acting replication element 
(5BSL3.2) consisting of 50 bases located in a large predicted cruciform structure at 
the 3‟ end of the HCV NS5B-coding region (149). HCV RNA replication is initiated 
by interactions between proteins of the replication complex, the 3′X region of the 
3′NTR, and 5BSL3.2 that forms a pseudoknot structure with a stem loop in the 3‟NTR 
(149, 150). 
Cellular and other viral factors, in addition to NS5B, are also required for RNA 
replication. For example, the NS3 helicase unwinds a stable double-stranded RNA 
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structure which facilitates replication. NS5A bind to NS5B and modulate its 
polymerase (poly A template/poly U primer) activity (151). NS5A stimulates 
replication on templates derived from the 3‟ end of the positive strand during 
elongation and this, could either be due to the stimulation of its catalytic activity or 
due to a conformational change induced by NS5A binding (152). However the 
mechanism of action is not fully clear.  
In addition, cellular factors which might be involved in HCV RNA synthesis have 
also been described. For instance, PTB was found to interact with sequences at the 3` 
NTR (153, 154). Also Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), bound 
efficiently to the full-length HCV RNA and revealed critical dependence upon the 
presence of the poly (U)-sequence in the 3′ NTR (155). Recent work has shown that 
cyclosporin A (CsA) inhibits HCV RNA replication in vitro, by targeting by 
cyclophilin B (156). Cyclophilin B interacts with NS5B thereby stimulating its RNA 
binding activity, and associates with cyclophilin A (CypA) via its enzymatic pocket 
and exploits the isomerase/chaperone activity of CypA to help HCV replication (157). 
 
1.6.5. Virion Assembly and Release 
The development of cell culture systems which allow the production of significant 
quantities of virus particles, has led to further understanding of the mechanisms of 
HCV assembly and release. The production of virus like particles (VLP), by 
expression of the structural proteins of the virus, demonstrated that viral 
nucleocapsids acquire their envelope by budding through the ER membranes which 
retain E1 and E2 in HCV infected cells and the virus may then be exported through 
the secretory pathway (22).  
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It has been established that core protein is associated with lipid droplets (LDs) (35, 
158). LDs are intracellular organelles that store neutral lipid. They are composed of a 
core of triacylglycerol and cholesterol ester, surrounded by a unique phospholipid 
leaflet, which in turn is surrounded by a protein layer (35, 158). Core protein recruits 
viral nonstructural proteins and replication complexes to lipid droplet-associated 
membranes, this recruitment is critical for producing infectious viruses (159). Plasma-
derived HCV has been reported to be in complex with low-density and very-low-
density lipoproteins (LDL and VLDL) (124). Furthermore, HCV production in 
hepatoma cells is dependent on assembly and secretion of VLDL lipoproteins (160). 
Thus, it appears that HCV particles interact with VLDL during the assembly of the 
lipoprotein particles and are secreted together with VLDL. 
Many studies have demonstrated that lipoproteins are required for HCV virion 
infectivity and virus production. Human apolipoproteins have been detected in 
infectious HCV virions purified from low-density fractions of cell culture 
supernatants. These are assembled as ApoE-enriched lipoprotein particles and can be 
specifically precipitated by anti-ApoE and anti-E2 monoclonal antibodies (161). 
Moreover, inhibition of ApoE by using ApoE-specific monoclonal antibodies 
efficiently neutralized HCV infectivity, resulting in a reduction of infectious HCV by 
nearly 4 orders of magnitudes. Knockdown of ApoE expression by specific siRNAs 
also reduced the levels of intracellular as well as secreted HCV virions (161).  
The infectious HCV cell culture model system has been used to demonstrate the role 
of NS proteins in virus production. Both intra- and inter-genotypic chimaeras require 
the JFH-1 derived NS proteins to produce infectious virus (162, 163). A detailed 
mapping study identified NS3, NS5B and the 3′-X tail of the JFH-1 isolate as 
important determinants of its unique ability to generate virions in cell culture (164). 
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Recent work has shown that the NS proteins are associate with or incorporated into 
the viral particles, suggesting a role of these NS proteins in the assembly and/or 
release of viral particles. NS2 and P7 (61), NS3 (165) and NS5A (166) have been 
shown to be required for the production of infectious viruses. The introduction of 
specific mutations into the NS5A showed that mutations in NS5A C-terminal domain 
III abolished core-NS5A colocalization in the HCV-replicating cells and hampered 
virion production (105). NS5A specifically interacted with ApoE but not with other 
viral proteins. The relevance of ApoE-NS5A interaction for viral infection was 
confirmed by co-immunoprecipitation and co-localization studies of ApoE and NS5A 
(167). 
 
1.7. Pathogenesis and Disease Progression 
The liver is the primary site of HCV infection and contains the highest levels of HCV 
RNA though relatively low levels of HCV antigens can be detected in the liver (1-
10% of cells). Using RT-PCR, HCV RNA can be detected in PBMCs (168), lymph 
nodes, pancreas, and less frequently within the adrenal glands, bone marrow, thyroid 
tissue and the spleen (169). 
Hepatitis C infection follows a slow progressive course. Initial infection leads to the 
establishment of an acute phase that is often asymptomatic making it difficult to 
detect at an early stage. Around 10–20% of HCV infected individuals spontaneously 
clear the virus during the acute phase, within 6 months after infection. The majority of 
HCV-infected individuals are unable to clear the virus during the acute phase and 
become chronically infected. Chronic hepatitis C is characterized by liver 
inflammation, fibrosis/cirrhosis and, in some patients, HCC (hepatocellular 
carcinoma) (170, 171). A broad clinical spectrum of extra-hepatic complications and 
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diseases are associated with chronic HCV infection including mixed 
cryoglobulinemia, non-Hodgkin‟s lymphoma, cutaneous vasculitis, 
glomerulonephritis, neuropathy, and lymphoproliferative disorders (172, 173). 
Approximately one-fifth of chronically infected individuals go on to develop cirrhosis 
over a 5–30 year period. Among those with cirrhotic livers, 1%–4% progress to 
hepatocellular carcinoma (figure 1.7). 
 
 
Figure 1.7: Natural course of HCV infection: progression of disease to the next level 
(arrows), percentage of patients progressing to the next disease state per year (%). In 
acute infection 20% of infected can clear and recover from infection. 80% develop 
chronic infection, among them 20% develop cirrhosis in over a 5–30 year period and 
1%–4% progress to hepatocellular carcinoma (HCC). Figure from Sharma, 2010 
(174). 
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The incubation period for HCV is approximately 7 weeks but may range from 
between 2 to 26 weeks. Acute hepatitis caused by HCV resembles other forms of 
acute viral hepatitis. Symptoms appear in about one third of patients and include 
malaise, nausea, right upper quadrant pain, dark urine and jaundice. HCV infection 
leads to an elevation level of serum ALT, which is observed in approximately 80% of 
cases (175). 
Chronic hepatitis has been shown to develop within the majority of patients infected 
with HCV, therefore one of the most important factors regarding HCV infection is its 
ability to cause persistent infection. Chronic infection is, in most patients, 
asymptomatic however, some may experience increased fatigue as their only 
symptom or alternatively others may suffer overt symptomatic liver disease. Patients 
may develop severe chronic liver disease over only a few years but more commonly 
this occurs over several decades (174, 176). 
In cell culture systems, HCV expression, replication and infection can induce 
oxidative stress (177, 178). Individual viral proteins, such as core, NS3 and NS5A, 
have all been reported to increase ROS production and induce oxidative stress (179). 
A role of ROS in liver fibrosis has been suggested by the ability of ROS to up-
regulate the profibrogenic cytokine TGF-β (transforming growth factor-β) (180). A 
recent microarray study, which the current study is associated with, of Huh7 cells 
infected with JFH-1- HCV revealed an increase in intracellular reactive oxygen 
species and the inhibition of antioxidant proteins (e.g., TXNIP gene) and the 
production of proteins which induce reactive oxygen species (e.g., DDAH1 and 
AOX1 genes). By contrast, the same study showed a decrease in the expression of 
genes involved in cellular antioxidant responses, including, genes transcribed 
following NRF2 activation (e.g., CAT and EPHX1 genes), members of the 
 51 
metallothionein gene family, genes for the glutathione S-transferase enzymes (e.g., 
GSTM1 to -4 genes), and genes for other key antioxidants (e.g., ATOX1 and GLRX 
genes) (177). Another proteomics study from patient biopsies identified 210 proteins 
exhibiting statistically significant differences associated with the fibrosis stage.  
Amongst the down-regulated proteins were mitochondrial proteins of the oxidative 
phosphorylation system and proteins responding to oxidative stress and reactive ROS. 
Similarly more proteins were also upregulated in this study including mitochondrial 
and antioxidant proteins, for example, glucose-regulated protein, calreticulin, ER 
protein 29, heat shock protein 1B, protein disulfide-isomerase A3 precursor, and 
ubiquitin-activating enzyme E1) (181). The study suggests a correlation between the 
down-regulation of antioxidant proteins and the later stages of liver fibrosis, 
consistent with a role of oxidative stress in the progression of liver fibrosis and 
cirrhosis (181).  
Hepatic steatosis, an excessive lipid accumulation in the cytoplasm of hepatocytes, is 
a frequent histological feature in patients with chronic hepatitis C infection. It occurs 
in between 40% and 80% of chronic HCV patients and is also associated with the 
development of HCC (182, 183). The prevalence of steatosis varies depending on the 
features of the population studied in terms of, alcohol consumption, prevalence of 
obesity, diabetes and other risk factors of fatty liver (184). An association of HCV 
core protein in insulin resistance and hepatic steatosis has been proposed. Core 
induces lipid droplet accumulation and redistribution in cell culture and significant 
correlation between the steatosis score and titre of intra-hepatic HCV RNA was found 
in patients infected with genotype 3 (183). 
It has been proposed that liver steatosis in hepatitis C could be a storage disease 
induced by the effects of the virus and of its proteins on the intracellular lipid 
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machinery and on microsomal triglyceride transfer protein (MTP) (185). MTP gene 
expression and protein activity in liver biopsy specimens from patients with CHC 
were significantly reduced in the presence of severe steatosis, particularly in patients 
infected with HCV-3 and that impairment in MTP activity showed a direct relation to 
levels of HCV replication (185, 186). This reduction is correlated with reduced serum 
cholesterol, ApoB, and low-density lipoproteins (185). Moreover, MTP 493 G/T 
polymorphism showed significant association between MTP polymorphism and liver 
fat accumulation. The MTP T allele was shown to be an independent risk factor for 
high grades of steatosis in the total cohort of HCV patients (187). Recently, an inverse 
relationship was also found between HCV related steatosis and liver expression of 
SREBP-1c and GPAT, two genes involved in fatty acid and triglyceride synthesis 
(186). These findings support the hypothesis that HCV may cause accumulation of 
lipids in infected hepatocytes by perturbing hepatic lipid metabolism through a direct 
interference with MTP, leading to VLDL/triglyceride retention (185). 
 
1.8. Humoral and cellular Immune Responses to HCV infection: 
The humoral immune response determines the outcome of infection. HCV 
neutralizing antibodies were first described after the experimental infection of 
chimpanzees. These antibodies were directed against epitopes in the hypervariable 
region-1 (HVR-1) of HCV envelope glycoprotein E2 (45) and antibodies directed 
against HVR-1 has also been associated with viral clearance in HCV-infected humans 
(42). However, despite the high titres of these antibodies they fail to clear the virus as 
they continue to exert selection pressure on HCV quasispecies and thereby contribute 
to the evolution of the HCV envelope sequences throughout the course of infection 
(188).  Using a single-source outbreak of HCV it was shown that viral clearance was 
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associated with a rapid induction of neutralizing antibodies in the early phase of 
infection (189). However, HCV specific antibodies do not prevent reinfection and are 
not maintained in many individuals who have recovered from HCV infection (190).  
There is evidence for an important role of both virus-specific CD4
+
 and CD8
+
 T-cells 
in controlling the levels of virus present as well as in causing liver injury. CD4
+
 T-
cells recognize antigens presented by major histocompatibility complex (MHC) class 
II molecules on the surface of professional antigen presenting cells (APCs). 
Subsequently, CD4
+
 T-cells perform multiple effector functions, including direct 
activation of macrophages and antigen-specific B-cells as well as activation of CD8
+
 
T-cells in a cytokine-dependent manner. CD8
+
 T-cells, in contrast, recognize antigens 
presented by MHC class I molecules on the surface of infected cells. The effector 
functions of CD8
+
 T-cells comprise two different mechanisms. The killing of infected 
target cells (cytotoxicity), which has been thought to be the primary function of CD8
+
 
T-cells and secretion of cytokines such as IFN-γ and tumour necrosis factor that can 
inhibit viral replication without killing the infected cell (31, 191).  
HCV-specific CD4
+
 T cells are essential in the generation of a successful HCV-
specific immune response (31). Rapid clearance of circulating HCV is associated with 
a vigorous and sustained response of IFN-γ production and proliferating CD4+ T cells 
in the blood.  In contrast, those who showed a weak IFN-γ (+) T-cell response 
maintained small quantities of circulating HCV (192, 193). 
Several studies have shown that HCV-infected patients who develop chronic infection 
typically have only weak, oligo-/mono-specific or no virus-specific CD4+ and CD8+ 
T cell responses in the acute (194) and chronic phases of infection (195, 196). Several 
studies have shown that cytotoxic T-cell dysfunction may occur either due to primary 
T-cell failure or due to T-cell exhaustion and that this plays a role in virus persistence. 
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The expression of high levels of PD-1 (a mediator of T-cell exhaustion and viral 
persistence) on HCV specific CD8
+
 and CD4
+
 has been shown early in acute 
infections irrespective of clinical outcome (197). It has also been suggested that 
antigen presentation by dendritic cells (DCs) and macrophages might be impaired in 
HCV infection (31).  
 
1.9. Treatment and Prevention 
The limitations and the side effects of the current treatments for chronic HCV 
infection have led to the search for new antivirals. The primary goal of treatment of 
chronic HCV infection is to eliminate the virus from the body so that the level of 
HCV RNA is undetectable. When achieved clinically it is called a sustained 
virological response (SVR) (198). 
In 1991, IFN-α became the first treatment for chronic HCV infection. This treatment 
was improved by binding IFN-α to polyethylene glycol (Pegylated-IFN-α) which 
increases the half-life of circulating IFN-α without significantly reducing its 
effectiveness and also reduces the dose needed to once a week (199). Ribavirin was 
then combined with IFN-α, as an additional antiviral agent, used in the treatment of 
HCV. Ribavirin is a nucleoside analog of guanosine which has been shown to have 
antiviral activity against many RNA and DNA viruses (200).  However the mode of 
action for Ribavirin is not completely understood. It has been suggested that it acts 
directly by becoming incorporated into RNA during replication causing chain 
termination, or indirectly by inhibiting inosine monophosphate dehydrogenase 
(IMPDH). Inhibition of IMPDH leads to reduced intracellular levels of GTP which is 
required for HCV RNA synthesis. Another suggested mode of action is that ribavirin 
causes the RNA-dependent RNA polymerase to become more error-prone causing it 
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to introduce higher numbers of mutations which dramatically reduce the infectivity of 
the new virions (201, 202). 
Combination therapy of ribavirin with peg-IFN-, which is the present standard 
treatment regimen, results in a sustained response rate close to 90% for patients 
carrying the less common genotypes 2, 66-80% for genotype 3, but is less effective 
for genotype 1, with around 50% SVR (198). 
However in addition to these limitations in its efficiency the therapy is expensive, 
produces unpleasant side effects that include depression, haemolytic anaemia, fever 
and chills. This means that new and effective therapeutic agents are needed to 
increase the SVR.  
In last decade, different promising new therapeutic approaches based on antiviral 
agents that target specific steps in the virus life cycle have been developed and are 
collectively called Specifically Targeted Antiviral Therapy for hepatitis C (STAT-C). 
The first small molecule to be used in clinical trials was BILN 2061, a macrocyclic 
peptidomimetic inhibitor designed to inhibit NS3/4A activity. Oral administration of 
BILN 2061 in patients infected with genotype-1 was found to dramatically reduce 
HCV RNA levels within 1–2 days (203). This was considered a landmark study which 
demonstrated for the first time that potent small molecule inhibitors were effective 
against HCV in vivo. However in spite of these impressive results, further clinical 
development of BILN 2061 had to be terminated as it was found to be toxic. It was 
also found that replicons containing single mutations in the NS3 protease gene 
(A156V or D168V), resulted in high levels of resistance to BILN-2061 (204). Similar 
findings were confirmed with single amino acid substitution A156T, R155Q, or 
D168V which resulted in 357-fold, 24-fold, and 144-fold reductions, respectively, 
compared to the wild-type replicon (205).  
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These results opened a new era for the development of new protease inhibitors (PI) 
which, aimed to produce high levels of inhibition of viral replications with less 
toxicity and resistance. Currently, multiple HCV PI are in various stages of clinical 
development, including telapravir/VX-950 (Phase 3), VX-500 (Phase 1), VX-813 
(Phase 1), boceprevir/SCH503034 (Phase 3), ITMN-191/R7227 (Phase 1b), TMC435 
(Phase 2), MK-7009 (Phase 2) and PHX1766 (Phase 1) (198). 
VX-950 for example VX-950 is a peptidomimetic compound that has been 
structurally optimized to inhibit NS3/4A activity and can be taken orally, shows 
potent inhibition of HCV replication (206), and like BILN 2061, VX-950 also 
generates resistance mutations within NS3 (207). Lin et al, have identified mutants 
that contain cross-resistance mutations, conferred by substitution of Ala (156) with 
either Val or Thr that resist inhibition by BILN 2061 are sensitive to VX-950, or vice 
versa (207).  
The RNA-dependent RNA polymerase (NS5B) enzyme is essential for HCV genome 
replication indicating that it would be a good target for anti-viral intervention. To 
date, several nucleoside and non-nucleoside NS5B inhibitors have been developed. 
NM-283 (Valopicitabine), is a nucleoside analog, prodrug of 20-C-methyl-cytidine 
and, serves as a substrate for viral RNA polymerase where its incorporation leads to 
premature chain termination (208). In phase-II clinical trials NM-283 treatment in 
patients infected with HCV genotype-1 either alone or in combination with interferon-
alpha results in synergistic inhibition of HCV genome replication in cell culture (209). 
 
1.10. Vaccination: 
Development of an effective vaccine against the hepatitis C virus (HCV) remains a 
challenge. This is due to several factors including; (1) The large number of mutations 
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in the HCV genome, for example, the hypervariable regions HVR1 and HVR2 within 
the E2 gene; (2) the observation that convalescent humans and chimpanzees could be 
re-infected after re-exposure. HCV envelope proteins can induce broadly neutralizing 
antibodies against conserved domains for HCV binding to the cellular receptors (45) 
(42). Consequently the HCV envelope proteins have been considered as the major 
HCV vaccine candidates. A vaccine based on the E1 and E2 glycoproteins has been 
tested in chimpanzees (210, 211). However, the neutralizing activity of HCV specific 
antibodies is: low in infected patients, short lived and needs to be boosted frequently 
and it only gave partial protection against challenge with HCV of the same genotype 
as the E1 and E2 proteins used in the vaccine (212, 213). Other virus proteins have 
also been used e.g. TG4040 is a candidate vaccine based on the attenuated modified 
vaccinia Ankara (MVA) expressing NS3, NS4 and NS5B proteins (214). 
Since naturally produced HCV antibodies do not seem to completely eradicate the 
virus, there is interest in stimulating the production of antibodies and promoting T-
cell activity. Many current vaccine candidates aim to stimulate both types of immune 
response and mainly prime broad HCV-specific Th1 and CTL responses (215).  
 
1.11. Interferons (IFNs): 
Interferons are critical signalling proteins which are secreted by cells in response to 
viral infections and which activate host cell antiviral responses. Three classes of IFN 
have been identified, designated types I, II and III, and are classified according to the 
receptor complex they signal through. Class II contains one member, IFN-γ produced 
by T cells and NK cells in response to immune and inflammatory stimuli.   IFN-γ 
binds the IFN-γ receptor (IFNGR) complex, and mediates broad immune responses 
(figure 1.8) (216, 217).  
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More recently a third type of IFN designated type III IFN-λ (represented by IL-28 and 
IL- 29), shown to be structurally and functionally related to type I IFNs. They are 
regarded as a distinct family and signal through a separate receptor complex, which 
signal through receptors containing IFNLR1 (IFN-λ receptor 1; also known as IL-
28Ra) and IL-10R2 (also known as IL-10Rβ). There are several type I IFNs, subtyped 
IFN-α (13 subtypes) and one subtype of IFN-β one gene, IFN-κ, IFN-ε, IFN-ο, IFN-τ 
and IFN-δ of which bind to IFNAR (IFN-α receptor) (216, 217). Type I IFNs are the 
most important for the innate host response viral infections. 
 
1.11.1. IFN signalling: 
Interferons (IFN) effect their responses by binding to specific receptors on the cell 
surface. The binding of IFN-α and β to the extracellular domains of their receptor 
initiates a signal transduction cascade. Type I IFNs binds to a common heterodimeric
 
receptor interferon alpha receptor 1 and 2 (IFNAR1 and IFNAR2), inducing 
oligomerization. Prior to activation, the cytoplasmic
 
tail of IFNAR1 is associated with 
tyrosine kinase 2 (Tyk2) and
 
the IFNAR2 subunit is associated with the tyrosine 
kinase JAK1. This cascade involves activation of Jak1 and Tyk2 and the subsequent 
tyrosine-phosphorylation of STAT1 and STAT2 results in their translocation to the 
nucleus. The STAT1–STAT2 complex associate with a monomer of IRF9 to form the 
ISGF3 heterotrimer
 
that binds to the IFN-stimulated response element (ISRE), located
 
in the promoters of most IFN-responsive genes, and enhances
 
transcription. 
IFN- binds to IFNGR1 and JAK2 binds to the intracellular domain of IFNGR2. 
JAK1 and JAK2 are then, activated by autophosphorylation. Once activated, two 
latent STAT1 proteins bind to these JAKs. STAT1 proteins are phosphorylated by the 
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JAKs, and dissociate from the receptor and translocate to the nucleus. The activated 
STAT1 binds to specific gamma activated sequence (GAS) and stimulates the 
expression of the genes downstream (figure 1.8) (216, 217). 
 
 
 
Figure 1.8: IFN signaling: IFNs bind to three receptor complexes: a heterodimer of 
IFN-α receptor 1 (IFNAR1) and IFNAR2 binds type I IFNs; the interleukin-10 
receptor 2 (IL-10R2) associates with IFNLR1 (IFN-λ receptor 1) to bind the three 
IFN-λ subtypes; and a tetramer consisting of two IFNGR2 (IFN-γ receptor 2) chains 
and two IFNGR1 chains binds dimers of the type II IFN-γ. Following IFN binding 
translocated to the nucleus to induce IFN-stimulated genes from IFN-stimulated 
response elements (ISREs) or GAS promoter elements, for type I and type III, or type 
II IFN responses, respectively. Figure from Sadler & Williams, 2008  (217).  
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1.11.2. IFN biological effects: 
IFN α/β induce an antiviral effect in cells on the onset of viral infection through 
activation of expression of more than 300 IFN-stimulated genes (ISGs) which have 
antiviral, antiproliferative, and immunomodulatory functions. Some ISGs are 
mediated through a cascade of antiviral pathways leading to several antiviral 
responses including proteins that catalyse cytoskeletal remodeling, that induce 
apoptosis, that regulate post-transcriptional events (splicing, mRNA editing, RNA 
degradation and the multiple steps of protein translation) and proteins that are 
involved in subsequent post-translational modification. Several IFN-induced proteins 
have documented anti-HCV activity ISG15 (IFN-stimulated protein of 15 kDa), the 
GTPase Mx1 (myxovirus resistance 1), ribonuclease L (RNaseL) and protein kinase R 
(PKR). 
IFN induces resistance to viral replication in uninfected cells by activating genes that 
cause destruction of mRNA and inhibit the translation of viral and host proteins.  A 
good example is protein kinase R (PKR) which is normally present in an inactive 
form in uninfected cells, but on binding to double stranded RNA it undergoes 
autophosphorylation and a conformational change unmasking its C terminal catalytic 
domain (218). Activated PKR phosphorylates the alpha subunit of the initiation factor 
eIF2, which results in the formation of an inactive complex resulting in the rapid 
inhibition of translation (219). Another inhibitory pathway is activated through 
oligoadenylate synthetase, which converts ATP into a series of 2‟ – 5‟ linked 
oligomers which activate RNase L that then degrades cellular and viral RNA (208, 
220). ADAR 1 catalyzes the deamination of adenosine on target dsRNAs to yield 
inosine which destabilizes the secondary structure due to a change from an AU base 
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pair to a less stable IU base pair and it also causes mutations which accumulate within 
the viral genome (221). 
Several microarray studies performed with HCV infected liver samples, obtained 
from transiently infected chimpanzees and chronically infected humans, have shown 
that more genes are involved in the induction of interferon (IFN)-stimulated genes 
(ISGs) in HCV infection compared to uninfected controls (222). Helbig et al, revealed 
that viperin has antiviral effects on HCV infection (223). Viperin is identified as an 
antiviral pathway that works together with ISG20 and PKR, to mediate the IFN 
response against HCV infection (224). This work revealed the molecular mechanism 
of viperin, which is a putative radical S-adenosyl-L-methionine (SAM) enzyme (224), 
induces the formation of crystlliod ER and interferes with protein secretion (225). 
Therefore, it is hypothesized that viperin inhibits HCV replication by interfering with 
the formation activity of HCV RC on ER (226). Murao K et al, demonstrated that 
IFN-α inhibits the expression of hSR-BI/CLA-1, a cell surface receptor that probably 
serves a dual role; which might facilitate the entry of HDL particles into liver cells 
and function as a receptor for HCV (227). IFN-α/ β help to activate the immune 
response by induction of MHC class I expression on cells newly infected by the virus 
to enhance the degradation by CTL. HCV infection also increases production of class 
II MHC in macrophages. 
1.11.3. Inhibition of IFN pathway by HCV: 
Several HCV structural and non-structural proteins have been shown to have a 
significant influence in suppressing the antiviral effects of interferon which helps to 
promote the persistence of HCV infection. The HCV E2 protein contains a sequence 
identical to phosphorylation sites of the interferon (IFN)-inducible protein kinase 
(PKR), and the translation initiation factor, eIF2, a target of PKR. E2 therefore acts as 
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a pseudosubstrate for PKR and consequently it can confer resistance to PKR in HCV 
infected cells by increasing the level of protein translation (47, 228).  
HCV replicons were found to replicate more efficiently in PKR deficient mouse 
embryonic fibroblasts (MEFs) than wild type MEF, and PKR expression knockdown 
by specific siRNAs significantly enhanced the level of HCV RNA replication (229). 
NS3/4A serine protease blocks the phosphorylation and effector actions of IFN 
regulatory factor 3 (IRF-3), the key molecule in the antiviral signalling pathway 
(230). NS5A has also been shown to block the activation of interferon regulatory 
factor 1 (IRF1) through the PKR pathway which is important for IFN-induced 
transcriptional programs (231).  
 
1.11.4. Innate immunity and HCV: 
The innate immune response is the first line of defence against an invading pathogen. 
Interferon type I (IFN-α and IFN-β) responses are key to innate antiviral immune 
defences. To trigger this antiviral state it is necessary to 1. Detect the invading 
pathogen and 2. Initiate a cascade of signalling proteins that regulate the synthesis of 
type I IFN. To achieve this, the cells of the innate immune system express sensing 
proteins called Pattern Recognition Receptors (PRR) which recognises various 
molecules from pathogens collectively known as pathogen associated molecular 
patterns (PAMP) (232, 233). 
 
1.11.4.1.  Antiviral innate immunity induction by Toll Like 
Receptors (TLRs): 
TLRs are transmembrane receptors that recognize PAMPs through leucine-rich 
repeats (LRRs) in their extracellular domains and transmit this information by the 
Toll/IL-1R (TIR) intracellular signaling domain. TIR interacts with several TIR-
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containing adaptor molecules including, myeloid differentiation primary response 
protein88 (MyD88), MyD88 adaptor-like (also known as TIR domain-containing 
adaptor protein, TIRAP), TIR domain-containing adaptor inducing IFN-β (TRIF) and 
TRIF-related adaptor molecule (TRAM). These interaction results in the activation of 
different intracellular signalling cascades, generally resulting in the activation of NF-
κB and activating protein-1 (AP-1) in MyD88-dependent pathways and the activation 
of type I interferons (IFNs) in TRIF-dependent anti-viral pathways (234).  
Among the eleven members of the human TLR family, TLR2, TLR 3, TLR 4, TLR 7, 
TLR8 and TLR9 are involved in the initial sensing of viral components. TLR3 
recognizes dsRNA and may also be involved in sensing dsRNA released from dying 
cells. Detection of dsRNA by TLR3 in Dendritic cell requires phagocytosis of 
infected material (235). TLR7 and TLR8 are receptors for ssRNA associated with 
viruses that enter cells through endocytosis. TLR9 recognizes unmethylated CpG 
DNA present in DNA viruses such as herpesvirus. TLR4 may also be involved in the 
recognition of viral glycoproteins. These receptors are localized in the endosomal 
membranes, with the ligand binding domain facing the lumen of the endosomes, and 
the TIR signaling domain positioned on the cytoplasmic side (234, 236). 
 
1.11.4.2. Antiviral innate immunity induction by RIG-I and MDA5 
pathways: 
TLR3 was first identified as the main dsRNA receptor capable of inducing IFN 
expression. However, TLR3 was found not to be required in four different infectious 
viral models (lymphocytic choriomeningitis virus (LCMV), vesicular stomatitis virus 
(VSV), murine cytomegalovirus (MCMV), and reovirus) when TLR3 genetically 
deficient (-/-) mice were infected. This showed that TLR3 absence does alter either 
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viral pathogenesis or impair the host's generation of adaptive antiviral responses to 
these viruses (237). This led to the subsequent identification other crucial dsRNA 
sensors. These include cytoplasmic RNA helicases Retinoic acid – inducible gene I 
(RIG-I) and melanoma differentiation-associated gene (MDA5), which ensure that 
viruses that avoid recognition by TLRs in endosomal locations will still be detected 
by the innate immune system (238). RIG-I and MDA5 recognize a variety of RNA 
viruses and trigger innate antiviral responses independently from TLR dependent 
pathways. RIG-I is a member of the DExD/H box-containing RNA helicase family of 
proteins that unwind dsRNA in an ATPase dependent manner (238). The helicase 
domain of RIG-I can bind both synthetic dsRNA poly (I:C) and viral dsRNA. Besides 
the C-terminal helicase domain, RIG-I also contains two tandem caspase recruitment 
domains (CARDs) at its N-terminus. MDA5 has also been identified as a cytoplasmic 
DExD/H box RNA helicase sensor that activates innate antiviral immune responses. 
Like RIG-I, MDA5 also contains two N-terminal CARD domains which can activate 
the IFN-β promoter (239, 240). Through the CARD domain, both RIG-I and MDA5 
recruit an adaptor protein containing an N-terminal CARD, designated MAVS (also 
known as IPS-1, VISA, or Cardif) (238).  
Various studies have demonstrated that the IκB kinase (IKK) family members are 
critically involved in virus-triggered and MAVS mediated induction of type I IFNs. 
IKK-α and IKK-β are essential for virus-triggered NF-κB activation, the noncanonical 
IKK family members TBK1 and IKK3 are responsible for phosphorylating and 
activating IRF3 and IRF7 (241-243). The core complex of IKKs also contains the 
regulatory unit IKK-γ (called NEMO) protein (244). The NEMO protein is essential 
for ensuring the oligomerization state of the complex since without NEMO, the 
complex is inactive (245). MAVS can interact with tumour necrosis factor (TNF) 
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receptor-associated factor 6 (TRAF6) through its conserved TRAF6-binding motifs. 
MAVS mediated NF-κB but not IRF3 activation is diminished in TRAF6-deficient 
fibroblasts, suggesting that TRAF6 acts downstream of MAVS in the NF-kB but not 
IRF3-activation pathway (246). Finally, MAVS mediates the sequential recruitment 
and activation of TANK-binding kinase-1, inducible IκB kinase (IKK-ε), IFN 
regulatory factor 3 (IRF3) and NF-κB transcription factors leading to type I IFN 
synthesis and secretion (figure 1.9) (244, 245). 
Although the links between MAVS and these transactivators is not completely 
elucidated, recently many novel proteins have been discovered to be involved in the 
downstream signalling of IFN. In two independent studies,  a protein called stimulator 
of interferon genes (STING) (247) also called MITA (248) was identified as a 
significant component to this downstream pathway able to activate both NF-κB and 
IRF3 transcription pathways to induce expression of IFN-α and IFN-β and exert a 
potent anti-viral state following expression (247, 248). Experiments by both groups 
were able to show that STING localize to the outer membrane of mitochondria and 
interacts with both MAVS and RIG-I and is needed for transmission of virus-induced 
signals through these molecules. Both groups found that overexpression of STING 
activated IRF3, whereas knockdown of MITA inhibited virus-triggered activation of 
IRF3, expression of type I IFNs, and cellular antiviral response (247, 248). 
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Figure 1.9: Induction of IFN gene expression by dsRNA. On dsRNA binding within 
endosomes, TLR3 recruits the adaptor TRIF through a TIR–TIR interaction. TRIF, in 
turn, recruits RIP1 to activate NF- B, via TRAFs and the IKK (I B kinase) complex. 
TRIF also recruits TBK1/IKKε and TRAF3 to activate IRF3/7. RIG-I and MDA5 
recruits mitochondrially anchored MAVS, which, in turn, recruits appropriate IKKs 
to activate NF-κB and IRF, resulting in the induction of type I IFN. During an HCV 
infection, both TRIF and MAVS are cleaved and inactivated by the HCV NS3/4A 
protease. NS3/4A of HCV interrupts these pathways by cleavage of TRIF or MAVS. 
Figure adapted from Bode et al, 2007 (249). 
 
Recent work with different viruses has led to the suggestion that RIG-I and MDA5 
detect different subtypes of RNA ligands and this reflects virus-specific recognition 
by these helicases. For instance, when poly (I:C) is added to cells it activates TLR3, 
but when directly introduced into the cytoplasm, it preferentially activates MDA5, 
whereas RIG-I is activated by in vitro transcribed dsRNAs (250). Recently, it was 
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discovered that ssRNA with 5′ triphosphate (5′ppp ssRNA) is a ligand for RIG-I (251) 
(252). Thus, it could be defined that dsRNA and 5′ppp ssRNA are recognized by 
innate immune sensors as “nonself” RNA, whereas “self” RNAs escape from 
detection because of capping of the 5'-triphosphate end or by nucleoside modification 
of RNA, both occurring during posttranscriptional RNA processing in eukaryotes 
(252).  However, work conducted by Gale et al, has shown that 5'ppp is necessary but 
not sufficient for RNA binding by RIG-I and they identified a 100-nucleotide poly-
U/UC region of the HCV genome and replication intermediate RNA as a ligand of 
RIG-I signalling which is independent of MDA5, MyD88 or TRIF dependent PRR 
pathways (253). 
It has also become clear that RIG-I and MDA5 function differently in the recognition 
of RNA viruses (250, 254). RIG-I is essential for the production of interferons in 
response to RNA viruses including, influenza virus and Japanese encephalitis virus, 
whereas MDA5 is critical for picornavirus detection. The importance of MDA5 as an 
anti-viral protein had been suggested based on the finding that paramyxovirus V 
protein binds MDA5 and inhibits its function (250). In addition a recently discovered 
paramyxovirus Human metapneumovirus (HMPV), that causes a significant 
proportion of respiratory infections, activates the RIG-I/MAVS signalling pathway in 
airway epithelial cells, but MDA5 does not play a significant role (255). HMPV G 
protein was identified as virulence factor which inhibits the production of antiviral 
mediators by targeting RIG-I (255). 
 
1.11.4.3. Negative regulation of RIG-I/MDA5: 
The RIG-I/MDA5 signalling pathway is regulated by several specialized proteins 
which act as negative regulators and inhibitors of the JAK-STAT pathway. The 
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suppressor of cytokine signalling (SOCS) proteins specifically prevent STAT 
activation by binding to activated cytokine receptors, inhibiting the activity of JAKs, 
and targeting bound signalling proteins for proteasomal degradation (256).  The 
SOCS family proteins is comprised of eight members (SOCS-1 to SOCS-7 and CIS) 
all sharing a central SH2 domain and a C-terminal SOCS box. SOCS-1 and SOCS-3 
are the most effective members of this family and act as negative regulators of several 
intracellular pathways and particularly the Jak–STAT pathway. There is evidence that 
SOCS-1 and SOCS-3 inhibit the IFN-induced signal cascade and in hemopoietic 
tumour cells, overexpression of SOCS-1or SOCS-3 inhibits the antiproliferative and 
antiviral activity of IFN-α/β (257, 258) and also IFN-γ (259). Silencing either SOCS1 
or SOCS3 by small interfering RNA dramatically augments the production of IFN-γ 
in T cells. In chronically infected HCV patients, it has been shown that the HCV 
core/gC1qR-induced T-cell dysfunction involves the induction of SOCS (260). Recent 
studies showed a relationship between treatment failure and expression of SOCS3 in 
HCV patients who did not respond to type I IFN treatment, causing lack of response 
to IFN therapy (261, 262). 
Recent findings have identified tumour suppressor CYLD (cylindromatosis) as a 
negative regulator of RIG-I-mediated innate antiviral response. These results showed 
that expression of CYLD inhibits the IRF3 signalling pathway and IFN production 
triggered by RIG-I; in contrast CYLD knockdown enhanced the response. CYLD 
removes polyubiquitin chains from RIG-I as well as from TANK binding kinase 1 
(TBK1), the kinase that phosphorylates IRF3, coincident with an inhibition of the 
IRF3 signalling pathway (263). 
Recently several regulatory proteins of the RIG-I pathway have been identified. It has 
been demonstrated that RIG-I-mediated signalling is positively and negatively 
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controlled by ubiquitination of RIG-I and this ubiquitination is necessary for efficient 
activation of the RIG-I signalling pathway (264, 265). CARD domains of RIG-I 
undergo Lys 63-linked ubiquitination by tripartite motif (TRIM) 25, a ubiquitin E3 
ligase composed of a RING finger domain, a B box/coiled-coil domain and a SPRY 
domain (265). TRIM25−/− cells showed impaired production of type I IFNs against 
viral infection. RIG-I also undergoes ubiquitination by the ubiquitin ligase RNF125, 
which leads to its proteasomal degradation (264).  
As described before LGP2, which lacks a CARD, also function as a negative regulator 
of RIG-I/MDA5 signalling. LGP2 contains repressor domain (RD), which interact 
with the RD of RIG-I and suppress its self-association (266). Overexpression of Lgp2 
inhibits Sendai virus and Newcastle disease virus signalling to IFN-stimulated 
regulatory element- and NF-κB-dependent pathways (239, 267). LGP2 is a negative 
regulator of RIG-I, but not of MDA5 (268). Lgp2-/- mice exhibited resistance to 
lethal VSV infection, by an enhanced RIG-I response to viral replicative 
intermediates, which triggers an increase in the production of type I IFN. However, 
mice lacking LGP2 were observed to exhibit a defect in type I IFN production in 
response to infection by the encephalomyocarditis virus (EMCV), the replication of 
which activates MDA5-dependent innate immune responses (268). These results 
showed that that both poly (I:C) and EMCV are recognized by MDA5. 
 
1.11.4.4. HCV innate immune response evasion: 
Persistence of HCV infection reflects its ability to disrupt virus-induced signalling 
pathways activating cellular antiviral defenses. As mentioned above, NS3/4A can 
inhibit IRF3 phosphorylation and activation (269). Different studies demonstrated that 
NS3/4A has the ability to inhibit both TLRs and RIG-I mediating signalling pathways 
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(230). NS3/4A cleaves Toll-IL-1 receptor domain which contains an adaptor-inducing 
interferon-β (TRIF or TICAM-1) by specific proteolysis (270, 271). Another study 
demonstrated that HCV NS3/4A interacts directly with (TANK-binding kinase-1) 
TBK1, and that binding inhibits the association between TBK1 and IRF-3, leading to 
the inhibition of IRF-3 activation (272). 
In a similar way, NS3/4A disrupts the RIG-I pathway through proteolysis of essential 
signalling components of IRF-3 activation (269). Two independent studies have 
shown that HCV NS3/4A protease cleaves MAVS to block RIG-I signalling (273, 
274). This cleavage by NS3/4A results in subcellular redistribution of MAVS and loss 
of interaction with RIG-I which preventing downstream activation of IRF-3 and IFN-
β induction (273). 
Interferon (IFN) therapy is the current therapy for chronic HCV infection, either IFN 
alone or in combination with ribavirin. Approximately 70% of patients infected with 
type 1b HCV are non-responders in terms of viral elimination (275). 
Studies to elucidate the mechanism influencing IFN sensitivity in HCV infected cells 
may be crucial for improving the strategy of IFN therapy. Consequently, the study of 
the HCV genotype specific IFN responses by comparing the effects of the genotype 
2a full-length JFH-1 genome and genotype 1b proteins on IFN signalling pathways 
should lead to a greater understanding of the mechanisms of IFN signalling 
suppression. By elucidating the innate immune response induction pathways, it is 
possible that new strategies that modify these pathways could lead to the development 
of novel antiviral agents against HCV. 
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1.12. Aims of Project: 
 
 Examine the expression and activity of key innate immune response proteins 
including TLRs, RIG-I, MDA5, TRIF, MAVS and MyD88 in the presence and 
absence of HCV NS proteins in RNA replicons and HCV infected cells.  
 Identify possible novel innate response proteins that are up or down regulated 
by IFN-α, in RNA replicons and HCV infected cells, by microarray analysis. 
 Identification of the IFN components in the regulation of innate immune 
reponses such as apoptosis, oxidative stress and cell cycle regulation. 
 Examine the roles of interferon response pathway proteins to HCV expression 
by using RNAi to knock out the expression of individual host genes, in 
particular TLRs, RIG-I, MDA5, TRIF, MAVS and MyD88 in RNA replicons 
and HCV infected cells. 
 Compare the effects of expressing NS3, and other HCV NS proteins from 
different genotypes on the interferon response pathway, in liver cell lines.  
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CHAPTER TWO:  
2. MATERIALS AND METHODS 
2.1. Materials 
2.1.1. Molecular biological reagents 
2.1.1.1. Chemicals and Molecular biological reagents 
Agarose (Molecular biological grade, 
Invitrogen)  
4% agarose stock was prepared by 
dissolving 4µg of agarose and in 100 ml 
distilled sterile water. The solution was 
autoclaved at 121°C for 20 minutes to 
sterilize. Before use the solution was 
equilibrated at 65°C in a water bath. 
DEPC water Milli Q water treated with 0.1% v/v 
diethylpyrocarbonate (DEPC) (Sigma) 
for at least 1 hour at 37°C and then 
autoclaved (at least 15 min) to inactivate 
traces of DEPC 
EDTA solution 0.5M EDTA in Milli Q water pH 8.0.                                         
Ethidium bromide stock          10mg/ml ethidium bromide in sterile 
Milli Q water 
MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide; Thiazolyl 
blue (Sigma) 
5mg/ml MTT stock solution was 
prepared in PBS. The solution filtered 
by syringe and stored at +4°C 
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Paraformaldehyde  4% paraformaldehyde solution: 4g of 
paraformaldehyde was dissolved in 100 
ml PBS. 
Phosphate Buffered Saline (PBS) 137mM NaCl, 2.7mM KCl, 4.3mM 
Na2HPO4•7H2O, 1.4mM KH2PO4. (pH 
7.1). Or prepared by dissolving 1 PBS 
tablet (Sigma) per 200 ml Milli Q water. 
Autoclave to sterilize 
PCR dNTPs (50x stock) 10mM each of dATP, dTTP, dCTP, 
dGTP (Promega) in                                                   
water and stored at -20C. 
Phenol: Chloroform     Phenol : Chloroform : Isoamyl alcohol 
125:24:1, pH 4.7 
Sodium Acetate 3M Sodium Acetate in distilled water. 
Adjust pH to 5.2 with glacial acetic 
acid. Autoclave to sterilize. 
TAE Buffer (50x)  2M Tris base, 50mM EDTA, 5.71% 
(v/v) acetic acid. 
TBE Buffer (5x)   
 
0.9M Tris base, 0.9M boric acid, 25mM 
EDTA. 
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TE buffer 10mM Tris-HCl pH 7.5, 1mM EDTA 
Triton X-100 (Sigma) 0.1% (v/v) Triton X-100 in PBS 
2.1.1.2. Tissue culture materials and reagents 
Dulbecco‟s Modification of Eagle‟s 
Minimum essential medium (DMEM) 
(GIBCO, Invitrogen) 
DMEM growth media supplemented 
with 2mM L-glutamine, 10% Fetal 
Calf Serum (FCS), 100 IU/ml 
penicillin and 100g/ml 
streptomycin 
Fetal Calf Serum (FCS) (Invitrogen) Inactivation of complement in FCS 
was achieved by incubation at 56C 
for 60 minutes 
Trypsin-EDTA (TE) (GIBCO, Invitrogen) 10x (TE-EDTA) 
Penicillin-Streptomycin (GIBCO, 
Invitrogen) 
10,000 units penicillin; 10,000µg 
streptomycin) 
2.1.1.3. Reagents used for transfection purposes and assays preformed 
prior to transfection: 
Lipofectamine 2000 Invitrogen  
OptiMEM Invitrogen 
Trizol Invitrogen 
Geneticin (50mg/ml) Invitrogen 
Lipopolysaccharide (LPS) (E. coli O111:B4) Sigma  
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poly (I:C) 10μg/ml. (polyinosinic-polycytidylic acid dsRNA) Sigma 
2.1.1.4. Bacterial growth media 
Luria Broth (LB) 1% (w/v) tryptone, 0.5% (w/v) yeast 
extract, 1% (w/v)  NaCl 
Luria Broth agar (LBA) Bacto-agar added to 1.5% (w/v) to LB 
SOC medium 2% Tryptone, 0.5% Yeast Extract, 
10mM NaCl 
2.5mM KCl, 10 mM MgCl2, 10mM 
MgSO4 
20 mM glucose 
2.1.1.5. FACS analysis solutions 
Propidium iodide (PI) (Sigma) 200 mg of PI was dissolved in 10 ml of 
PBS, aliqouted into 1.5 Eppendorf tubes 
and kept at -20 °C in the dark. 
Ribonuclease A (RNase A) (Sigma).  1:100 RNase A (50µg/ml) 
Staining buffer PBS, pH 7.4-7.6 
2% (v/v) heat inactivated FCS 
0.2% (w/v) sodium azide 
4% paraformaldehyde (fixation buffer) 
 
14 ml 10x PBS 
10.8 ml 37.5% formaldehyde 
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75.2 ml PBS 
Permeabilization (PERM) buffer 
 
FACS staining buffer + 0.5% saponin 
(Sigma S-2149) 
SUPERPERM buffer 
 
75% (v/v) PERM buffer, + 25% (v/v) 
FCS (filtered) 
2.1.1.6. SDS-PAGE 
Protein lysis buffer 
 
 
 
 
 
 
50mM Tris, 150mM NaCl pH 7.4. 1% (v/v) 
NP40, 2.4M Sodium deoxy cholate, 1% (v/v) 
Triton X-1-00, 100mM Ethylene glycol-bis 
(- Aminoethylether)-N-N-N‟-N‟- Tetra 
acetic acid (EDTA).  Made up to 100ml and 
stored at 4oC.  
Protease Inhibitor Cocktails Protein inhibitor: 0.1% of inhibitors cocktail 
(20mM Phenylmethylsulfonyl fluoride 
(PMSF),  20mM Sodium orthovanadate 
(Na3VO4), 20mM NAF, 0.5mM Aprotinin, 
0.01mM Leupeptin, 0.5mM Pepstatin) 
 
SDS-PAGE separation gel  30% w/v acrylamide, 0.8 % w/v bis-
acrylamide (National Diagnostics) 1.5M 
Tris-HCl,  pH8.8, 0.1% (w/v) Sodium 
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dodecyl sulphate (SDS) 0.1% (w/v) 
ammonium persulphate (APS) 0.5% (v/v) 
N,N,N‟,N‟-tetramethyl-ethylenediamine  
(TEMED). 
SDS-PAGE stacking gel   30% w/v acrylamide, 0.8 % w/v bis-
acrylamide (National Diagnostics), 1M Tris-
HCl,  pH6.5 0.1% (w/v) SDS 0.1% (w/v) 
ammonium persulphate (APS) 0.5% (v/v)  
N,N,N‟,N‟-tetramethyl-ethylenediamine 
(TEMED).  
10x SDS-PAGE Gel Running 
Buffer  
25mM Tris, 192mM Glycine, 3.5mM SDS 
(National Diagnostics). 
2.1.1.7. Western blot reagents 
APS 10% (w/v) (ammonium per 
sulphate) 
0.5g in 5ml of water, aliquoted  and stored 
at -20°C  
10x Tris –EDTA reducing buffer  
 
Prepared by adding: 10% (v/v) Beta-
mercaptoethanol, 0.5M Tris HCl, 8% (w/v) 
SDS. Aliquots and stored -20°C. 
Bromophenol- blue/glycerol 
 
0.02% Bromophenol blue in EDTA = 5ml.  
5ml glycerol + 5ml bromophenol blue 
Transfer Buffer                                 25mM Tris, 192mM Glycine, 20% (v/v) 
Methanol   
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PBS/Tween buffer solution 1x PBS/0.1% (v/v) Tween 
PBS/Tween/skimmed 1x PBS/0.1% (v/v) Tween/2% (w/v) 
skimmed milk 
2.1.2. Kits used in experiments 
MEGAscript kit (Ambion)                   
DNA-free Kit (Ambion) 
First-Strand cDNA Synthesis (Invitrogen) 
ECL Western blotting detection reagents and analysis system (Amersham 
Biosciences) 
QuantiTect
™ 
SYBR
®
 Green PCR (QIAGEN) 
QIAquick PCR Purification Kit (QIAGEN) 
QIAquick Gel Extraction Kit (QIAGEN) 
HiSpeed Plasmid Midi Kit (QIAGEN) 
ViraPower Adenovirus Expression System (Invitrogen) 
pAd/CMV/V5-DEST vector (Invitrogen)  
LR Clonase enzyme (Invitrogen) 
2.1.3. Molecular weight markers  
100bp DNA ladder (Promega): contains DNA molecules of 100, 200, 300, 400, 500, 
600, 700, 800, 900, 1000, and 1500 base pairs. (Appendix 1) 
1000bp DNA ladder (Promega): contains DNA molecules of 250, 500, 750, 1000, 
1500, 2000, 2500, 3000, 4000, 5000, 6000, 8000 and 10000 base pairs. (Appendix 1) 
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RNA marker (Ambion): contains RNA molecules of 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, and 
9 kilobases. (Appendix 1) 
SDS-PAGE prestained molecular weight marker (Invitrogen). (Appendix 1) 
 
2.1.4. Oligonucleotides 
Oligonucleotides were synthesized by Invitrogen. The primers were dissolved in 
distilled water at a concentration of 100µM and stored at –20ºC.  
 
2.1.4.1. DNA primers for qRT-PCR of innate immune response genes: 
Table 2.1 primers used in qRT-PCR for innate immune response genes. Sequences, 
gene accession numbers and PCR product size are detailed. 
 
Target 
gene 
Primers sequences Accession 
number 
PCR 
product  
size 
TLR3-F 5- CCGCCAACTTCACAAGGTAT NM_003265 130 bp 
TLR3-R 5-AGCTCATTGTGCTGGAGGTT   
TLR7-F 5- GCTCTGTGGGAGTTCTGTCC NM_016562 129 bp 
TLR7-R 5- ACCGTTTCCTTGAACACCTG   
TLR8-F 5-TGAAGCACATCCCAAATGAA NM_138636 126 bp 
TLR8-R 5-GCAACTCGAGACGAGGAAAC   
MDA5-F 5-GGGGCATGGAGAATAACTCA AF095844 132 bp 
MDA5-R 5- TGCCCATGTTGCTGTTATGT   
RIG-I-F 5- GTTGTCCCCATGCTGTTCTT NM_014314.3 124 bp 
RIG-I-R 5- GCAAGTCTTACATGGCAGCA   
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MAVS-F 5-GGGTAAACAGGGTGCAGAGA NM_020746 129bp 
MAVS-R 5-ACAGGCATCAAGGTGGTAGG   
TRIF-F 5- TCCTCCTCCTCCTCCTTCAT AB093555 120 bp 
TRIF-R 5- GCGTGGAGGATCACAAAGTT   
MyD88-F 5- GCACATGGGCACATACAGAC NM_002468 132bp 
MyD88-R 5- TAGCTGTTCCTGGGAGCTGT   
IFN-β-F 5-GACATCCCTGAGGAGATTAAGCA NM_002176 130bp 
IFN-β-R 5-CAACAATAGTCTCATTCCAGCCA   
JFH-1 F 5-TCTGCGGAACCGGTGAGTA AB047639 131bp 
JFH-1 R 5-TCAGGCAGTACCACAAGGC   
GAPDH 5-TCTCTGCTCCTCCTGTTCGAC 
 
NM_002046 118 
GAPDH 5-CGGATTTGGTCGTATTGGG   
 
2.1.4.2. Primers sequences for AdNS3 and AdNS3/4A construction:  
Table 2.2: primers used in cloning NS3 and NS3/4A genes which were amplified 
with PCR using high fidelity Taq polymerase for cloning into TOPO vector. 
Primer Name Sequence 
NS3 1a F CACCATGGCGCCCATCACGGCGTA  
NS3 1b F CACCATGGCGCCTATTACGGCCTA  
NS3 2a F CACCATGGCTCCCATCACTGCT  
NS3 1a R CGTGACGACCTCCAGCA  
NS3 1b R CGTGACGACCTCCAGGTCAG  
NS3 2a R GGTCATGACCTCAAGGTCAGC  
NS3/4A 1 R GCACTCTTCCATCACATCG  
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NS3/4A 1b R GCACTCTTCCATCTCATCG  
NS3/4A 2a R GCATTCCTCCATCTCATC  
Bold italic: start codon 
Underline: “CACC” topoisomerase recognition directional cloning sequence. 
 
2.1.4.3. Primers used for plasmids sequencing:  
Table 2.3 primers used for sequencing insert in vectors that were used for, NS3 and 
NS3/4A constructs. 
Vector Primer Sequence 
pENTR TOPO M13 forward 5‟ GTAAAACGACGGCCAGT3 
pENTR TOPO M13 reverse 5‟ GGAAACAGCTATGACCATG  
pAd/CMV/V5-DEST T7 promoter 5′ TAATACGACTCACTATAGGG 
2.1.4.4. Primers used for adenovirus quantitation: 
Table 2.4 primers used in quantifying NS3 and NS3/4A genes which cloned into 
adenovirus vectors. 
Primer Sequence 
NS3-2a qRT-PCR forward  GGCGCCATAGTGGTGAGTAT 
NS3-2a qRT-PCR reverse  TCCGTGGTAAACAGTCCACA 
NS3-1a qRT-PCR forward  AGGGCTACAAGGTGTTGGTG 
NS3-1a qRT-PCR reverse  GGCTGCCAGTGGTAATTGTT 
NS3-1b F qRT-PCR forward 5‟ ATGGCGCCTATTACGGCCTA 
NS3-1b R qRT-PCR reverse 5‟ ACACACGCCATTGACGCAGG 
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2.1.4.5. Synthetic siRNAs sequences duplexes used for RNAi work: 
Table 2.5 siRNAs used in RNAi for various genes knockdown and their sequences. 
 
Target gene Sequence Position 
RIG-I sense 5- GGAAGAGGTGCAGUAUAUUuu 263-281 
RIG-I antisense 5- AAUAUACUGCACCUCUUCCuu   
MDA5 sense 5- GGUGAAGGAGCAGAUUCAGuu 345-362 
MDA5 antisens 5- CUGAAUCUGCUCCUUCUCCuu  
MAVS sense 5'-UAGUUGAUCUCGCGGACGAuu 411-429 
MAVS antisense 5- UCGUCCGCGAGAUCAACUAuu  
TRIF sense 5- GACCAGACGCCACTCCAACuu 1238-1259 
TRIF antisense 5-GUUGGAGUGGCGUCUGGUCuu  
MyD88 sense 5'AAGGCAAUGAAGAAAGAGUUCuu 995-1015 
MyD88 antisense 5-AACUCUUUCUUCAUUGCCUUuu  
SOCS3 sense 5-UGAUUUGGUUUAAACCUGAtt 1484-1502 
SOCS3 anti sense 5-UCAGGUUUAAACCAAAUCAaa  
Non-Targeting 1  5-GAUCAUACGUGCGAUCAGAtt  
 5-UCUGAUCGCACGUAUGAUCtt  
 
 
2.1.4.6. Primers used for microarray validation work: 
Table 2.6 primers used in qPCR for microarray validation work and their sequences 
and PCR products size. 
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Target gene Primers sequences Accession 
number 
PCR 
products 
size 
SOCS1 F GACCCCTTCTCACCTCTTGA NM_003745.1 116 
SOCS1 R TAGGAGGTGCGAGTTCAGGT   
SOCS2 F AGGGACTCGTTTTGGGATTC NM_003877 111 
SOCS2 R GGGTCATGAGAGAAGGGTCA   
SOCS3 F AGTTGTGTGTTGGGGTGGTT NM_003955.3 178 
SOCS3 R TAGCCTCAAGGGCCTGAGTA   
IRF1 F ACCCTGGCTAGAGATGCAGA NM_002198                131 
IRF1 R AGGCATCCTTGTTGATGTCC   
IRF9 F (ISGF3) ATGGATGTTGCTGAGCCCTA NM_006084                140 
IRF9 R (ISGF3) ATGGCATCCTCTTCCTCCTT   
CCNB1 F ATAAAGCTTGTGGCCCCTTT NM_031966 149 
CCNB1 R TCAATTGGATCCCCAGGTAA   
CDC25C F ATGCATCATCAGGACCACAA NM_001790    139 
CDC25C R GCCAGTGGCTGGAATGTTAT   
GADD45-α F GGCCCGGAGATAGATGACTT NM_001924 120 
GADD45-α R TTTTCCTTCCTGCATGGTTC   
GADD45-β F ACAGTGGGGGTGTACGAGTC NM_015675 127 
GADD45-β R GGATGAGCGTGAAGTGGATT   
SKP2 F GCTGAAGAGCAAAGGGAGTG NM_005983 137 
SKP2 R GGAGGCACAGACAGGAAAAG   
MxA1 F CCACATCCCTTTGATCATCC NM_002462                111 
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MxA1 R TTCAGGAGCCAGCTGTAGGT   
OAS3 F TGCTGTGTACCCAAGAGCAG NM_006187 117 
OAS3 R GGGATCTGAGACAGGTCCAA   
IFNAR2 F GTGAGCAGTGGAGAGAAGGG NM_207585.1  121 
IFNAR2 R GGAATTCCAATTGCAGGAGA   
STAT1 F CAGCTGAACATGTTGGGAGA NM_007315 120 
STAT1 R CCAAAGCCAGAAGGGAAAAT   
STAT2 F AAGCACTGCTAGGCCGATTA NM_005419                132 
STAT2 R ACCATGTCTCCAGCTGTTCC   
IFNAR1 F AGGCAGTTGCATTCCACTCT NM_000629                124 
IFNAR1 R TACCCCCAAGTGCATGGTAT   
PIAS1 F TCCACATCAAGCATCTCCAG NM_016166                125 
PIAS1 R AGTCGTAAGGCATGGGTGTC   
PIAS2 F AGTTTGGATGGTGGCTCATC NM_173206                122 
PIAS1 R TGAAGCAGCACAGAACCAAC   
 
2.1.5. Antibiotics: 
Antibiotics used for bacterial cell culture were purchased from Sigma. Antibiotics 
were made as stock solutions 1000 times the working concentration, filter sterilized 
(0.2m) and were stored as aliquots at -20C. The autoclaved media were cooled to 
45C prior to addition of antibiotic. 
1000x antibiotic stock solutions: 
Ampicillin: 50mg/ml in Milli Q water. 
Kanamycin 25mg/ml in Milli Q water. 
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2.1.6. Antibodies for immuneflorescence staining and Western blotting: 
Table 2.7 Antibodies used in immuneflorescence staining and Western blotting and 
their concentration used during the experiments. 
Antibody Isotype Supplier Working 
concentration 
Polyclonal sera 
NS3-7 
Rabbit IgG Raised against the 
NS3 peptide 
FIPVENLETTMRS 
(amino acids 1195 
– 1207). Wardell et 
al, 1999 (88) 
1:40 
Anti V5 Mouse IgG Invitrogen  1:1000 
Anti GADD45-β Mouse IgG  Guido Fransozo 
(Department of 
Medicine, Imperial 
College). 
200ng/mL 
Anti cyclin B1 Mouse IgG1 Santa Cruz 
Biotechnology. 
200ng/mL 
Anti tubulin Mouse IgG1 Sigma 1:10000 
Anti core  Mouse IgG Abcam  IF: 1:400 or WB: 
2µg/ml 
Anti NS3 Mouse IgG Novagene IF: 1:100 or WB: 
2µg/ml 
 86 
Anti NS5A Sheep IgG Mark Harris, 
University of Leeds 
1:100 
Anti rabbit Sheep  IgG-HRP Sigma 1:2000 
Anti mouse  Goat IgG-HRP Sigma  1:2000 
anti-rabbit  AlexaFluor 488-
conjugated IgG 
Invitrogen 1:1000 
anti-mouse  AlexaFluor 594-
conjugated IgG 
Invitrogen 1:1000 
 
2.1.7. Restriction enzymes: 
Table 2.8 restriction digestion enzymes used in plasmids cloning and their incubation 
time, temperature and concentration. All enzymes were from commercial suppliers. 
Enzyme Source Incubation conditions Concentration
/dilution 
EcoRI Promega  Buffer H. 37°C. 4 h 1μl (10u/μl) 
BamHI Promega  Buffer E. 37°C. 4 h 1μl (10u/μl) 
HindIII Promega  Buffer E. 37°C. 4 h 1μl (10u/μl) 
PacI New England Biolab 1X NEB buffer 1. 37°C. 18 h 2.5μl (10u/μl) 
 
2.1.8. X-Ray film: 
X-OMAT AR film was used for Western blots and BioMax MR was used for all 
radiography, both were from VWR. 
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2.1.9. Cell lines: 
2.1.9.1. Bacterial Cells: 
Table 2.9: The following strains of chemically component E.coli cells were purchased 
from Invitrogen: 
 Cells  Genotype Characteristics 
Subcloning Efficiency  DH5α F- φ80lacZΔM15 Δ(lacZYA-argF)U169 
recA1 endA1 hsdR17(rk -, mk +) 
phoAsupE44 thi-1 gyrA96 relA1 λ- 
MAX Efficiency DH5α F- φ80lacZΔM15 Δ(lacZYA-argF) U169 
recA1 endA1 hsdR17 (rk-, mk+) phoA 
supE44 λ- thi-1 gyrA96 relA1 
Competent TOP10 F- mcrA Δ(mrr-hsdRMS-mcrBC) 
80lacZΔM15 ΔlacX74 recA1 araD139 
Δ(araleu) 7697 galU galK rpsL (StrR) 
endA1 nupG 
INVαF´ F´ endA1 recA1 hsdR17 (rk-, mk+) 
supE44 thi-1 gyrA96 relA1 
φ80lacZΔM15 
Δ(lacZYA-argF)U169 λ- 
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2.1.9.2. Mammalian cell lines: 
Table 2.10 cells lines used during the experiments. 
Cells  Characteristics 
Huh7 A differentiated human hepatoma cell line established 
from a hepatocellular carcinoma (276). Huh7 cells were a 
gift from John Monjardino (277) 
Huh7.5 Derivative of Huh7 contained defective RIG-I mutant 
pathway. Highly permissive to replicate HCV than in the 
parental Huh7 cells (278). Huh7.5 cells were a gift from 
Charles Rice (Rockefeller University, USA). 
HEK293A A subclone of the 293 Cell Line. The 293 cell line is a 
permanent line established from primary embryonal 
human kidney transformed with sheared human 
adenovirus type 5 DNA (279) (280).  
Rep4 Huh7 cell lines carrying S1179I HCV subgenomic 
replicons. Produced in Dr McGarvey‟s laboratory 
(Department of Medicine, Imperial College). 
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2.1.10. Plasmids 
Table 2.11 plasmids used during the experiments. 
Plasmid Source 
pHCV JFH-1 isolate  Dr Takaji Wakita (Tokyo Metropolitan 
Institute for Neuroscience, Tokyo, Japan.).  
pHCV 1a, isolate H77 Dr. Charles Rice (Rockefeller University, 
New York USA). 
pHCVrep1bBB7 (S1179I) Dr. Charles Rice (Rockefeller University, 
New York USA). 
pCR®2.1 Invitrogen  
pENTR TOPO Invitrogen   
pAd/CMV/V5-DEST Invitrogen   
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2.2. Methods 
2.2.1. Cells Culture methods 
2.2.1.1. Growth and maintenance: 
Huh-7, Huh7.5 and 293A cell lines were routinely grown in Dulbecco‟s Modification 
of Eagle‟s Minimum essential medium supplemented with 1X nonessential amino 
acids, 100 unit/ml penicillin, 100μg/ml streptomycin and 10% Fetal Calf Serum 
(FCS). Inactivation of complement in FCS was achieved by incubation at 56C for 60 
minutes. 10x Trypsin-EDTA (TE-EDTA) was also purchased from Invitrogen. Cells 
were grown as a monolayer in 25, 75 or 175 cm
2
 sterile tissue culture flasks in humid 
incubators at 37°C and 5% CO2. Once the cells had reached confluence, growth 
medium was removed and the cells were washed once with sterile PBS pre-warmed at 
37°C. 1X Trypsin-EDTA solution was added and incubated at 37°C until cells began 
to detach from the flask. Trypsin activity was neutralized by the addition of 5 volumes 
of DMEM contains 10% FCS and the cells were transferred to 15 ml sterile falcon 
tubes and spun for 5 minutes at 400 x g. The supernatant as discarded to remove dead 
cells and the pellet resuspended in DMEM and pipetted up and down until a 
homogenous cell suspension was achieved. An aliquot was transferred to a new flasks 
containing fresh DMEM with 10% FCS and then incubated at 37°C. Cells were 
passaged two or three times per week by adding them at a ratio of 1:4-1:8 and 
transferring them to new flasks depending on the growth characteristics of each 
individual cell line.  
Huh7 cell lines carrying S1179I HCV subgenomic replicons (Rep4) were grown in 
DMEM with the supplements indicated above plus 500μg /ml G418 (geneticin, 
GIBCO/ Invitrogen). 
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2.2.1.2. Stimulation of cells with LPS and poly I:C 
Huh7 and replicon cells were seeded into 6 wells or 24 well plates and allowed to 
grow until 60 - 70% confluent. Cells were then stimulated either by the addition of 
100ng/ml of LPS (E. coli O111:B4, Sigma) or poly (I:C) 10ng/µl. At specified times 
post-stimulation, cells were lysed and RNA extracted using TRIZOL /chloroform 
method as described below and genomic DNA digested. 
 
2.2.2. Preparation of real-time PCR samples: 
2.2.2.1. RNA extraction: 
The cells were plated in six well plates and treated with the appropriate stimulus. The 
medium was removed and 0.5ml Trizol (Invitrogen) was added and left for 5 minutes 
to allow for complete dissolution of the cells. The Trizol system uses a formulation of 
guanidinium thiocyanate and urea together with a phenol solution. The Trizol cell 
extract solution was then mixed by pipetting up-and-down and then placed in a 1.5ml 
Eppendorf tube. 250l of chloroform were added and the mixture was shaken 
vigorously for 15 seconds and incubated at room temperature for 5 minutes. The 
organic and aqueous phases were separated by centrifugation at 12,000g for 15 
minutes at 4ºC. The aqueous phase (top layer) was then transferred to a new tube and 
the RNA was precipitated by the addition of an equal volume of isopropanol. The 
mixture was incubated at room temperature for 15 minutes and then centrifuged at 
12,000g for 30 minutes at 4ºC. The RNA pellet was washed with 70% ethanol and 
resuspended in 50l of DEPC-treated water and stored at –80ºC until further use.  
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2.2.2.2. DNAse treatment: 
This was carried out by using a DNA-free Kit (Ambion). 3µl of 10x volume DNase I 
buffer and 1μl of DNase I (2units) were added 1-5µg RNA in 30µl reaction, mixed 
gently, and incubated at 37
o
C for 20-30 minutes. 0.1 volume of DNase Inactivation 
Reagent was added to the mixture, which was then vortexed, and incubated for 2 
minutes at room temperature. The tube was centrifuged at 10,000 x g for 1 minute to 
pellet the DNase Inactivation Reagent and the RNA was then transferred to a new 
tube. 
2.2.2.3. Agarose gel electrophoresis of RNA 
The horizontal gel electrophoresis apparatus used for DNA gels was also used for 
RNA gels but the apparatus was pre-treated to remove RNases which could degrade 
the RNA. Pre-treatment involved washing the apparatus with detergent and Milli Q 
water, then soaking it with a 3% (v/v) hydrogen peroxide solution (using a 30% (v/v) 
stock H202 solution and diluted in DEPC treated water). Lastly the hydrogen peroxide 
was washed off with DEPC water and the apparatus was left to air dry before use. 
RNA gels were prepared in a similar way to DNA gels, 1% (w/v) agarose in 1x TAE 
buffer (made and diluted with DEPC treated water) was melted in a microwave oven, 
5g/ml ethidium bromide was added, it was allowed to cool to 65C and then poured 
into the assembled apparatus taking care not to introduce air bubbles. Once the gel 
had set it was covered to a depth of 5mm of appropriate 1x buffer (diluted in DEPC 
treated water) and the combs removed to reveal the wells. 5µl of RNA samples were 
added to 5µl of glycerol based loading buffer (glycerol: DEPC water (50% v/v) and 
the mixture was carefully pipetted into the wells. 1x agarose gel sample buffer (which 
contained blue tracking dye) was added to the last well of the gel and the gel was run 
at constant voltage of 80 volts (or at a constant current of 100mA until the sample, as 
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indicated by the position of the blue tracking dye present in the agarose sample 
buffer) had migrated to the end of the gel. The bands were visualized on a UV 
transilluminator and photographed.  
2.2.2.4. Primer design: 
Primers were designed using Primer3 software (available online at: 
http://www.broad.mit.edu/cgi-bin/primer/primer3_www.cgi/) and had a low 
probability of forming duplexes and hairpin loops using Oligo6 software (available 
online at: http://www.oligo.net). All primers were tested for specificity using standard 
PCR with total cDNA obtained from Huh7 or HCV RNA replicon cell RNA. These 
PCR products were characterized by agarose gel (1%) electrophoresis.  
2.2.2.5. First-strand cDNA synthesis using M-MLV RT 
RNA was extracted from mammalian cells and cDNA was synthesized by MMLV 
reverse transcriptase (Promega). In a nuclease-free microcentrifuge 1.5 ml tube: 1µl 
of 50µM oligo (dT) and 2µg total RNA were combined. The mixture was heated to 
65
o
C for 5 minutes and quickly chilled on ice. The following were added to the 
contents of the tube: 5µl 5x MMLV Buffer, 2µl 0.1 M DTT, and 1µl RNasin (40 
units/µl) (Promega) and 1µl 10 mM dNTP Mix. The mixture was then mixed gently 
and incubated at 37
o
C for 2 minutes. 1µl (200 units) of MMLV RT was added to the 
mixture and mixed by gently pipetting up and down. The tubes were then incubated at 
37
o
C for 50 minutes. The reactions were inactivated by heating at 70
o
C for 15 
minutes. Subsequently, 900ng of the first-strand cDNA was used for PCR. 
2.2.2.6.  Polymerase Chain Reaction (PCR): 
PCR was performed by using specific sets of primers (table 2.1) separately in 
individual reactions for each sample. In a sterile Eppendorf tube, a mastermix 
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prepared by adding 5µl 10X Red Taq (NH4) polymerase buffer (Biolone), 1µl of 
2mM MgCl2, 1µl (100M each dNTPs, 10pmole of each primer) and 1 units of Red 
Taq polymerase (Bioline) and the volume adjusted to 50l with HPLC water. Red 
Taq polymerase has a nontemplate-dependent terminal transferase activity that adds a 
single deoxyadenosine (A) to the 3´ ends of PCR products. This allows PCR inserts to 
be ligated into the vector which has single overhanging 3´ deoxythymidine (T) 
residues, as described below in section 2.2.2.7.  
Reaction tubes were then placed in a thermal cycler (The GeneAmp® PCR System 
9700, Applied Biosystem) and the DNA template was melted at 94C for five minutes 
and then amplified by 30 rounds of 1 minute at the annealing temperature between 55-
60C for 1 minute at 72C (elongation step), and 1 minute at 94C (denaturation step). 
Following the final annealing step, the polymerization was allowed to proceed for 7 
minutes to minimize the formation of single strands at the ends of the amplified DNA 
molecules. The PCR products were stored at -20C and 10l analysed by agarose gel 
electrophoresis. To avoid PCR contamination negative PCR controls were always 
included. If these gave positive results, then the experiment and reagent aliquots were 
discarded. 
2.2.2.7. Cloning into pCR2.1: 
PCR products of each target gene plus β-actin that showed single, clear and distinct 
bands of the correct predicted size bands were then ligated separately into pCR2.1 by 
TA cloning (TA cloning kit, Invitrogen) and transformed into INVα competent cells 
overnight. TA cloning provides a highly efficient cloning strategy were used for the 
direct insertion of Taq polymerase-amplified PCR products into a plasmid vector. The 
plasmid vector pCR2.1 was linearized and contains overhanging 3´ deoxythymidine 
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(T) that allows PCR inserts produced previously Red Taq polymerase to be ligated 
efficiently using T4 DNA ligase. In a 0.2ml sterile PCR tube 10µl ligation reactions 
were performed by adding 1µl fresh PCR product, 1µl 10x ligation buffer, 2µl 
pCR2.1 vector (25ng) and 1µl T4 DNA ligase enzyme then the reaction was 
completed to 10µl final total volume with sterile water. The tubes were incubated at 
14°C overnight. Next day, 2µl of each ligation reaction was directly pipetted into a 
vial of 50µl INVαF´ E.coli competent cells for transformation. The cells were 
incubated on ice for 30 minutes and then heat shocked the cells for 30 seconds at 
42°C without shaking. Immediately, the vials were transferred to ice. 250µl of SOC 
medium were added to each vial and incubated in shaking horizontally at 37°C for 1 
hour at 225 rpm in an orbital incubator. Finally, 50µl to 200µl from each 
transformation vial were spread on LB agar plates containing X-Gal and 50µg/ml of 
kanamycin.  
The next day, white colonies on X-Gal plates were selected and into 50ml tubes 
containing 5ml of LB plus 50µg/ml kanamycin were inoculated with individual 
bacterial colonies. The tubes were incubated at 37°C with shaking for a minimum of 
six hours and DNA minipreparation were carried out for plasmid extraction as 
described on 2.2.3.1 section. The ligation of fragments within the pCR2.1 was 
confirmed by sequencing samples with an M13 forward primer. 
2.2.2.8.  Real-time PCR:  
QuantiTech SYBR RT-PCR (Qaigen) kit was used to carry out Real-Time PCR 
analysis. The QuantiTech™ SYBR Green Master Mix contains an optimized 
concentration of the fluorescent dye SYBR Green. SYBR Green binds to all double-
stranded DNA molecules during PCR, emitting a fluorescent signal on binding. The 
reactions are characterized at the point, during cycling, when amplification of the 
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PCR product is first detected, rather than by the amount of PCR product accumulated 
after a fixed number of cycles.  
A master mix for PCR was prepared as follows: 10μl of SYBR Green, 0.2μl of RT 
enzyme, 1μl of 3.2µM of each primer, and 6.8μl of water per reaction. The master 
mix was then distributed into the tubes, mixed, and centrifuged for 3 seconds in PCR 
capillaries. 300-500ng of each RNA sample was added to the individual capillaries 
and the LightCycler was programmed as follows: initial activation step at 95
o
C for 15 
min, denaturing at 94°C for 15 s, annealing at between 55 - 60°C for 30 s, and 
extension at 72
o
C for 30 s. PCR capillaries were placed in the LightCycler machine 
and the cycling program was started. Finally, PRISM software was used to draw the 
peaks of the different samples.  
 
2.2.2.9. Absolute and fold change calculation in host gene expression  
RNA standards required for absolute quantification were generated by in vitro RNA 
transcription. RNA transcript levels were quantified by using a spectrophotometer and 
then diluted to generate a standard curve ranging from 4ng/µl – 400fg/µl. Fold change 
in host gene expression was calculated from the qRT-PCR data using both absolute 
quantification, using standards curves and relative quantification by fold change 
calculation.  
 
2.2.2.10. mRNA quantification using standards curves: 
Absolute quantification was used to quantify the amount of target gene mRNA 
transcript present within the Huh7 and Rep4 cells RNA samples. An RNA standard 
curve was included in each qRT-PCR experiment to quantify the abundance of target 
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RNA. The levels of the β-actin mRNA transcript were also quantified for each cellular 
RNA sample using an RNA standard curve. Fold change in host gene expression was 
calculated from the absolute quantification of the target gene, by dividing the quantity 
e.g. (in µg) of the target gene by quantity (in µg) of β-actin to give a normalised 
measure of gene expression. Then, the normalised value of treated target gene divided 
by normalized control gene (non- treated). The following equation: 
 
Quantity of target RNA   
1) Normalized target gene expression =    
            Quantity of β-actin RNA 
 
 
             Normalized expression treated sample 
2) Fold change in target gene expression =   
                           Normalised expression untreated sample  
 
Absolute quantification was also used to calculate the abundance of JFH-1 RNA 
present in infected Huh7.5 cells using an RNA standard curve (appendix 8.3).  
 
 
2.2.2.11. Relative quantification 
The higher the starting copy number of the DNA target, the earlier the increase in 
fluorescence is observed. The parameter CT (threshold cycle) is defined as the first 
detectable increase in fluorescence (281, 282). The target gene copy number in 
unknown samples is quantified by measuring the CT to calculate fold change in gene 
expression using the comparative CT method.  CT or „cycle threshold‟ values 
obtained from the qRT-PCR reaction were used to calculate fold change in gene 
expression using the ΔΔCT equation.  
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The ΔΔCT equation: 
CT target gene – CT reference gene = ΔCT 
ΔCT treated sample – ΔCT untreated sample = ΔΔCT 
Fold change in gene expression = 2
- ΔΔCT
 
Reference genes used to normalise the host gene expression data included; GAPDH, 
and β-actin (281, 282). Finally, Results graphs representing fold change in host gene 
expression were generated using software and error bars represent mean values +/- 
standard deviation (appendix 8.3). 
 
2.2.3. Plasmids preparation: 
 
2.2.3.1. Extraction of plasmid from bacteria: Mini-prep:  
Plasmid Mini Prep kit (Qiagen) was used in this method according manufacturer‟s 
protocol. 5mls of an overnight culture of E. coli containing a plasmid was used to 
inoculate 50ml of LB and 100µg/ml ampicillin selective antibiotics. This was 
incubated at 37C overnight. The bacterial cells were harvested by centrifugation at 
3000g for 20 minutes at 4°C. All traces of supernatant were removed and the bacterial 
pellet was resuspended in 250μl buffer P1. Next 250μl Buffer P2 was added to the 
resuspended pellet and was mixed by inverting 4–6 times. This was incubated at room 
temperature for 5 minutes. 250μl buffer N3 was added to the lysate after the 
incubation period and mixed immediately but gently by inverting 4–6 times. After 
addition of Buffer P3, a fluffy white precipitate containing genomic DNA, protein, 
cell debris, and SDS became visible. The lysate was centrifuged for 10 minutes. 
Supernatant was applied to the DNA binding column and centrifuged for one minute. 
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The column was then washed with 750μl Buffer QC. The DNA attached to the resin 
was eluted into a sterile Eppendorf tube with 1ml of Buffer TE. 
2.2.3.2. Determination of DNA concentration 
DNA samples were diluted 1:100 so that an A260 absorbance of between 0.1 and 1.0 
was obtained. The absorbance of the sample was determined at 260nm and 280nm in 
a quartz cuvette using an Ultraspec 2000 spectrophotometer and the DNA 
concentration calculated from the standard estimation that 1.0 A260 absorbance unit is 
equal to 50g/ml double stranded DNA. 
 
2.2.3.3. Agarose gel electrophoresis of DNA 
1.0% agarose in 1x TBE buffer was melted in a microwave oven, allowed to cool and 
then poured into the assembled gel electrophoresis apparatus. Once the gel had set it 
was covered with 1x TBE buffer and the comb removed to reveal the wells. The gel 
was run at a constant current of 80mA for one hour. The gel was stained with 
ethidium bromide for 20 minutes and destained for 20 minutes with water. The DNA 
bands were then visualized on a UV transilluminator and photographed (GelDoc-It 
Imaging System, VPU). 
  
2.2.3.4. Plasmid DNA Digestion: 
1μg of each plasmid was linearized by digestion with EcoR1 restriction enzyme for 3 
hours at 37
o
C. To each reaction, 2μl of restriction enzyme buffer (10x buffer H), 1μl 
of restriction enzyme, 2μl of BSA (1mg/ml) and 14μl of sterile nuclease free water 
were added. After 3 hours incubation, each plasmid DNA was checked to ensure that 
complete linearization had been achieved by agarose gel electrophoresis. 
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2.2.4. In vitro RNA transcription using T7 RNA polymerase. 
The RNA standards were in vitro transcribed using pCR 2.1 plasmid DNA templates 
and the T7 RNA polymerase.  The plasmid DNAs were linearized with Bam H1 
restriction enzyme downstream of the insert to be transcribed using 5μl buffer H, 2μl 
of BSA, 1μl of Bam H1 enzyme and 2μg of DNA template. 
The reaction was incubated at 37°C for a minimum of three hours and the linearized 
DNA templates were examined on a gel to confirm that cleavage was complete. After 
linearization the restriction digestion was terminated by adding the following: 
• 1/20th volume 0.5 M EDTA 
• 1/10th volume of 3 M sodium acetate 
• 2 volumes of ethanol 
The reactions were mixed well and chilled at –20°C for at least 15 min and then 
centrifuged for 15 min at 13000 x g. The supernatant was removed and re-centrifuged 
for a few seconds to remove the residual fluid. The pellet was suspended in dH2O at 
0.5–1μg/μl. 
2.2.5. Proteinase K treatment and phenol/chloroform extraction: 
This was performed to remove any residual RNases, restriction enzymes that could 
introduce RNase or other inhibitors of transcription from DNA preparation. The 
linearized plasmid DNAs were treated with 1μl proteinase K (100–200μg/ml) and 
0.5% SDS for 30 min at 50°C.  This was followed with phenol/chloroform extraction 
(using an equal volume) and ethanol precipitation. 115μl of nuclease-free water and 
15μl 5M ammonium acetate stop solution were added and mixed thoroughly, and then 
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an equal volume of chloroform was added to recover aqueous phase and transferred to 
a new tube.  
 
2.2.6. RNA transcription:  
To perform RNA transcription, the following components were added are for a single 
20μl reaction; 2μl of each ATP, CTP, GTP, and UTP solution, 2μl enzyme mix, 2μl 
10X reaction buffer and 1μg linear DNA template. The reaction was mixed gently and 
incubated at 37°C for 16 hours. RNA transcripts were precipitated by adding 30μl 
nuclease-free water and 30μl lithium chloride (LiCl 7.5M) precipitation solution. 
These were mixed thoroughly and chilled for 30 min at –20°C. RNA was pelleted by 
centrifugation at 4°C for 15 min in an Eppendorf mini-centrifuge at maximum speed. 
The supernatant was removed, and the pellet washed with 1 ml 70% ethanol, and re-
centrifuged to maximize removal of unincorporated nucleotides. Finally, the 70% 
ethanol was removed, and the RNA was resuspened in 10μl RNase free water. The 
concentration of the RNA transcripts within the sample was estimated by measuring 
absorbance at 260 nm and the RNA was stored frozen at –80°C until further use. 
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2.2.7. Construction of recombinant NS3 and NS/4A adenoviruses 
Adenoviruses containing individual NS3 and NS3/NS4A inserts from genotypes 1a, 
1b and 2a DNA were prepared using a ViraPower Adenovirus Expression System 
(Invitrogen) according to the manufacturer's instructions.  
2.2.7.1. Plasmids: 
DNA fragments encoding each of the HCV NS3 and NS3/4A nonstructural proteins 
were generated from full-length cDNAs containing the whole genome of HCV clones 
of three different genotypes namely: HCV genotype 2a, JFH-1 isolate (Accession no. 
AB047639), HCV genotype 1b Con1 isolate (Accession no.  AJ238799) and HCV 
genotype 1a, isolate H77 (Accession no. NC_004102).  
2.2.7.2. Primers design and PCR: 
Specific oligonucleotide PCR primers were generated to amplify the gene of interest. 
The sequence “CACC” was added to the 5‟ end of forward primers to enable 
directional cloning. ATG initiation codons were also added for proper initiation of 
translation within the primer sequences. 
Full-length NS3 and NS3/4A sequences were amplified by PCR with ACCUAZYME 
proofreading polymerase (Accuzyme polymerase; Bioline, Germany). Reaction tubes 
were then placed in a thermal cycler (The GeneAmp® PCR System 9700, Applied 
Biosystem). Thirty cycles of PCR were performed at 94°C for 60 s, at 55°C for 30 s, 
at 72°C for 120 s, and at 72°C for 10 min in 50μl reaction mixture containing 0.3μl (1 
U/μl) Taq polymerase, 5μl 10x PCR buffer, 1μl dNTPs (20 mmol/l), 1μl of each 
primer (10μmol/l), 1μl DNA as template, and 41.45μl of distilled water. The PCR 
products were subjected to electrophoresis on a 1% agarose gel for 60 min (voltage 
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80V) and visualized using a UV transilluminator and photographed (GelDoc-It 
Imaging System, VPU). 
 
2.2.7.3. Subcloning into the entry vector: 
The PCR products of NS3 and NS3/4A were subcloned into the pENTR/D-TOPO 
vector with a pENTR Directional TOPO Cloning kit (Invitrogen). The pENTR 
Directional TOPO cloning Kits utilize the blunt-end PCR products produced by 
adding CACC sequence from 2.2.7.2 into one of the pENTR TOPO vectors to 
generate an entry clone. These clones generate an expression construct by performing 
an LR recombination reaction between the entry clone and a Gateway destination 
vector of choice as described below.  In a 0.2ml PCR tube 2µl of fresh PCR product 
was combined with 1µl salt solution (1.2 M NaCl, 0.06 M MgCl2, Invitrogen) and 
sterile water to a final volume of 5µl. Finally 1µl of pENTR TOPO vector was added, 
mixed gently and incubated for 30 minutes at room temperature. At the end of 
incubation period, the reaction tubes were placed on ice until proceed to transforming 
into TOP 10 E. coli competent cells. Transformation was performed by mixing 2μl of 
cold TOPO cloning reaction mixture, and 50μl of competent E. coli cells (TOP 10). 
The mixture was incubated on ice for 30 minutes, and then heat shocked for 30 
seconds at 42 °C and placed back on ice. SOC medium (250μl) was added to cells 
which were then incubated at 37°C for 1 hour in an orbital shaker at 200 rpm. After 
incubation 50 and 100μl aliquots of the cell suspension were spread onto two LB agar 
plates which contained 50μg/ml kanamycin, and incubated at 37°C overnight. Next 
day, colonies were selected and grown in 50ml universal tubes which contained 5 ml 
of LB broth with 50μg/ml kanamycin at 37°C for 16 hours. A QIA Spin Miniprep Kit 
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was used to prepare the plasmid DNAs. The inserts were then sequenced with an M13 
forward primer to confirm that they were correct. 
2.2.7.4. Cloning into the pAd/CMV/V5-DEST adenovirus vectors plasmids: 
The cDNA inserts were then transferred to the pAd/CMV/V5-DEST vector 
(Invitrogen) by means of the Gateway system using LR Clonase (Invitrogen). 
pAd/CMV/V5-DEST vector E1/E3 is a replication-deficient adenovirus vector
 
based 
on the adenovirus serotype 5 (Ad5) E1/E3 deletion mutant. Recombination of the 
pENTR entry clones with the pAd/CMV/V5-DEST vector was performed using the 
LR Clonase enzyme mix. Briefly; 2μl 5x LR reaction buffer, 50-150ng entry clones 
and 300ng pAd/CMV/V5-DEST vector were mixed and made up to final volume 8μl 
with TE. Then 2μl of LR Clonase enzyme mix was added and mixed by briefly 
vortexing. The reaction was incubated at 25°C for one hour. To stop the reaction 1µl 
of Proteinase K was added and the reaction was incubated at 37°C for 10 minutes. 
The recombined plasmids were transformed into E. coli (TOP10) cells and expression 
resistant transformants were selected on LB plates containing 50μg/ml ampicillin. 
2.2.7.5. Sequence analysis 
To confirm that the HCV sequences had been correctly inserted, all samples with 
successful ligation were sent for DNA sequencing. For pENTR plasmids which 
contain M13 binding sequencing sites, 500ng of from each plasmid was mixed with 
3.2µM of forward or reverse M13 primers. While for pAd/CMV/V5-DEST, the 
plasmid contains T7 primer binding sequences was mixed with 3.2µM of forward or 
reverse T7 primers. All sequencing materials were sent to the DNA sequencing 
service at the MRC Clinical Science Centre, Hammersmith Campus, Imperial 
College. 
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2.2.7.6. Production adenoviruses in 293A cells 
Before transfection of the expression clones into 293A cells, the plasmids must 
expose the left and right viral ITRs on the vector to allow proper viral replication and 
packaging. pAd/CMV/V5-DEST vectors contain Pac I restriction sites. Digest at least 
4µg of purified plasmid DNA of pAd/CMV/V5-DEST expression constructs were 
linearized with Pac I (New England Biolabs)by adding, 2μl of restriction enzyme 
buffer (NEB buffer 1), 2.5μl of Pac I, 2μl of BSA (100μg/ml BSA) sterile nuclease 
free water to a volume of 50μl. After overnight incubation, each plasmid DNA was 
checked, to ensure that complete linearization had been achieved, by agarose gel 
electrophoresis. 
The linearized plasmids were then transfected into subconfluent 293A cells 
(Invitrogen) with lipofectamine 2000 in Opti-MEM medium. The day before 
transfection, 293A cells were seeded into 6-well plates at 5 x 10
5
 cells per well with 2 
ml containing 10% FCS DMEM. Next day the medium was removed and replaced 
with 1.5 ml of Opti-MEM I medium. Plasmid transformation solutions were prepared 
as follow, 4μg of Pac I-digested pAd-CMV-DEST expression plasmid DNA was 
mixed gently with 250μl of Opti-MEM I medium in a 1.5 Eppendrof tube. In a 
separate Eppendorf tube, 5μl of lipofectamine 2000 as added to 250μl of Opti-MEM I 
medium, mixed gently and incubated for 5 minutes at room temperature. After the 
incubation, the DNA with the Lipofectamine 2000 preparations were combined, 
mixed gently and incubated for 20 minutes at room temperature to allow the DNA 
lipofectamine 2000 complexes to form. Following the incubation the DNA-
lipofectamine 2000 complexes were added drop-wise to 293A cells in each well and 
the plates were rocked gently and incubated overnight at 37°C in 5% CO2. The next 
day, the transfection mix was remove and replaced with 10% FCS DMEM culture 
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medium.  48 hours post-transfection, the cells were trypsinized and transferred to a 
sterile T25 tissue culture flask containing 10 ml of complete culture medium. The 
culture medium was replaced with fresh 10% FCS DMEM culture medium every 2-3 
days until visible regions of cytopathic effect (CPE) were observed about 4-5 days 
post-transfection. The cells were kept until infections proceed until approximately 
80% CPE was observed. At 10-13 days post-transfection, the adenoviruses were 
harvested by detaching cells from the flask by vigorous pipettes and transferred into a 
sterile 15 ml tube. The tubes were placed at -80°C for 30 minutes, and then placed in 
a 37°C water bath for 15 minutes to thaw. The freezing and thawing steps were 
repeated twice, followed by centrifugation of the cell lysate in a bench-top centrifuge 
(HERAEUS, MEGAFUGE 1.0R) at 3000 rpm for 15 minutes at room temperature to 
pellet the cell debris and the adenovirus-enriched supernatants were obtained.  Six 
plasmids were transfected to produce six adenoviruses designated as AdNS3-1a, 
AdNS3-1b, AdNS3-2a, AdNS3/4A-1a, AdNS3/4A-1b and AdNS3/4A-2a. As a 
control, the pAd/CMV/V5-GW/lacZ vector (Invitrogen) was transfected into 293A 
cells to produce LacZ-bearing adenovirus.  
 
2.2.7.7. Adenovirus stock amplification: 
293A cells were trypsinized, counted and seeded in a T25 flask at 3 x 10
6
 cells with 
normal growth medium 10% FCS DMEM at 80 - 90% confluency. Next day, 100μl of 
a suspension of AdNS3 and AdNS3/4A adenoviruses stocks added to the cells, which 
were then gently swirled and incubated at 37°C in a CO2. The infection was allowed 
to proceed for 3 – 5 days until 80 - 90% of the cells had rounded up and either 
detached from or lightly attached to the tissue culture flask.  Adenoviruses were 
harvested by vigorously pipetting with a 10 ml tissue culture pipette and transferred to 
 107 
a sterile 15 ml tube. The tubes were placed at -80°C for 30 minutes to freeze the cells, 
and then placed in 37°C water bath for 15 minutes to thaw. The freezing and thawing 
steps were repeated twice, followed by centrifugation of the cell lysate in a bench-top 
centrifuge (HERAEUS, MEGAFUGE 1.0R) at 3000 rpm for 15 minutes at room 
temperature to pellet the cell debris. Finally, the supernatant containing viral particles 
was transferred to cryovials as 1.7 ml aliquots and stored at -80°C until further use. 
 
2.2.7.8. Titration of adenoviruses stocks: 
 A day before infection, of 293A cells were trypsinized, counted and plated in 6 well 
plates with 1 x 10
6
 cells per well and grown to 80 - 90% confluence. Next day, a vial 
of each six AdNS3 and AdNS3/4A adenoviruses stock in addition to AdLacZ viruses 
were thawed for 10 min at 37°C water bath. 10 fold serial dilutions ranging from 10
-4
 
to 10
-9
 were prepared, by dilution in 10% FCS DMEM, to a final volume of 1 ml. The 
culture medium from the cells was removed and each 1 ml dilution of adenoviruses 
was added to one well of cells. The plate was then swirled gently and incubated at 
37°C overnight. The following day, the medium containing virus was removed and 
the cells were gently overlaid with 2 ml of 4% agarose overlay solution per well. The 
overlay solution was prepared by mixing 12 ml of prewarmed 2% FCS DMEM (at 
37°C) and 1.2 ml of pre-warmed (at 65°C) 4% agarose in PBS. The overlay solution 
was applied to the cells by gently pipetting the overlay down the side of each well. 
The plate was placed in a level tissue-culture hood at room temperature for 15 
minutes or until the agarose overlay solidified and incubated at 37°C in a humidified 
atmosphere of 5% CO2. Two days following the initial overlay, the cells were 
overlaid with an additional 1 ml of agarose overlay solution per well (prepared as 
described in material section) and allowed to solidify before returning the plate to a 
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37°C humidified 5% CO2 incubator. The plates were monitored until plaques became 
visible, in about 8-12 days. After 8-12 days post-infection each well was gently 
overlaid with 300μl of 5 mg/ml MTT solution (1/10 the volume of the agarose 
overlay) on top of the solidified agar and incubated for 3 hours at 37°C.  Finally the 
plaques were counted and the titer of adenoviral stocks was calculated and expressed 
as plaque forming units (pfu) per ml. The titer was calculated as follow: the number of 
plaques each well was counted, then the following formula was used to determine the 
titer (pfu/ml) of viral stock.  
                     Number of plaques per well 
The viral titer =                                              = pfu/ml 
  Dilution factor X volume of diluted virus added to the well 
 
 
2.2.7.9. Adenoviruses genome copy number calculation using qPCR:  
To assess the number of adenoviruses genome copies per cell, DNA was extracted 
from virus stocks using the Trizol method. Copy numbers were assessed using real-
time PCR-based quantification. PCR was performed using a Light Cycler Real-Time 
PCR System using the SYBR Green PCR Mastermix as described for qRT-PCR. A 
set of primers was developed specifically for each genotype (table 2.4). Standard 
curves were run in duplicate and consisted of six ten-fold dilutions using total 
genomic DNA. Melting curve analysis confirmed the quality and specificity of the 
PCR products. The viral titer was expressed as number of viral particles per ml of 
supernatant (VP/ml). The virus concentration was calculated using the following 
equations.  
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The average genome size of an adenovirus is approximately 40 kbp, therefore,  
Number of VP per ng adenoviral DNA = 
 
 Mass of sample (g) x Avogadro‟s Number  
     Genome length (pb) x mass of bp 
       
 
              Amount of VP  
Virus Titer (VP/ml) =  
     Viral sample volume (ml) 
 
    (1x10
-9
) g 
1 ng adenoviral DNA =         = 2.3 x 10
7
 VP 
         40,000 bp x 660 g/bp) X 6 x 10
23
 
 
 
Virus Titer (VP/ml) = Amount of adenoviral ds DNA (ng) X 9.2 x 10
7
 VP/ng 
 
2.2.7.10. Adenovirus transduction: 
One day before transduction 1x 10
6
 of Huh7 cells were seeded in 6 well plates with 
10% FCS DMEM. Next day, the medium was removed and cells in each well were 
washed with PBS. The PBS was removed and adenovirus was added to the cells at an 
MOI of 100 pfu/cell. The cells were incubated with adenovirus overnight at 37C 
after which the virus inocula were removed and replaced with complete tissue culture 
medium and the cells were then incubated at 37C overnight.  
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2.2.8. Immunofluorescence confocal microscopy of HCV NS3 proteins in 
Huh7 cells: 
Glass cover slips (22 x 22 mm) were sterilized (dipped in alcohol and flamed) and 
placed in the bottom of the wells of 6 well plates. Huh7 cells were seeded at 2 x 10
5
 
per well with 10% FCS DMEM to grown to 60-70 confluence. Next day, the cells 
were transduced with the adenovirus constructs, AdNS3-1a, 1b, 2a, AdNS3/4A-1a, 
1b, 2a and AdLacZ recombinant adenoviruses at MOI as detailed in section 2.5.11. 
After 72 hours post infection the cells were prepared for immunofluorescence staining 
to assess NS3 recombinant protein expression. First, the mix was removed from the 
wells and the cells were washed with 1ml PBS followed by adding 2ml of 4% 
paraformadehyde in PBS fixation solution and incubated for 20 minutes at room 
temperature in the hood. The mix was then removed from the wells and the cells were 
washed twice with 1ml PBS. The cells were permeabilised for 20 minutes with 0.1% 
Triton X-100 in PBS and then washed twice wash with PBS. Non-specific binding 
was blocked with 1ml 10% FCS for 30 minutes and then the cells were washed twice 
with PBS. Each of the cover slips was removed from the corresponding well and 
placed, cell coated face down, onto 50l of rabbit polyclonal anti-NS3 antibody 
(NS3-7) diluted 1 in 50 in sterile PBS or  50l mouse anti tag V5 antibody (anti-V5) 
diluted 1:5000 in sterile PBS on a clean glass microscope slide for one hour at room 
temperature. Unbound antibody was washed off by washing three times in PBS and 
the coverslips were then placed face down onto 50l of FITC conjugated AlexaFluor 
488-conjugated anti-rabbit IgG or AlexaFluor 594-conjugated anti-mouse IgG 
(Invitrogen), diluted 1:1000 in sterile PBS on a clean glass microscope and incubated 
for one hour at room temperature. The slide was washed again three times in sterile 
PBS, and placed face down on mounting medium (Vectashield with DAPI) on a clean 
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microscope slide. The cells were viewed at 400x magnification using an inverted 
microscope.  
2.2.9. RNA interference (RNAi): Synthetic siRNA transfection: 
A day before transfection, Huh7 or Huh7.5 cells were seeded at 1x10
5
 cells per well 
in a 24 well plate in 500μl 10% FCS DMEM and frown until 40-50% confluent at the 
time of transfection.  
For each well to be transfected, 1- 2μl of 50μM of synthetic siRNA duplex (siRNAs 
sequences table 2.5) was mixed with 50µl OptiMEM I reduced serum medium to a 
total volume of 50μl in a sterile Eppendorf tube. In a separate tube 1μl of 
lipofectamine 2000 was mixed with 50μl OptiMEM I reduced serum medium. Both of 
the preparations were incubated for 5 minutes at room temperature. The 
lipofectamine/ OptiMEM was then combined with the siRNA/ OptiMEM and 
incubated for 20 minutes at room temperature. Then 100μl of the transfection mixes 
were added into the wells and the cell were then incubated at 37°C in 5% CO2 for 8 
hours. Finally, the transfection mix was removed and replaced with 0.5 ml of 10% 
FCS DMEM and incubated again for 48 hours at 37°C in 5% CO2. In all experiments 
GAPDH and scrambled non-targeting siRNAs were used as a control to examine the 
efficiency of transfection 
 
2.2.10. HCV culture:  
2.2.10.1. HCV Constructs and Transcription: 
The HCV JFH-1 culture system was previously established in Dr. McGarvey‟s Lab. 
The JFH-1 clone was derived from a Japanese patient with fulminant hepatitis. This 
full genome cloned cDNA was inserted into a plasmid behind a T7 promoter to create 
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the plasmid pJFH-1, as well as a replication-defective NS5B negative control 
construct pJFH-1 GND (118) . These two plasmids, the pJFH-1 and pJFH-1- GND, 
were linearized at the 3' end of the HCV cDNA by XbaI digestion. The linearized 
DNA was then purified and used as a template for in vitro transcription (MEGAscript; 
Ambion, Austin, TX). 4µg of transcribed JFH-1 RNA was transfected into Huh7.5 
cells using lipofectamine 2000 for 24 hours and then the cells were passaged every 2–
3 days before the cells became confluent. The generated virus was checked by 
immunofluorescent staining for core protein and the titer of HCV RNA by 
quantitative RT-PCR after extracting RNA from medium, as described before. 
 
2.2.10.2. Titration of Infectious HCV:  
Cell culture supernatants which contained HCV were serially diluted 10-fold in 0.5 ml 
of 10% FCS DMEM and used to infect 10
5
 naïve Huh7.5 cells per well in eight well 
chamber slides (Labtek). The inocula were incubated with cells for 4 h at 37°C and 
then supplemented with fresh 0.5 ml of 10% FCS DMEM. The level of HCV 
infection was determined 3 days post infection by immunofluorescence staining, the 
cells were washed with PBS, fixed with 0.5 ml 4% paraformadehyde for 30 minutes at 
room temperature and then washed twice with PBS. The cells were permeabilised for 
20 minutes with 0.5 ml 0.1% Triton X-100 (in PBS) at room temperature and 
incubated with 50µl HCV anti-core antibodies 1:400 dilution (C7-50, Abcam) for one 
hour at room temperature. The cells were washed with PBS three times, then 50µl of 
secondary antibody (Alexa-594 DAM dilution 1:1000 in 1% BSA in PBS) for 1 hour 
at room temperature. The cells were washed again for 5 minutes in PBS three times 
with a final wash in sterile distilled water.  Excess water was removed and slides 
mounted with Mowiol plus DAPI. A fluorescence microscope (Nikon EclipseT2000S) 
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was used to visualize and count the number of positive staining foci. The viral titres 
were expressed as focus forming units per ml of supernatant (ffu/ml). 
2.2.10.3. Production of HCV virus stock: 
To generate viral stocks, infectious HCV cell culture media were diluted in 10% FCS 
DMEM and used to inoculate naive 10–15% confluent Huh7.5 cells at an MOI of 0.01 
in a 175 cm
2
 tissue culture flask. Infected cells were trypsinized and replated before 
confluence at day 4–5 postinfection. The infected cell culture media (35 ml per flask) 
were collected in sterile 50 ml tubes and cell debris was removed by low-speed 
centrifugation (5 minutes at 400 x g).  The culture medium was then passed through a 
0.45-μm syringe-top filter unit to remove dead cells debris. To concentrate the virus, 
the filtered culture medium was pipetted into an Amicon Ultra-15 filtration unit, 
(maximum volume of 15 ml per unit) and centrifuged for 30 minutes at 3,600 x g and 
4°C (MSE Mistral 3000i centrifuge). The centrifugation supernatant was then 
collected and aliquoted into 1.7 ml cryogenic tubes for storage at -80°C. The titer of 
viral stock was determined as described above. 
 
2.2.11. Flow cytometry analysis: 
2.2.11.1. Cell FACS analysis of DNA fragmentation and Cell cycle using 
propidium iodide (PI) staining 
PI is a fluorogenic compound that binds stoichiometrically to nucleic acids so that 
fluorescence emission is proportional to the DNA (and RNA, which has to be 
removed if DNA is to be measured) content of a cell. When apoptotic cells are stained 
with PI and analyzed with a flow cytometery, they display a broad hypodiploid (sub-
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G1) peak, which can be easily discriminated from the narrow peak of cells with 
normal (diploid) DNA content in the red fluorescence channels. 
Huh7 and Huh7.5 cells were seeded in 6 well plates at 2 x10
5
 per well and the next 
day they were infected or mock infected with HCV JFH-1 for an indicated time. At 
different time points, the cells were harvested by trypsinization at 37°C for 2-3 
minutes, 2 ml of PBS was added and the cell suspensions were transferred to 12 x 75 
mm polypropylene tubes and centrifuged at 1200 rpm for 5 minutes at 4°C. Then the 
supernatant was discarded and 1 ml of PBS was added to the cell pellet, mixed gently 
and centrifuged again at 1200 rpm for 5 minutes at 4°C. The supernatant was 
discarded completely and clean tissue paper was used to remove any residual PBS. 
The cells were fixed by adding 1ml of 70% (v/v) cold ethanol to the cell suspension 
drop-wise while being vortexed and then the tubes were incubated overnight at -20ºC. 
Next day, the tubes were centrifuged at 1200 rpm for 5 minutes at 4°C and the 
supernatant was discarded. The cells were then washed twice with 1 ml of PBS for 
each tube, mixed gently and centrifuged again at 1200 rpm for 5 minutes at 4°C. The 
supernatant was discarded and the cells resuspended in 1 ml of DNA staining solution 
which containing 20μg/ml propidium iodide and 1:100 RNase A (50μg/ml). The cells 
were incubated for at least 3 hours on ice in the dark, and then the cell cycle profiles 
were determined by flow cytometry using a FACScan (Becton-Dickinson, USA). 
Cells were analyzed by flow cytometry using 488-nm and measure red fluorescence 
620 nm and side scatter, which allow the discrimination of true apoptotic nuclei from 
nuclear debris. The apoptotic cells displayed a broad hypodiploid (sub-G1) peak, 
which can be discriminated from the narrow peak of cells with normal (diploid) DNA 
content. Also, the distribution of cells in the various phases of the cell cycle indicates 
a proliferating cell population: G1 and S (DNA synthesis phase), G2 and M-phase 
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(mitosis). To set the acquisition parameters correctly, experiments included the 
following; 1. Non-infected, unstained (no PI) negative control cells, 2. Mock infected 
stained with PI negative control and 3. Positive infected and stained with PI positive 
controls cells. 
For accurate FACS analysis, at least 20,000 events were collected for reading; the 
first gate was performed to gate out residual debris.  A second gate was carried for 
doublet discrimination. Then, the cell cycle profiles were obtained by detecting the 
cells stained with PI. The cells were also stained with anti-core antibodies and the 
infection efficiency was evaluated by calculating the percentage of FITC core positive 
cells. (appendix figures 8.4  and 8.5 show an example of this analysis) 
 
2.2.11.2. FACS analysis of HCV core intracellular staining: 
A day before infection 2 x 10
5
 of Huh7 and Huh7.5 cells were seeded in six well 
plates and infected with HCV JFH-1 at different MOI as indicated and times as 
described in 2.9.1. For FACS staining all steps prior to fixation were carried out on 
ice. The cells were harvested by trypsinization at 37°C for 2-3 minutes, 2 ml of PBS 
was added and the cell suspensions were transferred to Falcon 12x75 mm 
polypropylene tubes and centrifuged at 1200 rpm for 5 minutes at 4ºC. The 
supernatant was then discarded and 1 ml of PBS was added to the cell pellet, mixed 
gently and centrifuged again at 1200 rpm for 5 minutes at 4ºC. The supernatant was 
discarded and 300µl of fixative (4% paraformaldehyde and formaldehyde in PBS) 
was added to each cell pellet, mixed gently and incubated on ice for a minimum of 30 
minutes. After incubation, 1 ml of PBS was added to each tube, mixed gently and 
centrifuged again at 1200 rpm for 5 minutes at 4°C. The supernatant was discarded 
and then resuspended in 200µl PBS and transferred to a V-shape 96 well plate 
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(Becton-Dickinson). For intracellular staining all of the subsequent steps were carried 
out using saponin containing buffers. First 200μl PERM buffer (staining buffer with 
0.5% (w/v) saponin) was added to each well, mixed thoroughly and then centrifuged 
at 1200 rpm 5 minutes using a plate centrifuge (SCI Quip, DJB Labcare, Sigma). This 
washing step was repeated once with 200µl SUPERPERM buffer. The supernatant 
was discarded and 80µl (1:400 in PBS) of the mouse monoclonal (anti core C7-50 
Abcam) was added to each sample except the negative control and left for at least 1 
hour at room temperature. Then, the cells were washed twice with 200µl PERM 
buffer per sample and spun as before.  After removing the supernatant, the cell pellets 
resuspended in 100µl of the rabbit anti mouse IgG-FITC secondary antibody 
(DAKO), diluted 1:50 in PBS and left for at least 1 hour at room temperature. The 
plate was spun as before and the supernatant was removed. The cell pellets were 
washed with 200µl of PERM buffer, spun as before, and the supernatant was 
discarded again. After the last step, the cells were washed with PBS once as described 
before and the cells were then resuspended in 200µl of staining buffer (2% FCS in 
PBS), mixed gently and transferred to FACS analysis tubes.  
Cell fluorescence signals were determined by a FACS caliber flow cytometer (Becton 
Dickinson). FITC was identified at 530nm. The analysis was performed using 
CELLQUEST software, version 4.3, (Becton Dickinson). The primary gate was set to 
exclude dead cells or debris. The background level was then estimated by comparison 
with cells in which primary antibody had been omitted during the staining procedure. 
2.2.12. Protein and Western blotting work  
2.2.12.1. Extraction from Mammalian Cells 
Cells were grown to 70% confluence. On the day of protein extraction, cells were 
washed twice with 2ml cold PBS. 1 ml of protein lysis buffer was added to each flask 
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and cells were scraped off with a sterile scraper. The cells were then transferred to 
pre-cooled (to 4°C) 1.5 ml Eppendorf tubes and centrifuged for 12 minutes at 
maximum speed at 4
o
C (SORVALL Biofuge Fresco). The supernatant from each tube 
was transferred to a new pre-cooled Eppendorf tube and stored at -20
o
C.  
2.2.12.2. Bradford assay of protein estimation using a 96 well plate: 
10μl of each soluble cell extract was diluted 1/20 with the addition of 190μl milli Q 
water. 0.4 ml of each known BSA stock concentration protein standards were used to 
make serial dilutions of the 1mg/ml. The following 0.4 ml dilutions of BSA were 
made: serial dilutions in water of 1µg/µl BSA in water were used as known protein 
concentration in the Bradford assay; 0.0µg/µl, 0.05µg/µl, 0.1µg/µl, 0.25µg/µl, and 
0.5µg/µl.  
200μl of 1x Bradford reagent was added to each well in addition to 10μl of either 
BSA standards or an unknown protein sample. All samples were mixed and incubated 
at room temperature for 30 minutes. The absorbance for each sample was measured at 
595 nm and the test protein concentrations were calculated by generating a graph of 
the standards (the standard curve) with the dependent variable (µg/ml) on the X axis 
and the independent variable (595 nm) on the Y axis. 
 
2.2.12.4. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE): 
Separation gel 
A separation gel (10 or 15%) was prepared by the addition of 3.3 or 5 ml protogel 
(30% acrylamide,  0.8 % w/v bis-acrylamide, National Diagnostics), 2.5 ml resolving 
buffer (1.5M Tris, pH 8.8, 0.1 ml of 10% SDS, National Diagnostics), 100µl of 10% 
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ammonium persulphate, 10µl TEMED (Sigma) and made up to 10 mls with milli Q 
water. The separation gel mixture was pipetted into the pre-assembled glass plates in 
the mini gel apparatus. Once the mixture was added, propanol was pipetted above the 
separation gel to form a thin airtight layer, allowing polymerisation to proceed. The 
gel was left to stand at room temperature for 1 hour. Just before adding the stacking 
gel mix, the propanol was removed.   
 
Stacking gel 
A stacking gel mix consisted of 1.5 ml of protogel (30% acrylamide, 0.8 % w/v bis-
acrylamide), 2.5ml staking buffer (contain 0.5M Tris, 0.1 ml 10% SDS, National 
Diagnostics), 0.1ml 10% ammonium persulphate, 10µl TEMED and 5.7ml double 
distilled water. The stacking gel pipetted above the separation gel and an 8 well comb 
was placed. The stacking gel was allowed to polymerise for 30 minutes at room 
temperature. Following polymerisation, the gel was transferred to the running gel 
apparatus and 1x running buffer (1.92 M glycine, 0.25 M Tris and 3.5mM  SDS) was 
poured into the upper and lower compartments of the tank and the combs removed 
from the stacking gels.  
 
2.2.12.3. Preparation of samples 
Protein samples were prepared by adding 10μg of protein in sample buffer (2.5µl 10x 
Tris–EDTA reducing buffer and 10µl bromophenol blue/glycerol. The protein 
samples were then loaded into the gel in a total volume of 40μl. 15µl SDS-PAGE 
prestained molecular weight marker (Invitrogen) was also loaded onto each gel. 
Before loading, all protein samples were mixed with the sample buffer and boiled in a 
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heater block for 5-10 minutes, spun briefly transferred and loaded into pre-assembled 
apparatus (Bio-Rad). Once loaded, the gel was run at a constant voltage of 100V for 1 
hour or when the dye front was 0.5cm from the bottom the power was switched off 
and the gels were prepared for either Western blotting or Coomassie staining. 
 
2.2.12.4. Coomassie Blue staining 
Staining was carried out using 0.1% (w/v) Coomassie Blue (CBB) dissolved in 
methanol: water: glacial acetic acid (ratios 45:45:10, by volume). This acid-methanol 
mixture acts as a denaturant to fix the protein in the gel, which prevents the protein 
from diffusing within the gel or being washed out while it is being stained. Gels were 
stained overnight, by gentle agitation, at room temperature. Following the staining, 
the gels were immersed in a destain solution (30% propan-2-ol, 10% acetic acid) for a 
minimum of 2 hours. Once they were sufficiently destained, the gels were placed in 
transparent plastic paper for scanning. 
 
2.2.12.5. Western blotting 
Nitrocellulose membrane and blotting paper were cut to the correct dimensions. The 
membrane was then immersed in Western transfer buffer (1.92 M glycine, 0.25 M 
Tris and 3.5mM SDS, 20% methanol). The scotch bright pads (from the Western blot 
transfer tank-BIO-RAD), blotting paper and the nitrocellulose membrane were then, 
placed in transfer buffer. SDS-PAGE gels were disassembled from the running 
apparatus, rinsed gently in transfer buffer, and set up in the transfer sandwich. This 
sandwich was prepared as follow; the plastic holder (black side) 1x sponge, 2 x filter 
paper, protein gel, membrane, 2x filter paper, 1x sponge, plastic holder (clear side). 
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The sandwich and cooling unit were placed in the transfer tank containing transfer 
buffer. The transfer unit was then run at 120V for 1 hour at 4°C to allow the transfer 
of the proteins from the gel to membrane. 
 
2.2.12.6. Immunolabelling of the membrane 
Following the transfer of proteins, the membrane was removed from the transfer tank 
and placed in water. The membrane was wiped gently to remove any acrylamide. To 
ensure there had been a successful transfer of proteins to membrane, membrane was 
immersed into Ponceau S solution (SIGMA) for 30-60 seconds. Ponceau S binds to 
proteins and allows their detection but does not interfere with the immuno-detection 
steps that follow. The membrane was then transferred to water and washed a further 
three times with water. The membrane was then transferred to a container and water 
added to ensure the membrane did not dry. The membrane was removed from the 
water and immersed in 10 ml of 10% blocking solution (PBS/Tween/4% skimmed 
milk). The membrane was left on a rocker (10-20 revolutions/min) at room 
temperature for 1 hour. Following incubation, the membrane was washed twice for 5 
minutes with 10ml 0.1% PBS/Tween. The membrane was then placed on plastic film 
and 2µg of primary antibody diluted in 2ml of PBS/ Tween/BSA solution was added. 
A sheet of plastic film was placed on top and it was incubated on ice for overnight on 
(30 rev/min on rocker). Following the incubation, the membrane was washed three 
times for 5 minutes (30 rev/min on rocker) with 10ml 0.1% PBS/Tween/BSA solution 
and the secondary antibody (horseradish peroxidase (HRP) labelled anti-mouse or 
anti-rabbit) was added to the membrane at a dilution of 1:1000 in 2mls 0.1% 
PBS/Tween/BSA and incubated at room temperature for an hour, on a rocker (30 
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rev/min). Following the incubation, the membrane was washed three times for 5 
minutes with PBS/Tween/BSA solution.  
2.2.12.7. Western blotting detection               
Following the final wash of the membrane (section 2.2.12.6) the PBS/Tween/BSA 
solution was removed. For blot detection SuperSignal West Pico Chemiluminescent 
Substrate was used (Thermo scientific). An equal volume of detection solution 1 
(Lumino/ Enhancer solution) and 2 (stable peroxide solution) were mixed, ensuring 
there was a sufficient volume to cover the membrane. The excess wash buffer was 
drained away from the washed membrane which was placed protein side up on a sheet 
of cling film. The detection solution was then pipetted onto the membrane and 
incubated for 1 minute at room temperature. The detection solution was then drained 
away by holding the membrane gently with forceps and touching the edge of it against 
paper towel. The membrane was then placed protein side down onto fresh cling film, 
wrapped up and any air bubbles expelled by smoothing out. The wrapped membrane 
was then placed protein side up in an x-ray film cassette and a sheet of 
autoradiography film (Hyperfilm ECL, Amersham Biosciences) was placed on top of 
the wrapped membrane. The cassette was closed and the membrane was exposed for 
15 seconds minutes. Following exposure, the film was developed immediately, and on 
the basis of its appearance, it was possible to estimate time required to produce an 
optimal signal with a second sheet of film. The second exposure time varied from 1 to 
10 minutes. 
2.2.13. Immunofluorescence double staining microscopy and subcellular 
localization of HCV proteins and cyclin B1 in Huh7 cells: 
Glass cover slips were sterilized (dipped in alcohol and flamed) and placed in the 
bottom of the wells of 24 well plates. 1 x 10
5
 Huh7 cells were seeded in half of the 
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wells and infected with HCV JFH-1 at an MOI of 3. In other wells Huh7 (1 x 10
5
) 
cells were mock infected. The infected and mock infected cells were incubated for 72 
hours at 37°C at 5% CO2. 
The media were then removed from the wells and the cells were washed with 0.5 ml 
PBS followed by fixation with 0.5 ml of 4% paraformadehyde in PBS for 20 minutes 
at room temperature. The cells were permeabilized for 20 minutes with 0.5 ml 0.1% 
Triton X-100 (in PBS) at room temperature. Non-specific binding of antibodies was 
blocked by adding 0.5 ml of 10% BSA in PBS for 30 minutes at room temperature 
and washing twice with 0.5 ml PBS. Each of the coverslips were removed from the 
corresponding well and placed, cell coated face down, onto 50l of mouse 
monoclonal anti-cyclin B1 antibody (Santa Cruz), diluted 1 in 50 in sterile BSA, at 
room temperature on a clean parafilm sheet for one hour. Unbound antibody was 
washed off by washing three times in PBS and the coverslips were then placed face 
down onto 50l AlexaFluor 594-conjugated anti-mouse IgG (Invitrogen), diluted 
1:1000 in sterile 1% BSA/PBS and incubated for one hour. The coverslips were 
washed three times in sterile PBS and placed onto 50l of sheep polyclonal anti-
NS5A secondary antibody diluted 1 in 100 in sterile BSA at room temperature on a 
clean slide for one hour. Unbound antibody was washed off by washing three times in 
PBS and the coverslips were then placed face down onto 50l FITC-conjugated anti-
sheep IgG (DAKO), diluted 1:50 in sterile 1% BSA/PBS and incubated for one hour. 
Finally, the coverslips were washed again three times in sterile PBS, and placed face 
down on mounting medium (Vectashield with DAPI) on a clean microscope slide. 
The cells were viewed at 400x magnification with a fluorescent microscope (Nikon 
EclipseT2000S). 
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CHAPTER THREE 
 
3.0. Effects of HCV replication on the host innate immune responses 
 
3.1. Quantification of host gene expression:  
Quantitative methods were used to measure the difference in the levels of host gene 
mRNAs in Huh7, Rep 4 and JFH-1 infected cells. RNA was extracted and cDNAs 
were generated and used for PCR using primers for individual host genes. Standard 
curves were generated using PCR standards of known concentration and the test PCR 
samples should then fall within the range of these standard curves. To create real-time 
PCR standards, PCR products were cloned in a plasmid vector. Small quantities of 
PCR products amplified by host gene specific primers, which also include β-actin and 
GAPDH primers that were used as a controls, were run on agarose gels. They were 
then eluted and ligated into pCR2.1 (Invitrogen), as described in the Materials and 
Methods. Plasmid DNAs corresponding to the standards were purified and samples 
were digested with EcoR1 restriction enzyme and separated on agarose gels to 
confirm that the ligations had been successful. Furthermore, the plasmids were 
sequenced to confirm the sequence orientation of the inserts. After confirmation of 
ligation, the plasmids were linearized using Pst1 and transcribed using a T7 
transcription kit (Ambion). The transcripts were run on RNA gels to confirm that 
RNA transcripts of the correct size had been produced (figure 3.1). The transcripts 
were kept until needed for the real-time qRT- PCR reactions. 
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Figure 3.1: RNA transcripts for the host genes.1μl of the RNA transcription reaction 
was run with 3x RNA loading buffer on a 2% agarose gel stained with SYBR safe. 
RNA ladders were included for RNA size estimation. Lane 1, RNA ladder, lane 2 
RIG-I, lane 3 MDA5, lane 4 MAVS, lane 5 TRIF, lane 6 TLR7, lane 7 TLR3, lane 8 
TLR8 and lane 9 MyD88. 
 
3.2. RT-PCR Standard curves production: 
Standard curves were produced to enable the determination of the copy numbers in all 
of the test samples. To generate a standard curve using a known template, the copy 
number had to be determined. Six sequential ten-fold dilutions were made for each 
standard. The unknown test samples from Huh7, Rep 4 cells, JFH-1 infected cells or 
siRNA transfected cells were compared to the 6 standards for the target standard 
curve of β-actin or GAPDH. The copy number of the target gene was normalized 
against β-actin or GAPDH by dividing it with the copy number of β-actin or GAPDH 
gene. This normalization is necessary to correct for any inaccuracies during the 
preparation of RNA e.g. RNA extraction from the cells or DNase treatment. In 
addition, each of the real-time RT-PCR runs included a water control to detect any 
contamination by PCR template.  
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Relative quantification is an alternative method for calculating fold change in the 
expression of host genes, in which RNA standard curves do not need to be included in 
the qRT-PCR reaction. Instead, fold changes in expression can be calculated directly 
from the qRT-PCR cycle threshold (CT) values using the ΔΔCT equation as described 
in materials and methods (section 2.2.2.11).   
 
3.3. JFH-1 cell culture system 
3.3.1. Production of JFH-1 infectious virus 
A cell culture system for the production of full length JFH-1 infectious virus was 
previously established in Dr McGarvey‟s laboratory according the protocol proposed 
by Wakita et al (118, 283). Virus production was carried out using the highly 
permissive Huh7.5 cell line which expresses high levels of CD81 and has a defective 
interferon response due to an inactive RIG-I gene. HCV infection was determined by 
staining for HCV core protein (figure 3.2A). 
 
3.3.2. Titration of Infectious HCV and determination of JFH-1 
infectivity in Huh7.5 cells: 
HCV culture cell supernatants were serially diluted 10-fold in 10% FCS DMEM and 
used to infect Huh7.5 cells using 8 well chamber slides. The original stock were 
diluted in 1:500, 1:1000 and 1:2000 dilution, and was incubated with cells for 4 h at 
37°C. The level of HCV infection was determined 2 days post infection by 
immunofluorescence staining for HCV anti-core and foci were counted from the 
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different dilution to determine the stock concentrations. The viral titer is expressed as 
focus forming units per ml of supernatant (ffu/ml).  
 
 
                 
 
 
Figure 3.2 (A): HCV core protein staining. Huh7.5 cells producing infectious JFH-1 
virus particles were stained for HCV core protein using a mouse monoclonal antibody 
(red staining). Cell nuclei were stained with DAPI (blue staining). Images were 
captured at a magnification of 40x with a fluorescenentce microscopey. (1). Mock 
infected Huh7.5 cells. (2). JFH-1 infected Huh7.5 cells. (B): Titration of JFH-1 viral 
stocks. Huh7.5 cells were seeded into 8-well chamber slides.  1µl and 0.1µl of the 
concentrated JFH-1 virus stocks were used to infect the Huh7.5 cells in duplicate. 
After 48 hours, the chamber slides were stained for HCV core protein and foci were 
counted at a magnification of 20x with a fluorescent microscope. 
2 1 A 
B 
 127 
3.4. Expression of extracellular and intracellular innate immune 
response receptors genes in Huh7 and replicon cells: 
To investigate the molecular mechanisms of interferon induction during HCV 
infection first the basal expression levels of components of the dsRNA response 
pathway in naïve (untransfected) Huh7 cells and Huh7 cells transfected with the HCV 
subgenomic replicon (Rep4), were examined. The quantification of mRNA by qRT-
PCR of the main intracellular and extracellular dsRNA (RIG-I, MDA5 and TLR3) 
and ssRNA recognition receptors (TLR7 and TLR8) in test samples was determined 
using standard curves. In Huh7 cells, RIG-I, MDA5 and TLR7 were expressed at 
higher levels than TLR3 and TLR8 was undetectable (Figure 3.3A). However, the 
presence of the HCV replicon causes the induction of gene expression of about 4-5 
fold for RIG-I, MDA5 and TLR3, whereas TLR7 was induced by around two fold 
(figure 3.3B).  
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Figure 3.3: (A) Expression of RIG-I, MDA5, TLR3, TLR7 and TLR8 mRNA in 
Huh7 and Rep4 cells.  Expression levels were determined from total RNA using real 
time qRT-PCR and normalized by comparison to β-actin. RNA standard curves for 
each target gene and the β-actin gene as control were used to quantify the mRNAs. 
(B) Fold change induction of RIG-I, MDA5, TLR3 and TLR7 mRNA in Rep4 cells. 
Fold change was calculated by comparing expression data for the Rep4 cells to the 
naïve control Huh7 cells. The expression data for relative quantification was 
normalized using β-actin. 
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To examine the effect of HCV non-structural proteins on the induction of IFN-β, cells 
were first treated with poly (I:C) a synthetic dsRNA which is a strong inducer of IFN-
β. Cells were either transfected with 5ng/µl of poly (I:C) or poly (I:C) was added to 
the cell culture medium. Upon poly (I:C) treatment, Huh7 cells showed large 
increases in expression levels for MDA5 (50 fold) and RIG-I (12 fold). Additionally, 
TLR3 expression levels were also stimulated up to 17 fold (figure 3.4).  
By contrast, although the expression of these genes was also induced in response to 
poly (I:C) treatment in Rep4 cells they were significantly less induced compare to 
Huh7 cells (figure 3.4). These data indicate that the HCV NS proteins have a role in 
reducing the induction of IFN-β and other components of the interferon induction 
pathway.  
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Figure 3.4: Fold change induction of RIG-I, MDA5 and TLR3 mRNA in Huh7 and 
Rep4 cells after stimulation with poly (I:C). RIG-I and MDA5 were measured after 
transfection with poly (I:C), whereas TLR3 was measured after extracellular 
stimulation with poly (I:C). Fold change was calculated by comparing expression 
data for the Rep4 cells to the naïve control Huh7 cells. The expression data for 
relative quantification was normalized using β-actin. 
 
3.5. Expression level of signaling mediator genes in Huh7 and replicon cells: 
RIG-I, MDA5, TLR3 and TLR7 signaling leads to the activation of NF-κB and IRF3 
transcription factors through pathways mediated by MAVS adaptors for RIG-I and 
MDA5, and TRIF for TLR3 and MyD88 for TLR7. To assess the consequences of 
pattern recognition receptors (PRRs) activation, the expression levels of components 
of the dsRNA response pathway were examined in Huh7 and replicon cells (Rep4). 
Upon transfection of Huh7 cells with poly (I:C), large increases in expression levels 
were observed for MAVS. TRIF expression levels were also stimulated by the 
presence of poly (I:C) in the medium  but to a lesser extent. By contrast, transfection 
of Rep4 cells with poly (I:C) or adding in the medium showed that the expression of 
MAVS and TRIF mRNAs was significantly less compared to Huh7 (figure 3.5), 
similar to what was seen with the signaling receptors (figure 3.4). Taken together 
these data indicate that HCV non-structural proteins can inhibit the induction of the 
innate immune response pathway triggered by dsRNA.  
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Figure 3.5: Relative expression of signaling mediators TRIF and MAVS mRNA in 
Huh7 and Rep4 cell and in response to poly (I:C) stimulation. MAVS was measured 
after transfection with poly (I:C), whereas TRIF was measured after extracellular 
stimulation with poly (I:C). The expressions levels were determined from total RNA 
using real time qRT-PCR and were normalized with β-actin. 
 
3.6.  HCV NS proteins affect IFN signaling via dsRNA dependent and 
ssRNA dependent pathways: 
The effect of HCV on the upstream components of IFN signaling, TRIF and MAVS, 
was examined by analyzing the effect of expressing NS proteins in Rep4 cells (figure 
3.5). However, there is also another important signaling pathway for IFN, in which 
signals for different TLRs are mediated by the adaptor protein, myeloid differentiation 
factor 88 (MyD88), and trigger the activation of transcription factors, such as NF-κB, 
that are essential for the expression of proinflammatory cytokine genes. This pathway 
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also leads to the potent production of type I interferon (IFN) through the activation of 
IFN regulatory factor 7 (IRF7) upon stimulation of TLR 4, 7 and 8. The basal 
expression of MyD88 mRNA was up regulated by 2.5 fold in Rep4 cells (figure 3.6). 
To further study the effect of the presence of replicon on other TLRs through the 
MyD88 signaling pathway, Huh7 and Rep4 cells were treated with 10ng/µl of 
lipopolysaccharide (LPS). LPS is strong stimulator of TLR4 through MyD88 leading 
to the production of IFN-α. Expression of MyD88 was reduced in cells expressing NS 
proteins by stimulation with LPS (figure 3.6).  
Taken together, these results indicate that NS proteins are responsible for the 
inhibition of IFN-α and IFN-β induction though dsRNA and ssRNA pathways by 
down regulation of adaptor proteins.    
 
Figure 3.6:  HCV NS proteins affect IFN signaling via ssRNA dependent pathways. 
MyD88 mRNA was measured in Huh7 and Rep4 and then both cell lines were 
stimulated with 10ng/µl LPS for 24 and expression MyD88 was measured by qRT-
PCR. Expression were determined by real time qRT-PCR and normalized to GAPDH 
expression level. 
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3.7. Ablation of IFN pathway components by RNAi: 
Like all RNA viruses HCV RNA replication involves the production of dsRNA in the 
cytoplasm of infected cells. Thus, the finding that dsRNA poly (I:C) induces IFN-β 
mRNA in Huh7, indicates that cytoplasmic sensors, such as RIG-I or MDA5, should 
also be able to sense HCV RNA. To examine which of these factors is required for the 
recognition of HCV RNA; RNAi was used to ablate individual genes in Huh7 cells 
using siRNAs corresponding to each of the target genes RIG-I, MDA5, TRIF, MAVS 
and MyD88 using duplex siRNAs. Additionally GAPDH and scrambled non-targeting 
siRNAs were used as a control to examine the efficiency of transfection.  First, the 
efficiency of these siRNAs to knock down gene expression was tested for each single 
duplex by transfection in Huh7 cells with 20µM of each siRNA and lipofectamine 
2000. 48 hours post-transfection, mRNA expression was examined by PCR and the 
inhibition level was determined by qRT-PCR. β-actin mRNA was used as an 
endogenous positive control for relative expression calculation.  This showed that the 
target genes were significantly and specifically reduced in their expression levels by 
more than 80 % (figure 3.7). 
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Figure 3.7: Quantification of siRNAs inhibition level. Huh7 cells were transfected 
with specific siRNA duplexes and 48 hours post transfection, the target genes were 
quantified by qRT-PCR. GAPDH siRNA was used to measure the efficiency of 
transfection. Control non-targeting duplex siRNA (siCon), with a scrambled 
sequence, was used as negative control. All mRNA levels were normalized against 
cellular β-actin. 
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Next, the cells treated with these siRNAs were used to measure their effect on IFN-β 
induction. Huh7 cells grown in 24-well plates were transfected with specific siRNAs 
for RIG-I, MDA5, MAVS, TRIF and MyD88 in addition to control scrambled 
siRNAs, 24h later; cells were mock-treated or stimulated with 5ng/µl poly (I:C) for 
6h. 48 h posttransfection, quantitative RT-PCR was used for the detection of IFN-β 
and β-actin mRNAs in control and siRNAs transfected cells. The results showed that 
the inhibition of RIG-I or MDA5 by siRNAs reduced the ability of Huh7 to produce 
IFN-β transcripts (figure 3.8). Moreover, the inhibition of IFN-β resulting from 
MDA5 ablation was greater than RIG-I. This appears to correlate with the finding that 
MDA5 was the highest induced receptor in response to poly (I:C) transfection (figure 
3.4). Taken together, these results indicate that MDA5 is the major sensor for poly 
(I:C), which agrees with the finding of other researcher groups. Since both 
intracellular receptors used MAVS as a signaling mediator, knockdown of this protein 
showed even more inhibition of IFN-β. By comparison, inhibition of TRIF had less 
effect than MAVS. Also, MyD88 knockdown showed a significant inhibition of IFN-
β indicating the importance of other TLRs in the innate the immune response (figure 
3.8). 
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Figure 3.8: Inhibition of poly (I:C)-elicited production of IFN-β. Huh7 cells were 
grown in 24 well plates and transfected with control siRNA or siRNAs targeting RIG-
I, MDA5, double knockdown RIG-I/MDA5, MAVS, TRIF and or MyD88. 48 hours 
later, cells were stimulated by transfection with 5ng/µl poly (I:C). After 48 h, the 
mRNA were analyzed by real time qRT-PCR for the IFN-β and normalized against β-
actin.  
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3.8. Weak induction of the IFN-β RIG-I pathway in Huh7 cells by HCV 
 
 
As seen previously, in figures 3.4 and 3.5; Huh7 cells respond strongly to dsRNA 
poly (I:C) stimulation by increased expression of the dsRNA pathway genes which 
induce the expression of IFN-β. These results led to a further examination of the role 
of the dsRNA recognition pathway for HCV and the host in response to virus 
infection.  
To examine induction of IFN-β and RIG-I pathway components by HCV, Huh7 cells 
were infected with JFH-1 virus at a high (3.0) multiplicity of infection (MOI) and the 
expression of IFN-β mRNA and other components (RIG-I, MDA5, MAVS, TLR3, 
TLR7 and MyD88) was measured by qRT-PCR over a time course of infection for 6, 
18, 24 and 48 hours. First to confirm the level of virus infection, HCV viral RNA was 
quantified by qRT-PCR during the time course of infection. As shown in figure 3.9A, 
after an initial lag period, the intracellular HCV RNA content increased exponentially. 
In contrast, there was a smaller change in the level of IFN-β (2.3 fold) and other 
dsRNA pathway expression genes RIG-I (3.2 fold), MDA5 (3 fold), MAVS (2.3 fold) 
and MyD88 (1.3 fold) at 48 post infection (figure 3.9B). HCV JFH-1 infection and 
poly (I:C) transfection of Huh7 cells were then compared for their ability to induce 
these genes over a similar time frame.  As shown in figure 3.10, IFN-β and RIG-I 
pathway expression were highly induced in the Huh7 cells 6 h posttransfection with a 
maximum stimulation at 48 hours post infection in response to dose (5ng/µl) of poly 
(I:C). These results indicate that HCV infection of Huh7 cells does not trigger the 
intracellular dsRNA signaling pathway as efficient as poly (I:C) or that the virus may 
suppress these responses.  
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Figure 3.9: HCV infection induction of IFN-β or dsRNA response genes. (A) 
Quantification of intracellular HCV RNA by qRT-PCR analysis. Huh7 cells were 
infected with JFH-1 at a high multiplicity (MOI = 3). At the indicated times, total 
cellular RNA was extracted and HCV RNA were quantified by qRT-PCR. (B) The 
intracellular gene expression of IFN-β, MDA5, MAVS and MyD88. The expressions 
of target genes are presented as fold-induction relative to mock infected cells.  
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Figure 3.10: Comparison of HCV JFH-1 infection and poly (I:C) transfection on 
dsRNA response gene induction activated pathways in Huh7 cells.  Huh7 cells were 
infected with JFH-1 or transfected with dsRNA (poly (I:C)) for the indicated times. 
IFN-β, MDA5, RIG-I, MAVS and MyD88 mRNAs were measured by qRT-PCR 
analysis and normalized on GAPDH.  
 
To test the hypothesis, that HCV either fails to trigger or suppresses the intracellular 
dsRNA signaling pathway co-stimulation experiments were carried out.  Huh7 cells 
were infected with JFH-1 for 48 hours and then stimulated intracellularly by 
transfection with 5ng/µl poly (I:C) or extracellularly by adding the same 
concentration to the infected cell medium for 24 hours.  Total cell RNA was then 
extracted and qRT-PCR performed to detect various mRNA expression levels in 
comparison to Huh7 cells mock infected poly (I:C) treated cells.  As seen in figure 
3.11, Huh7 cells infected with HCV JFH-1 showed a significant decrease in the 
induction of IFN-β and other components after treatment with poly (I:C) compared to 
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uninfected cells treated with poly (I:C) (figure 3.11). These results indicate that HCV 
infection reduced the ability of Huh7 cells to activate the dsRNA and ssRNA 
recognitions pathway, which increases the ability of the virus to evade innate immune 
system and help to establish a chronic infection. 
 
Figure 3.11: HCV suppresses the dsRNA recognition signaling pathway. Huh7 cells 
were infected with HCV JFH-1 for 48 hours and then treated with poly (I:C) followed 
by measuring the expression of IFN-β, RIG-I, MDA5, TLR3, MAVS and IRF3 48 
hours later. These expression inductions of these genes were also measured in 
uninfected Huh7 cells treated with poly (I:C). Quantification of the gene expression 
was performed by qRT-PCR and normalized with GAPDH. 
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3.9. siRNA knockdown of RIG-I and MDA5 receptors stimulates HCV 
replication:  
The results obtained confirm that MDA5 is an important sensor for dsRNA. These 
results led to the further examination of the role of MDA5 in the host in response to 
HCV infection. Huh7.5 cells, which contain a defect in the RIG-I pathway were used 
to examine the role of MDA5 in the host response to HCV replication. To measure the 
signaling activity of Huh7.5, the cells were transfected with 5ng/µl of poly (I:C) and 
the transcription levels of IFN-β and MDA5, TLR3 and MAVS mRNAs were 
determined by qRT-PCR. This experiment showed that the signaling pathway 
mediated through MDA5 stimulated high levels of IFN-β induction in addition to the 
both MDA5 and MAVS mRNAs. TLR3 was stimulated to much lesser extent 
indicating that the stimulation of IFN-β is mainly activated through the MDA5 
pathway (figure 3.12).  
Importantly, HCV JFH-1 infection in Huh7.5 cells showed a weak signaling induction 
(figure 3.13). Taken together, this further confirms that HCV infection leads to the 
inhibition of the IFN pathway. 
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Figure 3.12: Poly (I:C) induction of antiviral responses in Huh7.5 cells.  Huh7.5 cells 
were transfected with dsRNA poly (I:C) for 24 hours and IFN-β, MDA5, MAVS and 
TLR3 mRNAs were measured by qRT-PCR analysis and normalized with GAPDH.  
 
Figure 3.13: induction of IFN-β signaling pathway components in Huh7.5 cells by 
HCV infection. Huh7.5 cells were infected with JFH-1 at a high multiplicity (MOI = 
3) for 48 hours and total cellular RNA was extracted and mRNA levels of IFN-β, 
MDA5, MAVS and MyD88 were determined by qRT-PCR. The expression of the 
target gene is presented as fold-induction relative to mock infected cells. 
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To further examine the role of MDA5 in IFN induction in response to HCV infection 
of Huh7.5 cells, MDA5 siRNA was used to transfect naïve Huh7.5 followed by HCV 
JFH-1 infection for 48 hours. The total cellular RNA was then isolated and HCV 
RNA and IFN-β transcripts were quantified by RT-PCR. HCV infection led to 
stimulation of IFN-β production. However, MDA5 ablation reduced IFN-β production 
significantly demonstrating an important functional role of MDA5 in the IFN-β 
response pathway (figure 3.14). 
 
 
Figure 3.14: The role of MDA5 in the IFN-β response to HCV infection. Huh7.5 cells 
were transfected with control siRNA (siCon) or siRNAs targeting MDA5 (siMDA5), 
48 hour posttransfection, cells were either infected with HCV JFH-1 or mock infected 
and incubated for 24 hours. IFN-β mRNA levels were measured by qRT-PCR.  
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HCV was previously shown to replicate at much higher titers in Huh7.5 than in the 
parental Huh7 cells (278). Although RIG-I has an important role in sensing HCV 
RNA, the results of MDA5 ablation in Huh7.5 cells show that it also has a role in the 
induction of IFN-β in response to HCV infection. RIG-I and MDA5 belong to the 
same family of DExD/H box helicases. However, MDA5 is known to preferentially 
recognize picornavirus RNA and poly (I:C). To further investigate the role of MDA5 
in the host response to HCV replication, siRNA targeting MDA5 was transfected into 
Huh7.5 cells which were subsequently infected with HCV. 48 hours post infection the 
intracellular virus RNA levels and the virus release into the supernatant was 
measured. Importantly, the analysis of virus yield further revealed that MDA5 
knockdown increased HCV production by more than 17 fold and intracellular 
replication was enhanced by more than two fold (figure 3.15). Taken together, these 
data suggest that RIG-I and MDA5 are both important mediators for HCV elicited 
induction of type I IFN in infected Huh7.5 cells and that the knockdown of RIG-I or 
MDA5 reduces IFN-β induction. RIG-I and MDA5 expression are both highly up-
regulated during virus infection and are required for optimal sensing of virus 
infection. 
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Figure 3.15: MDA5 mediated cellular restriction to HCV infection. Huh7.5 cells were 
transfected with control or (siCon) MDA5 (siMDA5) siRNA, 48 hours 
posttransfection, cells were infected with HCV-JFH-1 and 48 hours post infection the 
HCV RNA levels were determined by qRT-PCR. (A) Intracellular HCV RNA. (B) 
Virus released into the cell culture medium. 
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3.10. Effect of siRNA knockdown of IFN signaling components on HCV 
replication:  
To examine the effects on HCV replication, siRNAs were also used to knock down 
the expression of MDA5 and other dsRNA and ssRNA signaling pathway 
components (MAVS, TRIF and MyD88) in naive Huh7.5 cells. Inhibition of these 
signaling mediators by siRNAs showed a corresponding increase in the level of HCV 
replication. There were four fold increases in HCV when MAVS was ablated, and 
also significant increases in HCV yields when either MyD88 or TRIF were targeted 
(figure 3.16). 
Taken these results together indicate the innate immune response play a vital role in 
host response and virus replication. 
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Figure 3.16: Effect of ablation of MAVS, TRIF and MyD88 on HCV replication. 
Huh7.5 cells were transfected with control siRNA (siCon) or siRNA which targeted 
the signaling mediators indicated and then infected with JFH-1 HCV. HCV quantified 
by qRT-PCR at 48 h after infection. GAPDH was used as a control. (A) Intracellular 
HCV RNA. (B) Virus released into the cell culture medium 
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CHAPTER FOUR: 
4.0. Effects of HCV NS3 and NS/4A expression on type I IFN pathway 
components 
4.1.  Cloning HCV NS3 PCR product into an entry plasmid: 
In order to generate HCV NS3 expression constructs in adenovirus vectors, it was first 
necessary to clone HCV genome sequences into entry vectors so that they could be 
modified and propagated as required. The pENTR Directional TOPO Cloning Kits 
(Invitrogen) utilize a highly efficient, cloning strategy to directionally clone a blunt-
end PCR product into a vector for entry into the Gateway System. Blunt-end PCR 
products clone at greater than 90% efficiency. The TOPO vector contains attL1 and 
attL2 sites for site-specific recombination of the entry clone with a Gateway 
destination vector and Kanamycin resistance gene for selection in E.coli (section 8.2 
appendix). 
DNA fragments encoding each of the HCV NS3 and NS3/4A nonstructural proteins 
were generated from a full-length cDNA containing the whole genome of HCV clone 
of three different HCV genotypes. HCV genotype 2a, JFH-1 isolate, HCV genotype 
1b Con1 isolate and HCV genotype 1a isolate H77.  PCR primers were designed to 
amplify the region of interest and a four nucleotides “CACC” sequence necessary for 
directional cloning was added to the 5‟ end of the forward primers. The overhang in 
the cloning vector (GTGG) complements the 5‟ end of the PCR product, and anneals 
to the PCR product in the correct orientation, which allows the inserts to be cloned 
efficiently. ATG initiation codons were also added for the proper initiation of 
translation. After the PCR developing strategy, the primers were used to produce 
blunt-ended PCR products using thermostable, proofreading polymerase. The PCR 
reactions were carried out as described in the Materials and Methods using 
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ACCUAZYME proofreading polymerase (Accuzyme polymerase) and the PCR 
products were subjected to electrophoresis, to verify the quality and quantity of the 
PCR product (figure 4.1). Once a single discrete band of the correct size for each PCR 
was produced (figure 4.1), the PCR products were then subcloned into the pENTR/D-
TOPO vector and TOP 10 competent E. coli were transformed with the recombinant 
vector into and cultured overnight in LB medium containing 50μg/ml kanamycin. The 
cDNA inserts were verified by DNA sequencing of the constructs to confirm that 
genes were cloned in the correct orientation. 
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Figure 4.1: NS3 and NS3/4A amplification by PCR for cloning into the pENTR 
TOPO vector. ACCUAZYME proofreading polymerase was used and the PCR 
products were subjected to electrophoresis and stained with ethidium bromide. The 
single bands represent the correct product size (1893bp) of NS3 and (2054pb) of 
NS3/4A from different genotypes. Lane 1: NS3-1a, lane 2: NS3-2a, lane 3: NS3-1b, 
lane 4: NS3/4A-1b, lane 5: NS3/4A-2a, lane 6: NS3/4A-1a. All PCR products were 
run alongside with 1Kbp DNA marker ladders (M). 
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4.2. Virus production by transfection of pAd/CMV/V5-NS3 and NS3/4A into 
293A cells: 
Once the entry clones containing NS3 and NS3/4A genes were obtained, 
recombination reactions were carried out to transfer the NS3 and NS3/4A genes into 
the pAd/CMV/V5-DEST vector by means of the Gateway system using LR Clonase. 
pAd/CMV/V5-DEST (36.7 kb) destination vectors are adapted for use with the 
Gateway Technology, and are designed to allow high-levels of transient expression of 
recombinant fusion proteins in dividing and non-dividing mammalian cells using the 
ViraPower Adenoviral Expression System (Invitrogen). The pAd/CMV/V5-DEST 
vector is a replication-deficient adenovirus vector which contains the adenovirus 
serotype 5 (Ad5) encoding genes with an E1/E3 deletion mutation. Additionally it 
also contains the following elements (Left and Right Inverted Terminal Repeats 
(ITRs), encapsidation signal sequence, late genes) required for proper packaging and 
production of adenoviruses. Two recombination sites, attR1 and attR2 required for 
recombination cloning of the DNA sequence of interest from a pENTR entry clones 
were also present in the adenovirus genome. A ccdB gene located between the attR 
sites was used for negative selection. A human cytomegalovirus (CMV) immediate 
early promoter gave high-level constitutive expression of the gene of interest. An 
ampicillin resistance gene provided for selection in E. coli and chloramphenicol 
resistance gene (CmR) located between the two attR sites for counter selection. For 
detection of the recombinant protein, this vector contains a V5 epitope at C-terminal 
(appendix 8.2).  
To carry out the LR recombination reaction, LR Clonase II enzyme mix (Invitrogen) 
was used. This enzyme contains the bacteriophage lambda recombination proteins 
Integrase (Int) and Excisionase (Xis), and the E. coli encoded protein Integration Host 
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Factor (IHF) which promotes in vitro recombination between attL- and attR-flanked 
regions on entry clones and destination vectors to generate attB-containing expression 
clones. A recombination reaction between the NS3 and NS3/4A pENTR Topo vectors 
and pAd/CMV/V5-DEST was performed as described in section (2.2.7.4) and the 
recombined plasmids were immediately transformed into Max efficient E.coli cells, 
and selected on LB plates containing 50µg/ml ampicillin. Resistant colonies were 
picked and grown and the plasmids were extracted. These were then tested for correct 
recombination of the inserts by DNA sequencing. Seven constructs of pAd/CMV/V5-
DEST were produced and subsequently designated as pAdNS3-1a, pAdNS3-1b, 
pAdNS3-2a, pAdNS3/4A-1a, pAdNS3/4A-1b, pAdNS3/4A-2a and in addition to 
pAdLacZ which used as a control. 
Once the correct size and sequence of the plasmid constructs were confirmed, they 
were then linearized by digestion with PacI and then transfected into subconfluent 
293A cells with Lipofectamine 2000. Before transfection of pAdNS3 and 
pAdNS3/4A expression clones into 293A cells, the left and right viral ITRs must be 
revealed to allow proper viral replication and packaging by digestion of the vector 
with Pac I. This also removed the bacterial sequences (pUC origin and ampicillin 
resistance gene, 2000bp). 
The 293A cell line was used to allow initial production, amplification and titeration of 
the recombinant adenovirus. The 293A cells contain a stably integrated copy of E1 
that supplies the E1a and E1b proteins required for adenoviruses production. 5µg of 
each plasmid was digested and then purified using a PCR purification kit (Qiagen). To 
test the complete digestion, the plasmids were run on 1% agarose gels (figure 4.2). 
The purified plasmids were then transfected into 293A cells. 48 hours post-
transfection, the cells were transferred to T75 tissue culture plates until visible regions 
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of cytopathic effect (CPE) were observed approximately 6-8 days post-transfection. 
The infected cells were grown until a CPE approximately of 80% was observed and 
the adenoviruses were then harvested. This virus preparation was designated as P1 
(first purification). From P1 virus stock, fresh 293A cells were infected to produce P2, 
and from this P3 were produced. Finally the virus stock were titrated by plaque assays 
and virus concentration determined between 10
8
-10
9
 plaque forming unit (pfu) as 
shown in table 4.1. Figure 4.3 summarizes the steps performed to produce the 
adenovirus constructs. 
Constructs Titre 
AdNS3-1A 9.1 X 10
7
 pfu/ml 
AdNS3/4A-1A 3.6 X 10
8
 pfu/ml 
AdNS3-1B 3.2 X 10
7
 pfu/ml 
AdNS3/4A-1B 2.3 X 10
8
pfu/ml 
AdNS3-2A 1.44 X 10
9
 pfu/ml 
AdNS3/4A-2A 9.6 X 10
8
 pfu/ml 
AdLacZ 4 X 10
9
 pfu/ml 
 
Table 4.1: Titration of recombinant adenoviruses by plaque assay: the constructed Ad 
NS3, NS3/4A and AdLacZ adenovirus vectors were titrated by plaque forming assay. 
Serial dilutions of virus were made in 2% FCS DMEM. An aliquot of 250μl of each 
dilution was added to a monolayer of 293A cells and incubated at 37°C for 2 h. Cells 
were then overlaid with 4% agarose in 2% FCS DMEM  and incubated for 10 days. 
Plaque-forming units (pfu) were counted and calculated as detailed in section 2.2.7.8. 
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Figure 4.2:  PacI restrictions digest of pAdNS3 and pAdNS3/4A recombinant 
adenovirus vectors. Digested products of each plasmid genotypes plus LacZ, as 
indicated were run alongside a 1 Kbp DNA marker ladder (M) on a 1% agarose gel 
and stained with SYBR safe. The top arrow showed linearized pAdNS3 and 
pAdNS3/4A (38.7 kb), while the below arrow showed the removed pUC origin and 
ampicillin resistance gene (2Kp). Lane 1:  pAdNS3-1a, lane 2: pAdNS3-2a, lane 3: 
pAdNS3-1b, lane 4: pAdNS3/4A-1a, lane 5: pAdNS3/4A-2a, lane 6: pAdNS3/4A-1b, 
lane 7: pAdLacZ. 
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Figure 4.3: Construction of recombinant adenoviruses that express NS3 and NS3/4a 
proteins (1). HCV cDNA (genotypes 1a, 1b and 2a, the amino acids are indicated) 
was amplified and (2). cloned into the pENTR/D-TOPO (3) recombined into 
pAd/CMV/V5-DEST vector which contains homologous recombination between 
these two plasmids. This vector includes adenovirus sequences (Ad5), a CMV 
promoter, a V5 tag epitope (4). transfection into 293 cells led to (5). the formation of 
replication deficient recombinant adenoviruses that have the HCV genes of interest in 
the adenovirus genome. 
 
4.3.  Expression of recombinant NS3 and NS/4A proteins in Huh7 cells: 
Recombinant adenovirus vectors containing coding sequence for HCV NS3, NS3/4a 
from genotypes 1a, 1b and 2a or the LacZ recombinant adenovirus control (Ad/LacZ) 
were incubated at 100–200 MOI with Huh7 cells for 72 hours. To determine the 
percentage of Huh7 cells expressing HCV NS3 or NS3/4A, confocal 
immunofluorescence staining was performed. Rabbit polyclonal anti-NS3 antibody 
(NS3-7) followed by FITC labeled donkey anti rabbit polyclonal antibody (data not 
shown) or anti-V5 tagged monoclonal antibody followed by Cyc3 donkey anti-mouse 
antibody, were used to detect the recombinant proteins. The staining indicated that 
more than 90 % of the cells were transduced with the recombinant adenovirus vectors 
to express HCV NS3 or NS3/4A (figure 4.4). Control adenoviral vector-infected 
Huh7 cells did not show fluorescence with anti-NS3 or tag V5 antibodies. 
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Figure 4.4: Confocal immunofluorescence staining of Huh7 cells expressing NS3 and 
NS3/4A proteins. Staining of V5 tagged peptide Cyc3 (red) with anti-V5 antibody to 
localize HCV-antigen expression. Each slide show expressed NS3 or NS3/4A from 
different genotype as indicated. (A) Fluorescence staining, (B) phase contrast and (C) 
merge. 
AdNS3-1a AdNS3-1b 
AdNS3-2a AdNS3/4a-1a 
AdNS3/4a-1b AdNS3/4a-2a 
AdLacZ Neg. con 
A B 
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The levels of expression of NS3 and NS3/4A in the transduced Huh7 cells were also 
quantified by performing real-time qRT-PCR analysis. For qRT-PCR reactions a 
specific set of primers for each NS3 genotype was used. 
DNA was extracted from viral stocks and from infected cells. Huh7 cells were 
infected with all adenoviruses constructs for 72 hrs, then DNA extracted from virus 
stocks and Huh7 infected cells. The adenovirus titers were determined by qRT-PCR 
(figure 4.5). This provided the basis for optimizing the MOI, which was used for the 
subsequent experiments under the same infection conditions. In adenovirus infections 
in Huh7 cells MOIs ranged from 50 to 100 in experiments to produce consistent 
protein expression in 90% or more of cells. 
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Figure 4.5: Quantitation of adenovirus vectors viral particles using qPCR. DNA was 
extracted from adenovirus stocks and trasnduced Huh7 cells. For each qPCR reaction 
a specific set of primers for each NS3 genotypes was used.  
  
0.0E+00
5.0E+08
1.0E+09
1.5E+09
2.0E+09
2.5E+09
3.0E+09
3.5E+09
stock Transduced 
cells 
V
ir
al
 p
ar
ti
cl
e
s 
(D
N
A
 c
o
p
ie
s/
m
l) AdNS3-1a
0
1E+09
2E+09
3E+09
4E+09
5E+09
6E+09
7E+09
8E+09
9E+09
stock Transduced 
cells 
V
ir
al
 p
ar
ti
cl
e
s 
(D
N
A
 c
o
p
ie
s/
m
l)
AdNS3/4A-1a
0.E+00
1.E+09
2.E+09
3.E+09
4.E+09
5.E+09
6.E+09
7.E+09
stock Trasduced 
cells 
V
ir
al
 p
ar
ti
cl
e
s 
(D
N
A
 c
o
p
ie
s 
m
l)
AdNS3-1b
0
1E+09
2E+09
3E+09
4E+09
5E+09
6E+09
7E+09
stock Trasduced cells 
V
ir
al
 p
ar
ti
cl
e
s 
(D
N
A
 c
o
p
ie
s/
m
l)
AdNS3/4A-1b
0.E+00
1.E+09
2.E+09
3.E+09
4.E+09
5.E+09
stock Transduced 
cells 
V
ir
al
 p
ar
ti
cl
e
s 
(D
N
A
 c
o
p
ie
s/
m
l)
AdNS3-2a
5.0E+08
7.0E+08
9.0E+08
1.1E+09
1.3E+09
1.5E+09
1.7E+09
1.9E+09
stock Transduced 
cells 
V
ir
al
 p
ar
ti
cl
e
s 
(D
N
A
 c
o
p
ie
s/
m
l) AdNS3/4A-2a
 160 
4.4.  HCV NS3 and NS3/4A proteins reduce gene expression of IFN 
components: 
Figure 3.4 and 3.5 showed that the presence of the HCV RNA replicon modulates the 
expression level of TLRs and RIG-I/MDA5 receptors and the mediator proteins 
MAVS and TRIF in Huh7 cells, and consequently reduced the ability of Huh7 to 
respond to dsRNA indicating a role of NS proteins in this inhibition. Many studies 
have shown that HCV NS3/4A serine protease inhibits IFN induction by disrupting 
the TLR-3 or RIG-I/MDA5 pathways by targeting two adaptor proteins, TRIF and 
MAVS, for proteolysis. To determine whether the NS3 protein and its cofactor NS4A 
could also inhibit at the transcription level, Huh7 cells were transduced with the 
AdNS3 and AdNS3/4A from genotypes 1a, 1b and 2a in addition to AdLacZ vector 
control for 72 hours. The cells were then stimulated with 5ng/µl poly (I:C) to induce 
an innate immune response via the dsRNA pathways. After 24 or 48 hours the effects 
on mRNA expression were measured for RIG-I, MDA5 and MAVS.  
The results show that the HCV NS3/4A protein or NS3 alone could efficiently block 
the dsRNA signaling pathway by reducing many of the key signaling factors 
including RIG-I, MDA5 and MAVS (figure 4.6).  
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Figure 4.6: Effects of HCV NS3 and NS3/4A on RIG-I, MDA5 and MAVS 
expression. Huh7 cells were grown in 24 well plates followed by transduction with 
AdNS3, AdNS3/4A or AdLacZ for 72 hour. Cells were stimulated with poly (I:C) 
(5ng/µl) for 8 hours. Total RNA was extracted, and the mRNA expression: at 24 and 
48 hour post transfection was determined by real-time PCR and normalized using β-
actin mRNA (A) RIG-I, (B) MDA5 and (C) MAVS.  
 
 
4.5.  ssRNA Induced IFN-α Expression is blocked by the HCV NS3: 
To investigate the role of HCV NS3/4A in inhibiting IFN-α promoter activation 
induced by MyD88, the signaling mediator for TLRs 4, 7 and 8, Huh7 cells were 
transduced with AdNS3 and AdNS3/4a viruses. Two days post infection cells were 
stimulated with 5ng/µl LPS for 24 and 48 hours. The results demonstrate that the 
HCV NS3/4A protein or NS3 alone could efficiently block the ssRNA signaling 
pathway by reducing the expression of MyD88 (figure 4.7).  
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Figure 4.7: Effects of HCV NS3 and NS3/4a on MyD88 expression. Huh7 cells were 
grown in 24 well plates followed by transduction with AdNS3, AdNS3/4A or 
AdLacZ for 72 hour. Cells were then stimulated with 10ng/µl LPS. Total RNA was 
extracted and analyzed by real time RT-PCR for MyD88 mRNA expression at 24 and 
48 hour post stimulation and normalized against the levels of β-actin mRNA.  
 
4.6.  Protease inhibitor rescue of RIG-I signalling: 
To investigate the molecular mechanism of the antiviral activities of NS3/4A protease 
inhibitors in the type I IFN pathway, (10µM) of BILN 2061 was added to the culture 
media of HCV subgenomic replicons (Rep4) cells and Huh7 cells infected with HCV-
JFH-1 for 24 hours incubation. To confirm the antiviral activity of the BILN 2061 
compound, HCV RNA levels were determined by qRT-PCR.  This showed, in 
agreement with many previous reports, that BILN2061 has potent antiviral activity 
against genotype 1b replicons (a 2 log reduction was observed), which indicate that 
these compounds have potent antiviral activity against HCV viruses (figure 4.8A). 
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mRNAs expression was then measured, showing that BILN 2061 treatment of 
replicon cells reduced the expression levels of these genes to the level of naïve Huh7 
cells (figure 4.8B). Additionally, BILN 2061 reversed the NS3/4A-mediated 
inhibition of RIG-I, MDA5 and MAVS expression in response to transfection with 
poly (I:C) as previously shown (figure 3.4). This failure to induce IFN-β promoter 
activation when NS3/4A is expressed is due to the cleavage of the RIG-I adaptor 
protein MAVS.  
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Figure 4.8: Rep4 inhibition in response to BILN 2061 protease inhibitor treatment. 
(A) Rep4 cells were treated with BILN 2061 and 24 hours post incubation the 
replicon RNA levels were determined by qRT-PCR.  (B) Relative expression of RIG-
I, MDA5 and MAVS mRNAs in Rep4 cell in response to BILN 2061.  (C) Relative 
expression of RIG-I, MDA5 and MAVS mRNAs in Rep4 cell in response to BILN 
2061followed by poly (IC) transfection. Expression levels were determined from total 
RNA using real time qRT-PCR and normalized with GAPDH.   
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CHAPTER FIVE: 
5.0. Microarray Analysis of JFH-1 Infected Huh7 Cells 
Gene Expression Analysis of Huh7 cells infected with HCV was conducted by Dr 
McGarvey‟s lab in collaboration with GlaxoSmithKline Lab in the USA. Huh7 cells 
were either infected with JFH-1 at a multiplicity of infection (MOI) of 3 or mock 
infected with an equal volume of concentrated conditioned growth medium. At 6, 12, 
18, 24 and 48 hours post-infection, RNA was extracted, quality tested using an 
Agilent Bioanalyser and hybridized onto Human U133 Plus 2.0 Affymetrix 
microarray chips for fluorescence data acquisition.  Raw microarray expression data 
was processed using Array Studio software (Omicsoft, USA) to generate values 
representing fold change in gene expression. An average of the triplicate values was 
used to calculate fold change and each value was assessed for its statistical 
significance using ANOVA (177). Heatmaps representing the microarray data were 
then generated using Multi Experiment Viewing (MEV) software available within the 
TM4 Microarray Software Suite. Hierarchical clustering by Pearson Correlation was 
used to cluster the genes in each heatmap (177). 
 
5.1. HCV JFH-1 Infection alters Gene Expression in Huh7 Cell 
The effect of acute HCV infection on host gene expression was investigated using 
Huh7 cells infected with JFH-1 for 6, 12, 18, 24 and 48 hours.  Genes showing at least 
a 2 fold change in expression (p ≤ 0.05) were considered to be significantly regulated 
by infection. The number of genes affected by infection increased over time as JFH-1 
infection progressed through the HCV replication cycle. Interpretation of the 
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microarray gene expression data was performed using gene ontology analysis using 
the PANTHER Classification System. PANTHER identifies biological processes that 
are over-represented within microarray expression datasets. The biological processes 
significantly regulated by JFH-1 infection which are broadly related to cellular 
defense mechanisms, including immunity, interferon response and, cell cycle and 
apoptosis are shown in table 5.1. 
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Gene 
Symbol 
Entrez Gene description Affymetrix Fold 
Change 
JAK/STAT pathway 
 KRAS  v-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog 
 1559203_s_at  2.290 
 MRAS  muscle RAS oncogene homolog  225185_at  2.460 
 PIAS2  protein inhibitor of activated STAT, 2  1555514_a_at  -2.200 
 PIK3R3  phosphoinositide-3-kinase, regulatory 
subunit 3 (gamma) 
 211580_s_at  -2.310 
 SOCS2  suppressor of cytokine signaling 2  203372_s_at  7.910 
 SOCS3  suppressor of cytokine signaling 3  227697_at  2.920 
 SOCS4  suppressor of cytokine signaling 4  1552792_at  2.350 
 STAT1  signal transducer and activator of 
transcription 1, 91kDa 
 M97935_5_at  -2.280 
Interferon signaling 
IFNAR2  interferon (alpha, beta and omega) 
receptor 2 
 204786_s_at  -2.120 
 IRF1  interferon regulatory factor 1  202531_at  2.090 
 IRF9  interferon regulatory factor 9  203882_at  5.880 
 MX1  myxovirus (influenza virus) resistance 
1 
 202086_at  3.880 
 STAT1  signal transducer and activator of 
transcription 1, 91kDa 
 M97935_5_at  -2.280 
Cell cycle: G2/M DNA damage checkpoints regulation 
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 CCNB1  cyclin B1  214710_s_at  -5.230 
 CDC25C  cell division cycle 25 homolog C   217010_s_at  -2.300 
 GADD45A  growth arrest and DNA-damage-
inducible, alpha 
 203725_at  2.950 
 SKP2  S-phase kinase-associated protein 2   203626_s_at  -2.320 
 TOP2A  topoisomerase (DNA) II alpha 170kDa  201291_s_at  -2.250 
CCNE1  cyclin E1  213523_at  -2.110 
 HDAC4  histone deacetylase 4  228813_at  2.050 
 HDAC9  histone deacetylase 9  205659_at  4.120 
Cell cycle: G1/S checkpoints regulation 
 NRG1  neuregulin 1  206343_s_at  2.740 
 SKP2  S-phase kinase-associated protein 2   203626_s_at  -2.320 
 TGFB2  transforming growth factor, beta 2  228121_at  2.980 
Cell cycle Arrest Proteins 
INHBE inhibin, beta E 210587_at 18.01 
CIP29 cytokine induced protein 29 kDa 229069_at 2.99 
STC2 stanniocalcin 2 203438_at 20.5 
CDKN3 cyclin-dependent kinase inhibitor 3 209714_s_at -5.09 
CDKN2C cyclin-dependent kinase inhibitor 2C 
(p18, inhibits CDK4) 
204159_at -6.87 
 
Table: 5.1. Microarray analysis showing changes in the expression of genes 
involved in the interferon signaling pathway and cell cycle in Huh7 cells 
infected with HCV JFH-1 (mRNA expression at 48 hours post infection). 
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5.2. HCV JFH-1 infection stimulates a pro-inflammatory host anti-
viral response 
Three families of proteins are known to negatively regulate the JAK/STAT pathway: 
one is the SH2-containing phosphatase (SHP) family, the second is the suppressor of 
the cytokine signaling (SOCS) family of proteins, and the third is the protein inhibitor 
of the activated STAT (PIAS) family of proteins. In human genomes, there are two 
SHPs (i.e., SHP-1 and SHP-2), eight SOCS (SOCS1 to SOCS7 and CIS), and four 
PIAS family consists of PIAS1, PIAS3, PIASx (also known as PIAS2) and PIASy 
(also known as PIAS4) (284). The induction of SOCS expression is Jak–STAT-
dependent thus forming part of a negative regulatory mechanism. 
Genes involved in multiple anti-viral signaling pathways increased in expression 
following JFH-1 infection including; the type I and II interferon responses (e.g. MX1 
and OAS3), and genes involved in IFN induction through JAK-STAT (e.g. IRF1, 
IRF9). Increased expression of genes encoding negative regulators of the interferon 
response was also observed, (e.g. SOCS and PIAS). On the other hand down 
regulation of IFN receptors (IFNAR1 and IFNAR2) and signaling mediators STATs 
(STAT1 and STAT2) was shown. 
There is evidence that SOCS-1 and SOCS-3 inhibit the IFN-induced signal cascade 
and in hemopoietic tumor cells, over expression of SOCS-1 or SOCS-3 inhibits the 
antiproliferative and antiviral activity of IFN-α/β and IFN-γ. In addition, many studies 
have shown a relationship between treatment failure and expression of the gene 
encoding SOCS3 in patients who did not respond to type I IFN treatment. Microarray 
analysis showed that expression of SOCS family mRNAs expression (table 5.1) was 
up regulated in response to JFH-1 infection. To validate these findings and examine 
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its role in IFN inhibition, infection of HCV JFH-1 in Huh7 cells was carried out in 
triplicate for 48 hours at an MOI of 3. Total RNA was isolated and cDNA synthesized 
to measure the expression of genes involved in IFN signaling in response to infection. 
In agreement with the microarray result, qRT-PCR showed significant induction of 
SOCS family (SOCS1, 2 and 3) of mRNA expression. Additionally other targets 
involved in IFN induction including IFNAR (1 and 2), STATs and PIAS family genes 
(PIAS1 and PIAS2) were down regulated. PCR analysis also confirmed that IFN 
effectors genes including MXA1, IRF9 and IRF1 and OAS3 were up regulated in 
response to HCV infection. Infection of Huh7.5 cells with JFH-1 also showed a 
similar effect on these genes (figure 5.1).  
 
 
Figure: 5.1. Relative expression of interferon response and regulatory mRNAs in 
Huh7 and Huh7.5 cells in response to HCV JFH-1 infection.  Expression levels were 
determined from total RNA using real time qRT-PCR and normalized with GAPDH 
gene. 
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5.3. Reduction of viral replication by suppression of SOCS3 expression: 
Over expression of two families of negative regulatory proteins SOCS and PIAS 
inhibited the antiproliferative and antiviral activity of IFN-α/β (257, 258) and IFN-γ 
(259). In addition, many studies showed a relationship between treatment failure and 
expression of the genes encoding SOCS3 and PIAS1 in patients who did not respond 
to type I IFN treatment (261, 262). However, since PCR analysis showed that the 
PIAS family mRNAs were not up regulated compare to SOCS family mRNAs (figure 
5.1), this led to further investigation of the role of SOCS proteins in viral replication 
and the IFN inhibition pathway. To investigate the role of SOCS3 in HCV antiviral 
mechanisms, siRNAs were used to suppress the expression of SOCS3 mRNA in 
Huh7.5 cells. Transfection of siRNA suppressed the SOCS3 expression level in 
Huh7.5 cells by around 80 % compared to cells transfected with scrambled siRNA 
(figure 5.2).  
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Figure 5.2: Inhibition of SOCS3 mRNA expression with siRNAs. Huh7.5 cells were 
transfected with specific siRNA duplexes and 48 hours post transfection, the target 
genes were quantified by qRT-PCR. Control non-targeting duplex siRNAs (siCon), 
with scrambled sequence, was used as negative control. mRNA levels were 
normalized against the cellular GAPDH gene. 
 
To show the effect of reduced SOCS3 gene expression on HCV replication, Huh7.5 
cells were transfected with 100µM of SOCS3 siRNAs for 24 hours followed by 
infection with HCV JFH-1. 48 hours post infection the level of SOCS3 knockdown 
and the HCV RNA level was determined by qRT-PCR. As seen (figure 5.3), a 60% 
reduction in SOCS3 mRNA level reduced the HCV RNA expression four-fold 
compare to negative controls transfected with scrambled siRNA (siCon).  This result 
confirms that SOCS3 expression affects HCV replication. 
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Figure 5.3: SOCS3 knockdown reduces HCV replication. Huh7.5 cells were 
transfected with control (siCon) or SOCS3 siRNA, 48 hour posttransfection, cells 
were infected with HCV-JFH-1 and 48 hours post infection the HCV RNA levels 
were determined by qRT-PCR. (A) quantitation of SOCS3 inhibition level on 
siSOCS3 and siCon transfected cells. (B) quantitation of JFH-1 RNA levels from 
total RNA.  
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To study the role of SOCS3 knockdown on IFN-α treatment for HCV infection, 
SOCS3 siRNAs were used to transfect the Huh7.5 cells for 24 hours before JFH-1 
infection for 48 hours and then they were treated with IFN-α (25 IU/ml). HCV RNA 
levels were then determined at 24 hours after IFN-α treatment using qRT-PCR. As a 
control, Huh7.5 cells were similarly treated with scrambled siRNA and infected with 
JFH-1 and treated with IFN-α. This experiment showed that after treatment with IFN-
α and siCon, the level of JFH-1 RNA was 7 fold lower than in Huh7.5 cell transfected 
with siSOCS3 (figures 5.4). Taken together, these results show that SOCS3 proteins 
play an important role in inhibition of the IFN pathway and provide evidence that 
increasing SOCS3 expression may be a mechanism by which a virus evades the host 
anti viral machinery and can increase its persistence. 
 
 
Figure 5.4: Reduction of viral replication by inhibition of SOCS3 expression and 
IFN-α combination treatment. Huh7.5 cells were infected with JFH-1 virus for 48 h, 
and then transfected with siRNAs, and treated with IFN-α. The level of viral 
replication was determined using qRT-PCR. 
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SOCS3 knockdown also showed a correlation between inhibition of STAT1 activation 
and induction of SOCS3 expression. Huh7.5 cells transfected with SOCS3 siRNA and 
infected with JFH-1 were used to measure STAT1 mRNA by qRT-PCR. As seen in 
(figure 5.5) inhibition of SOCS3 mRNA led to changes in the expression of STAT1 
from a 1.2 fold down regulation to a 2.5 fold increase. This indicates that SOCS3 
knockdown also increased STAT1 mRNA expression in JFH-1-infected cells (Figure 
5.5). This indicates that IFN signaling through STAT1 correlates with SOCS3 
induction and the inhibition of IFN signal related to synthesis of SOCS3.  
Taken together, these data indicate that the regulation of interferon mediated antiviral 
responses by SOCS3 is important for HCV replication. 
 
Figure 5.5: STAT1 induction correlates with SOCS3 inhibition. Relative expression 
of STAT1 mRNAs in Huh7.5 cells in response to HCV JFH-1 infection after SOCS3 
knockdown by siRNA.  Expression levels were determined from total RNA using real 
time qRT-PCR and normalized with GAPDH gene. 
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5.4. HCV infection regulates expression of genes that control apoptosis 
and the cell cycle: 
Genes controlling apoptosis and the cell cycle arrest were significantly regulated by 
JFH-1 infection. Genes regulating cellular proliferation and cell cycle arrest were also 
significantly regulated following JFH-1 infection.  
Transcriptional changes of genes involved in  cell proliferation, included an increase 
in the expression of genes that promote cell cycle arrest (e.g. INHBE and STC2) and a 
decrease in the expression of genes required for cell cycle progression (e.g. CCNB1, 
CCNE1 and SKP2) (table 5.1). The majority of the differentially expressed genes 
associated with cell cycle regulation were involved with cell cycle checkpoint/arrest 
and subsequent induction of apoptosis, rather than actual progression through the cell 
cycle. Cyclin B1 plays an important role in control of the G2-M transition of the cell 
cycle, and in the regulation of mitosis. This gene was down regulated more than 5 
fold during HCV infection. CDC25C and SKP2 play a key role in the regulation of 
cell division. Also GADD45-α and GADD45-β mRNA (growth arrest and DNA-
damage-inducible, beta) were up regulated by significant levels (i.e. greater than 2 
fold). GADD45-α and β are members of a group of genes whose transcript levels are 
increased following stressful growth arrest conditions and treatment with DNA-
damaging agents. Furthermore, these findings, based on microarray analysis, were 
validated by real time qRT-PCR which showed the  down regulation of different 
genes involved in cell cycle arrest (CCNB1, SKP2 and CDC25C) while GADD45-α 
and GADD45-β were up regulated in response to HCV JFH-1 infection. This was 
carried out in both Huh7 and Huh7.5 cells (figure 5.6). 
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Figure 5.6: Relative expression of cell cycle regulatory mRNAs in response to HCV 
JFH-1 infection for 48 hours by comparison to mock infected cells.  Expression levels 
were determined from total RNA using real time qRT-PCR using GAPDH as a 
control. 
  
qRT-PCR was also used to investigate the level of expression of cyclin B1 and 
GADD45-β at 6, 18, 24 and 48 hours post-infection.  Microarray and qRT-PCR data 
for the temporal regulation of expression for cyclin B1 and GADD45-β genes is 
shown in figure 5.7. GADD45-β was consistently transcribed at a high level from 12 
to 48 hours post-infection (figure 5.7A). In contrast cyclin B1 expression decreased 
between 6 and 48 hours post-infection reached the maximum inhibition level (figure 
5.7B).   
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Figure 5.7: Temporal regulation of GADD45-β and cyclin B1 expression. qRT-PCR 
quantification of host gene expression at 6, 18, 24 and 48 hours post-JFH-1 infection 
of Huh7 cells was performed for (A) cyclin B1 (CCNB1) and (B) GADD45β. Fold 
change in gene expression is shown for the qRT-PCR data (diamond) and the 
corresponding microarray data (square). The mean of triplicate infection samples are 
shown for each time point of the qRT-PCR and microarray data.  
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5.5. Analysis of cell cycle and apoptosis by propidium iodide staining 
using flow cytometry: 
To further examine the role of HCV infection in cell cycle modulation and apoptosis, 
FACS analysis was used to measure the cellular DNA content in infected cells. This 
method is commonly used to measure the number of apoptotic cells by staining 
fragmented DNA with the propidium iodide (PI). PI is a fluorogenic compound that 
binds stoichiometrically to nucleic acids (285), so that its fluorescence emission is 
proportional to the DNA content of a cell (cellular RNA, is first removed by RNase 
treatment). Apoptotic cells stained with PI were analyzed with FACScan Becton 
Dickinson (BD). They displayed a broad hypodiploid (sub-G1) peak, which can be 
discriminated from the narrow peak of cells with normal (diploid) DNA content. Also, 
the distribution of cells in the various phases of the cell cycle indicates a proliferating 
cell population: the G1 and S (DNA synthesis phase), G2 and M-phase (mitosis). 
However, G2 and M phase, which both have an identical DNA content, cannot be 
discriminated based on a difference in DNA content (286). 
 
Flow cytometry analysis was performed to determine if HCV infection was associated 
with the induction of apoptosis. Huh7.5 cells were infected with HCV JFH-1 for 72 
hours at different MOIs (0.5, 1, 2, and 3 MOI). 72 post infection the cells were 
collected and the DNA was precipitated, and stained before FACS analysis.  In 
addition, mock infected and non- treated cells were used as negative controls to 
discriminate true apoptotic nuclei from nuclear debris. These controls were used to set 
the acquisition parameters correctly and debris from necrotic cells was eliminated and 
gated-off by eliminating the corresponding region. 
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As seen in figure 5.8A, the DNA content distribution in Huh7.5 cells changed in 
response to JFH-1 infection. As the virus MOI increased, the percentage of cells in 
G2/M phase was increased with an increase of sub-G1 apoptotic peak (reaching a 
maximum of 20%), and those in S phase decreased in a dose-dependent manner. Also 
there was reduction in G0/G1 phase cell population compared to the mock infected 
cells. These results indicate that HCV infection causes inhibition of cell proliferation 
by inducing cell G2/M arrest, followed by apoptosis. This significant increase in the 
number of subdipliod cells stained with PI, which is a late stage of the process of 
apoptosis, indicates that there is a high level of apoptosis in HCV infected Huh7.5 
cells (figure 5.8). 
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Figure 5.8: DNA fragmentation profiles of Huh7.5 cells. (A) untreated (CTR), mock 
infected (mock) or HCV infected cell at MOI of 0.5, 1, 2 and 3, representative graphs 
show DNA fragmentation by the appearance of a sub-G0 peak and changes in DNA 
contents G1 and S phase and G2/M cell phases. (B) Histograms showing the 
percentages of the cells from (A) at different phases at the cell cycle. 
 
 
5.6.  The role of RIG-I expression on cell cycle in HCV infected cells: 
To determine whether RIG-I pathway plays a role in changes in cell cycle during 
HCV infection, similar experiments to those described in 5.5, were conducted using 
Huh7 cells. After 72 hour postinfection at similar MOI, FACS analysis was performed 
for DNA fragmentation staining. As seen in figure 5.9 the number of sub-G0 
apoptotic Huh7 cells was significantly less compare to Huh7.5 cells (which have a 
defective RIG-I pathway) and the relative changes of in G1, S and G2/M were less 
marked compare to HCV infected Huh7.5 cells (figure 5.9). This suggests that the 
RIG-I pathway may play a role in linking innate responses via the IFN pathway and 
apoptosis and might define a role for HCV viral load.  
 184 
 
 
0
10
20
30
40
50
60
70
80
%
 C
e
ll 
co
u
n
t
R3 (sub-G0)
R4 (G0-G1)
R5 (S)
R6 (G2-M)
A 
B 
 185 
Figure 5.9: DNA fragmentation profiles of Huh7 cells. (A) untreated (CTR), mock 
infected (mock) or HCV infected cell at MOI of 0.5, 1, 2 and 3, representative graphs 
show DNA fragmentation by the appearance of a sub-G0 peak and changes in DNA 
contents G1 and S phase and G2/M cell phases. (B) Histograms showing the 
percentages of the cells from (A) at different phases at the cell cycle. 
 
 
5.7.  Apoptosis induction mediated by HCV JFH-1 infection correlates 
with intracellular HCV core levels: 
To show if HCV infection is associated with increases in apoptotic cells, Huh7 and 
Huh7.5 cells were infected at MOIs of 0.5, 1, 2 and 3. 72 hours post-infection the 
cells were collected and analysed, as described before, using FACS analysis to 
quantitate the proportions of cells at different stages at the cell cycle including those 
that were apoptotic. The HCV viral load was also determined by measuring the 
intracellular core protein levels using specific anti-core monoclonal antibody. The 
results show that in Huh7.5 cells that as the number of infected cells increased there is 
an increase in the number of apoptotic cells (figure 5.10). The intracellular JFH-1 core 
reaches maximum levels when, more than 70% of the cells were positive for core and 
the number of apoptotic cells reached a maximum of around 20% (figure 5.10C). An 
increase in apoptosis coincided with peak levels of intracellular viral core, suggesting 
a causative link between the level of HCV replication and cell death and further 
indicates that the apoptosis correlates with the intracellular virus load. 
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Figure 5.10: Apoptosis induction and cell death is correlated to HCV level. Huh7.5 
cells were infected with JFH-1 at 0.5, 1, 2 and 3 MOI. The levels of apoptosis were 
quantitated by propidium iodide staining and flow cytometry analysis at 72 h post 
infection. Upper row demonstrate histograms of cell G1, S, G2/M and sub-G0 cells 
using PI staining in Huh7 cells, the lower row representative histograms of PI 
staining positive in Huh7.5 cells. (A) Graphs represent cells stained with PI indicating 
DNA fragmentation and apoptosis. (B): Cells were stained for virus core protein 
using specific monoclonal antibody. (C) Histogram represents percentage of 
apoptotic cells and HCV core protein positive cell.  
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Time course infections were also carried out for 24, 48 and 72 hours in Huh7 and 
Huh7.5 cells. Infections were carried out in duplicate for each infection and mock 
infected and untreated cells were used as controls. Cells were harvested as described 
before at different time and analysed for DNA staining and intracellular core protein 
staining. High levels of HCV core were detected from 48 hours post-infection and 
reached a maximum at 72 hours for both cell lines leading to apoptosis (figure 5.11 
and 5.12). HCV JFH-1 infection cause a significant effect and perturbation of cell 
cycle phase of G1 and S phase which was observed at 48 hours post-infection (figure 
5.12).  
 
 
A 
 189 
 
 
 
B 
C 
 190 
 
Figure 5.11: Effects of HCV JFH-1 infection on the induction of apoptosis. Huh7 and 
Huh7.5 cells were infected with JFH-1 (INF 1 and INF2) at MOI of 3 or mock 
infected. (A) DNA fragmentation profiles at 24h post infection, upper row Huh7 
cells, lower row Huh7.5 cells. (B) DNA fragmentation profiles at 48h post infection, 
upper row Huh7 cells, lower row Huh7.5 cells. (C). DNA fragmentation profiles at 
72h post infection, upper row Huh7 cells, lower row Huh7.5 cells. (D) Histogram 
representing percentage of apoptotic cells in Huh7 and Huh7.5. Infections were 
carried in duplicate (INF1 and INF2) and mean and SD± of two infections were 
calculated. 
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Figure 5.12: Quantitation of core expression level in HCV JFH-1 infected cells. Huh7 
and Huh7.5 cells were infected with HCV JFH-1 at MOI of 3 (INF1 and INF2) or 
mock infected.  Cells were stained for HCV core protein. (A) 24h post infection, 
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upper row Huh7 cells and the lower row Huh7.5 cells. (B) 48h post infection. (C) 72h 
post infection. (D) Histogram represents percentage (INF1 and INF2) of core positive 
cells in Huh7 and Huh7.5. Infections were done in duplicate and mean and SD± of 
two infections were calculated. 
 
Taken together the results indicate that cell cycle modulation and apoptosis induction 
correlate with intracellular viral replication significantly implicates the RIG-I pathway 
in the induction of apoptosis. 
 
5.8.  HCV arrest cell cycle in G phase promotes increase for viral 
replication: 
The results of HCV JFH-1 infection indicate that there is an increase in the population 
of G2/M phase cells in virus-infected cells and a decrease in the number the G0/G1 or 
S phase cells. To investigate the effect of host G2/M arrest on HCV replication, the 
levels of virus replication and G2/M arrest was compared between Huh7 and Huh7.5 
cells. HCV JFH-1 was used to infect Huh7 and Huh7.5 at equal MOI. Cells were 
harvested 72 h post infection, and infected cells (core positive) were assayed for their 
cell cycle profile using PI staining. These experiments showed that HCV can cause a 
G2/M arrest in Huh7.5 cells and that virus replicates at higher level at G2/M (figure 
5.13 and appendix 8.4 for detailed analysis). These data suggested that HCV induces a 
G2/M phase arrest in infected cells to promote favorable conditions for viral 
replication.  
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To further investigate the induction of a G2/M phase arrest by HCV infection, cells 
should also be synchronized by thymidine for G1/S arrest and nocodazol for G2/M-
phase synchronization. 
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Figure 5.13: HCV infection mediated G2 cell cycle arrest: (A) Huh7 and Huh7.5 cells 
were either mock infected or infected with HCV JFH-1 (MOI = 3).  Cells were 
harvested 72 h post infection and analyzed by double staining for DNA content and 
HCV core levels using anti-core antibody. (B) Percentage of core positive cells in 
Huh7 and Huh7.5 in different phases of the cell cycle (R8= G0/G1, R9= S and R10= 
G2/M). Infections were performed in duplicate and mean and SD± of two infections 
were calculated. 
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5.9.  HCV JFH-1 causes perturbations in cell cycle regulatory 
molecules and reduces cyclin B1 expression: 
Cyclin B1 plays an important role in the control of the G2-M transition of the cell 
cycle and controls entry into mitosis. To determine whether HCV JFH-1 infection had 
an effect on the levels of cyclin B1 protein, Western blots were used to measure 
cyclin B1 protein level in HCV infected and mock infected Huh7 and Huh7.5 cells at 
48 and 72 hours post infection. The level of tubulin was used to demonstrate equal 
loading of proteins on gels. This experiment was conducted in duplicate, and 
representative Western blot data are presented in (figure 5.14). To obtain a measure of 
JFH-1 infection, immunoblotting was also used to show the presence of core or NS3 
protein, at 48 and 72 hours postinfection (figures 5.14 and 5.15). Western blot data 
indicated that there was no change in the level of tubulin between mock infected and 
infected cells at any time point. Between 48 and 72 h post infection the level of cyclin 
B1 was lower in infected Huh7 and Huh7.5 cells than in mock-infected cells (figure 
5.14). Image J software were used to measure blot density. Analysis showed that there 
was fivefold less cyclin B1 in infected cells at 48 h postinfection compared to mock-
infected cells. This indicates that HCV infection reduces the expression level of cyclin 
B1 protein required for mitosis, leading to cell cycle arrest and reduced cell 
proliferation. 
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Figure 5.14: HCV infection decreases cyclin B1 expression levels in Huh7 and 
Huh7.5 cells. (A) Western blot analysis was performed at 48 and 72 hours post 
infection with JFH-1. Equal amounts of total cellular protein were separated by SDS-
PAGE, transferred to nitrocellulose membranes, and blotted to detect cyclin B1, core 
and tubulin. (B)  Representation of quantification of each band of cyclin b1 protein 
that appeared on the Western Blot was calculated using the Image-J program. 
Relative Intensity was calculated by dividing the absolute intensity of each sample 
band (on the table) of infected cells by the absolute intensity of mock. (C) Histogram 
presents relative intensity for each sample band. 
 
 
The expression of GADD45-β in JFH-1 infected Huh7 and Huh7.5 cells was also 
examined. Western blot analysis revealed that GADD45-β was induced between 
48 and 72 h post infection in Huh7.5 cells. In contrast in Huh7 GADD45-β 
accumulated lower levels at 48 hours but increased reaching high levels at 72 and 96 
hours post infection (figure 5.15). This finding is consistent with previous results 
which showed that HCV infected Huh7.5 cells showed higher levels of apoptosis 
compared to Huh7 cells. In general, GADD45-β protein was induced at levels 
consistent with alterations observed for the expression mRNA by microarray and 
qRT-PCR analysis. These changes are also consistent with the cell cycle arrest finding 
of HCV infected Huh7.5 cell indicating the possible roles of cyclin B1 and GADD45-
β in the induction of apoptosis and cell death by during HCV infection. 
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Figure 5.15: HCV infection increases GADD45-β expression levels in Huh7 and 
Huh7.5 cells. Western blot analysis of GADD45β, NS3 and tubulin performed at 48, 
72 and 96 hours post infection with HCV JFH-1. Equal amounts of total cellular 
protein were separated by SDS-PAGE, transferred to nitrocellulose membranes, and 
blotted to detect GADD45β, NS3 and tubulin. 
 
 
5.10. Colocalization of cyclin B1 with HCV JFH-1 Huh7.5 infected cells: 
To further investigate how HCV infection influences cyclin B1. Immunofluorescence 
staining in HCV infected cells was carried out. Cyclin B1 (red color) was mainly 
detected in the nucleus with very low levels in the cytoplasm of the mock infected 
cells (figure 5.16, upper line). By contrast, the Cyclin B1 was mainly in the nucleo- 
cytoplasmic distribution of JFH-1 infected cells at 48h post infection, with only small 
quantities observed in the nucleus. These results indicate that HCV JFH-1 infection 
leads to a redistribution of the nuclear localized cyclin B1 to the cytosol thus initiating 
cell division and subsequently over expression GADD45-β leading to DNA 
fragmentation and cell death.  
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To examine its possible direct interactions of cyclin B1 with NS5A protein, HCV 
infected cells were double stained with anti-cyclin B1 and anti-HCV NS5A. Staining 
of NS5A proteins (green) was predominantly detected in the cytoplasm throughout 
the infection period. The merged images did not show colocalization of cyclin B1 and 
NS5A in the cytoplasm during infection (figure 5.16). However, the redistribution of 
the nuclear localized portion of cyclin B1 to the cytosol in JFH-1 infected cells did 
confirm that HCV infection alters the distribution of components involved in the 
regulation of the cell cycle. Further work should be carried out to reveal the molecular 
mechanisms involved in the alteration of cyclin B1 expression levels and location in 
infected cells. 
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Figure 5.16: Colocalization of cyclin B1 and NS5A proteins in the JFH-1 infected 
cells. Double staining of cyclin B1 (CCNB1) (red) and NS5A (green) proteins in 
uninfected (Mock) or infected Huh7.5 cells. Cells were stained as for 72 hours post 
infection. Colocalization of both NS5A and cyclin B1 was evidenced by merged 
images (yellow). 
 
 
 
 202 
6.0. Chapter six: Discussion: 
The innate immune responses are the first line of defence against an invading 
pathogen. Interferon type I (IFN-α and IFN-β) responses are key to innate antiviral 
immune defences. Early immune or innate responses depend on the detection of 
viruses by TLRs and intracellular patterns recognition receptors sensing viral 
components. The intracellular pattern recognition receptors (PRRs), RIG-I and 
MDA5 are the main sensors for the induction of IFN-β mediated by dsRNA in 
Huh7 cells during HCV infection. This study investigated the effects of HCV on 
the expression of key proteins e.g. microbial PRRs: TLRs (3, 7 and 8), RIG-I and 
MDA5 and other signaling proteins e.g. TRIF, MAVS and MyD88, which are 
involved in the interferon response. The expressions were measured in the 
presence and absence of HCV NS proteins in RNA replicons and HCV JFH-1 
infected cells and treatment with artificial dsRNA in Huh7 and subclone Huh7.5 
cells. The measuring of the levels of mRNAs encodes these proteins using real 
time qRT-PCR.  
To accurately quantify the mRNAs encoding these proteins, control amplicons 
which contain the target DNA sequence for the different genes were constructed 
to produce standard curves for the amplification of target DNA sequences. For 
each gene examined, PCR amplified DNA fragments of approximately 150 base 
pairs were synthesized and ligated separately into plasmid pCR2.1. In addition a 
target DNA sequence for β-actin was also used to compare any changes in the 
expression of the interferon pathway associated genes to those of a 
“housekeeping” gene.  
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Effects of HCV replicon on the expression of TLRs and RIG/MDA5 
pathways: 
First, comparisons of the basal expression levels in hepatocyte cell lines were 
performed between HCV RNA replicons in Huh7 cells and the parental Huh7 
cells. In this project, it was found that Huh7 cells that contain HCV RNA 
replicons which showed upregulation of TLR3, TLR7, RIG-I, MDA5 and the 
signaling mediators TRIF, MAVS and MyD88 compared to normal Huh7 cells. 
These may indicate that nucleic acids sensors TLRs, MDA5 and RIG-I are 
functionally active in Huh7 and Huh Rep4 cells and work in concert to maintain 
the induction of the antiviral genes, while IFN functions to amplify and/or expand 
the response in an attempt to control viral replication.  
TLR3 recognizes dsRNA that is generated during viral infection and plays an 
important role in host defenses against viruses. In this study, quantification of 
TLR3 expression levels was demonstrated to be very low in Huh7 and Rep4 cells. 
Treatment of Huh7 cells by adding poly (I:C) (i.e. non specific dsRNA), showed 
little change in TLR3 expression. Similarly, the TLR3 signaling mediator TRIF 
was also found to have very low levels of expression in Huh7 cells. This agrees 
with the results from other groups which have reported that Huh7 cells possess a 
weak or defective TRIF signaling pathway (270). 
MDA5, RIG-I and MAVS, mRNAs basal expression were found to be expressed 
at high levels in Huh7 cells and upregulated up to four-fold in Rep4 cells (figure 
3.3). This is consistent with the detection of dsRNA in Huh7 cells being mainly 
mediated by the intracellular receptors RIG-I and MDA5 and that provides a 
useful model to elucidate the individual importance of RIG-I and MDA5 in HCV 
infection. This was supported by showing that in Huh7 cells, expression of both 
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RIG-I and MDA5 respond to poly (I:C) (figure 3.4, 3.10) and demonstrated that 
the parental Huh7 cells could induce IFN expression in response poly (I:C). In 
contrast to Huh7 cells, the expression of TLR3, TRIF, RIG-I, MDA5 and MAVS 
mRNA transcription in response to transfection of poly (I:C) , showed lower 
levels in the Huh7 Rep4 cells, indicating strong inhibition of IFN expression in the 
presence of the HCV replicon (figures 3.4 and 3.5). In this study, expression of 
MDA5 showed more stimulation with poly (I:C) (50 fold) compared to RIG-I (12 
fold), in Huh7 cells. This is consistent with previous findings on post-
transcriptional activation of RIG-I and MDA5, in that RIG-I is activated mainly in 
response to RNA bearing a triphosphate at the 5′ end and a polyuridine motif in 
the 3′ untranslated region (UTR) of HCV, while MDA5 is activated primarily by 
poly (I:C) and picornaviruses. 
TLR7 and TLR8 are receptors for ssRNA associated with viruses that enter cells 
through endocytosis and they induce interferon expression via MyD88. In 
humans, the expression of TLR7 is mainly confined to plasmacytoid dendritic 
cells and B lymphocytes. However, TLR7 mRNA has been detected in Huh7 
cells, and HCV replicon cells showed a two fold increase (figure 3.3), indicating 
that expression of TLR7 is functionally active in hepatocyte cells. Several reports 
have indicated that TLR7 ligands such as imiquimod and SM360320 can inhibit 
HCV replication in hepatocytes via a type I IFN-independent mechanism in 
addition to its IFN-mediated activity (287). This raised the possibility that TLR7 
stimulants may be able to control chronic HCV infection. TLR7 signaling is 
mediated primarily by MyD88, which triggers the activation of transcription 
factors, such as NF-κB, through the activation of IRF7 which leads to the 
production of type I interferon (IFN) mRNA. HCV NS5A interacts with the death 
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domain of MyD88 through the IFN sensitivity-determining region (ISDR) 
spanning amino acid residues 240 to 280 and can impair cytokine production in 
macrophage cells (288). To activate MyD88, LPS was used as it is a strong 
stimulator of TLR4 which acts through MyD88 leading to the production of IFN-
α. In this study, it was clearly demonstrated that the expression of MyD88 mRNA 
was reduced in HCV Rep4 cells in response to stimulation with LPS (figure 3.6). 
 
Effects of HCV JFH-1 infection on the expression of TLRs and RIG/MDA5 
pathways: 
Comparisons between the basal expression levels in Huh7 cells and cells that have 
been infected with HCV, by qRT-PCR, showed low levels induction of IFN-β and 
the dsRNA recognition receptors, RIG-I and MDA5, and signalling mediators,  
MAVS, MyD88 and IRF3. In contrast, poly (I:C) strongly induces dsRNA 
recognition components and induces IFN-β mRNA transcription in Huh7 cells. 
These comparisons of infection and transfection were performed, beginning early 
after infection, before the HCV NS3/4A protease could cleave MAVS and 
abrogate this pathway. 
The antiviral transcription activity in Huh7.5 cells was also examined as they lack 
an active RIG-I pathway. Huh7.5 cells transfected with poly (I:C) showed high 
levels of IFN-β, MDA5 and MAVS mRNAs. TLR3 mRNA transcription was 
induced to a much lesser extent indicating that in the absence of RIG-I the 
stimulation of IFN-β is likely to be activated through the MDA5 pathway (figure 
3.12). By contrast, HCV JFH-1 infection in Huh7.5 showed a weak signaling 
induction (figure 3.13) similar to that shown in Huh7 cells. Together, the results of 
HCV JFH-1 infection of Huh7 and Huh7.5 cells showed that HCV infection leads 
 206 
to the inhibition of the IFN induction pathway. Similar finding were observed in a 
recently published study which used Huh7.5 and TRIM25 permissive 
Huh7.25.CD81 cells (289). These results indicate the importance of the RIG-
I/TRIM25 pathway in the control of HCV expression since both Huh7.25.CD81 
and Huh7.5 cells, have defects in this pathway, at the level of RIG-I for Huh7.5 
cells and of TRIM25 for Huh7.25.CD81 cells (289). 
Loo et al, suggested that that HCV could induce the IFN-β pathway in infected 
cells by the production of dsRNA replication intermediates, which would then be 
suppressed by NS3 protein when it reached sufficient expression levels (273). 
However, in this study, the RIG-I pathway in Huh7 cells, fails to trigger IFN-β 
induction as early as 6 hours after HCV infection and at 48 hours infection (figure 
3.10). These results indicate that HCV may control IFN induction at the 
transcriptional level during infection in addition to the NS3/4A-mediated MAVS 
proteolysis cleavage.  
To further investigate this, the effects of double-stranded RNA on altering gene 
expression levels in hepatoma cells was carried out using poly (I:C). JFH-1 HCV 
infected Huh7 cells and mock infected Huh7 cell were stimulated with poly (I:C).  
Huh7 cells infected with HCV JFH-1 showed a significant decrease in the 
induction of IFN-β and other components after treatment with poly (I:C) leading 
to reduced gene induction, confirming that HCV infection reduced the ability of 
Huh7 cells to activate the dsRNA and ssRNA recognitions pathway. These results 
showed that HCV efficiently suppresses IFN-β pathway induction which increases 
the ability of the virus to evade the innate immune system and help to establish a 
chronic infection. 
Ablation of Interferon Pathway Components by RNA interference;  
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To examine the roles of innate immune proteins of the interferon response 
pathway during HCV expression, siRNAs corresponding to each of the target 
genes RIG-I, MDA5, TRIF, MAVS and MyD88 were used to knock out 
individual or combinations of genes of the interferon pathway. The knockdown of 
TRIF followed by poly (I:C) stimulation showed a direct effect on IFN-β 
transcription, whereas, the knockdown of MAVS after poly (I:C) stimulation 
showed a significant inhibition of IFN-β. Additionally, double knockdown of 
TRIF and MAVS showed further clear reduction in IFN-β levels indicating a 
minor effect of TRIF on IFN-β induction. Some reports have claimed that NS3/4A 
did not respond to poly (I:C) in Huh7 cells because it was unable to cleave TRIF. 
TLR3‟s involvement in host defense against HCV remains controversial. TRIF 
was shown to be cleaved by purified single chain NS3/4A protease in vitro, 
whereas TRIF cleavage products in HEK 293 cells expressing NS3/4A have not 
been found. Dansako et al. demonstrated that the TLR3/TRIF signaling pathway 
was not affected in the non-neoplastic human hepatocyte PH5CH8 cells 
expressing NS3/4A (290). However, this could be due to low levels of expression 
of TLR3 and TRIF proteins in Huh7 and Rep4 cells and their relative 
unimportance in these cells. 
Experiments also showed that even after ablation of MAVS and RIG-I in TLR3 
deficient Huh7 cells, the levels of IFN-β were still detectable. It is therefore 
possible that additional proteins could be important for host responses to HCV 
infection. Loo et al demonstrated that infection by DEN2 and Reovirus triggered 
IRF3 in wt, RIG-/- and MDA5-/- cells (273). Taken together, these results could 
support the hypothesis that as yet undefined cytoplasmic components are also 
involved in innate immune signaling in HCV infected Huh7.5 cells.  
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The role of MDA5 in HCV infection: 
Several recent reports have clarified the molecular pathways recognized by RIG-I 
and MDA5 during virus infection. RIG-I has been shown to trigger innate immune 
defenses during infection by paramyxoviruses, orthomyxoviruses, and 
rhabdoviruses, (vesicular stomatitis virus) (238, 250). In measles virus (MV) 
infection, RIG-I and MDA5 are both involved in virus recognition. The V protein 
plays an important role in MV growth by inhibiting the MDA5-mediated 
induction of the host IFN responses (291). Also herpes simplex virus-1 and 
adenovirus which are both DNA viruses, were shown to replicate to much higher 
titers in RIG-I mutant human hepatoma cells Huh7.5.1 than in the parental Huh7 
cells (292). In contrast, MDA5 triggers innate immune defenses during 
picornavirus (250, 254) and rhinovirus (RV) infection (293). Other recent reports 
have shown that members of the Flaviviridae exhibit differential triggering of the 
innate immune responses. Japanese encephalitis virus and hepatitis C virus 
initiated a primarily RIG-I dependent response (250, 294), whereas West Nile 
virus and dengue virus triggered RIG-I- and MDA5-dependent signaling (295), 
suggesting that flaviviruses may have different features that can be discerned 
separately by RIG-I and MDA5 (295).  
However, the importance of RIG-I in HCV replication was shown in the JFH-1 
replication system in Huh7.5 cells which lack RIG-I. However, despite 
experimental evidence, the roles played by other individual pattern recognition 
receptors in the restriction of HCV infection are still not clearly understood. This 
study demonstrated that MDA5 has a role in triggering HCV elicited induction of 
IFN-β and virus replication, and that MDA5 silencing by siRNA increases the 
release of progeny virus. Moreover, this study indicates further roles of different 
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signaling mediators MAVS, TRIF and MyD88 in HCV replication. Taken 
together these results indicate that both RIG-I and MDA5 are involved in 
induction of IFN response in HCV infected cells and that several innate immune 
response components play a vital role in the host response to virus replication and 
consequently disease outcome. 
Identification of novel innate response proteins: 
To identify novel host genes involved in the innate host responses to HCV 
infection. Gene profiling by microarray analysis was used to identify mRNAs that 
are up regulated or down regulated during HCV infection. mRNAs were extracted 
from Huh7 cells infected with HCV JFH-1. Genes identified by microarray 
analysis were characterized from sequence databases and by RT-PCR. According 
to the microarray results, HCV infection showed a remarkable modulation of the 
pathways involved in the innate immune response. Quantitative PCR analysis of a 
number of the IFN-regulated genes identified from the microarray analysis 
demonstrated a good correlation with the gene expression data from the 
microarrays, although the ratios calculated from RT-PCR generally exceeded 
those obtained using microarrays. 
Analysis of the expression of genes encoding proteins involved in interferon (IFN) 
signaling pathways and genes that regulated by IFN has shown that chronically 
infected HCV individuals show evidence of an IFN response. One of the main 
characteristics of HCV is its tendency to persist despite the massive type I ISG 
expression response that it induces in the liver (6, 170, 296). Gene expression 
analysis of liver tissue from HCV-infected mice also demonstrated an up-
regulation of many known IFN-stimulated genes (ISGs). These included key 
genes associated with the IFN signalling pathway, such as IFNAR1, STAT1, 
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IRF1, IRF9, OAS3, and Mx1, (table 5.1). qRT-PCR confirmed these findings in 
HCV-infected cells indicating that HCV can induce ISG mRNA transcription, 
indicating that HCV does not completely block IFN signaling. These results 
confirm previous observations in vitro showing comparable induction of ISG 
mRNAs (297, 298), and are also consistent with the strong ISG mRNA induction 
in the liver during HCV infection (6). 
No changes in gene expression were observed in infected cells of the antiviral 
response to HCV JFH-1 which occurs through the activation of the RIG-I/MDA5 
pathway, indicating that viral attachment/entry does not significantly impact host 
gene expression. Similar results were obtained from HCV infection in Huh7.5 
cells (299). In comparison to functional gene analysis conducted with other 
viruses, Influenza A infection showed, that in contrast, both RIG-I and MDA5 
changes are observed during acute virus infection. In addition to both cytosolic 
recognition receptors, RIG-I and MDA5, TLR3, MAVS, MyD88 and TRIF were 
also upregulated (295, 300). However, in response to the highly lethal 1918 virus, 
RIG-I and MDA5 were not induced (300). Dengue virus also showed upregulation 
of TLR3, TLR8, RIG-I and MDA5 mRNA along with an increase in IFN-β 
expression (301). Moreover, intra-hepatic gene expression during HCV infection 
of chimpanzees showed that RIG-I was strongly induced. This discrepancy may 
be a reflection of the inherent differences in the host response to acute versus 
chronic viruses. Chronic viruses such as HCV may have evolved to cause minimal 
impact upon entry into cells in an effort to delay cellular changes that may trigger 
an immune response, as evidenced by the minimal effect on innate immune host 
gene expression even at 48 hrs post-HCV infection and by reduction of gene 
expression in response to poly (I:C) induction.  
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On the other hand, functional genomic analyses show that infection of influenza A 
and Dengue viruses typically trigger the rapid expression of immune system-
related genes responsible for mediating transient immune responses that 
effectively resolve infection (300, 302). Importantly, many of these disease-
related genes induced by pandemic influenza virus infection are present in the 
RIG-I-responsive genes (295). From all of this it might be concluded that the 
processes that trigger and control RIG-I/MDA5 signalling during virus infection 
and the products of RIG-I/MDA5 responsive genes could be important 
determinants of viral pathogenesis and disease outcome during HCV infection.  
 
Alternative IFN inhibition by SOCS3 
The results from the microarray analysis of host gene expression during HCV 
infection also showed an up-regulation of genes associated with the JAK/STAT 
pathway, including SOCS1, SOCS2, SOCS3, PIAS2, which play a role in 
regulating the Jak-STAT pathway. Many of the up-regulated ISGs in HCV-
infected mice are also induced during the acute phase of HCV infection of chimps 
as well as chronically infected human patients. The SOCS family proteins are of 
particular interest as SOCS3 is expressed at high levels in patients who are 
nonresponsive to IFN treatment (261, 262, 303, 304). HCV genotype 1b infected 
patients exhibit higher level of expression of SOCS3 than genotype 2a-infected 
patients (304). It has been hypothesized that SOCS3 overexpression may explain 
why HCV genotype 1b-infected patients do not respond to IFN and suggested that 
reducing SOCS3 gene expression may be an approach to treating HCV infection 
(304). In this study, HCV JFH-1 infected cells were used to investigate the 
relationship between SOCS3 and HCV replication. HCV infection increases 
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SOCS3 mRNA levels and SOCS3 expression inhibits phospho-STAT1 
expression, which impairs the IFN defense pathway. In addition, it has been 
previously reported that HCV core protein induces SOCS3 expression in cell lines 
causing impaired IFN and specifically STAT1 signaling (305). By contrast, recent 
work has shown that core did not alter SOCS3 levels (306). But from genotype 1 
replicon cells and JFH-1 infection did cause overexpression of SOCS3 and 
inhibited IFN induced STAT1 phosphorylation (306). In agreement with this, the 
current study showed that JFH-1 infection causes upregulation SOCSs (1, 2 and 3) 
mRNA expression when measured by microarray and qRT-PCR. These results led 
Chao et al to suggest that the antiviral actions of SOCS3 are mediated by an 
independent pathway (306). Importantly, this study showed that knockdown of 
SOCS3 clearly caused an inhibitory effect on HCV replication. Also, SOCS3 
knockdown leads to the restoration of the expression level of STAT1 mRNA 
(figures 5.3 and 5.5). Taken together, we conclude that HCV has evolved an 
additional mechanism to evade host innate immune responses, also providing a 
possible therapeutic candidate.  
Analysis of the Effect of HCV NS proteins on the Interferon Pathway  
The HCV NS3/4A protease can disrupt antiviral signaling in various hepatic cell 
lines. Both TRIF and MAVS adaptors of antiviral signaling pathways were 
identified as cellular substrates of HCV NS3/4A protease (270, 273, 292, 307). 
However, the effect of NS3/4A on the expression of genes involved in the 
recognition of dsRNA and ssRNA in primary human hepatocytes is not known.  
In this study, recombinant adenoviruses that express NS3 and NS3/4A from 
different genotypes were constructed and examined for the effects of viral proteins 
on dsRNA induction. The expression of the NS3 and NS3/4A proteins inhibits the 
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expression of dsRNA sensing receptors RIG-I, MDA5 as well as inhibiting 
MAVS. In this study, it was shown, that NS3 alone or in combination with NS4A 
could reduce the expression of the different IFN-β signaling component mRNAs 
and the inhibition efficiency of NS3 with NS4A was similar to NS3 alone. This 
was observed with NS3 and NS4A from the three different genotypes 1a, 1b and 
2a. Furthermore, expression of NS3 and NS3/4A using the adenovirus vectors led 
to a reduction in MyD88 gene expression, which can cause a defect in the TLR7-
mediated pathway for ssRNA detection. These results indicate that NS3 and 
NS3/4A proteins are responsible for the inhibition of IFN-α and IFN-β induction 
though dsRNA and ssRNA pathways.  
 
HCV standard treatment is the combination of pegylated interferon and ribavirin. 
Efficacy of treatment is approximately 80% in patients infected by HCV genotype 
2 or 3, whereas in patients infected by HCV genotype 1 the response to treatment 
is less than 50% (170, 308, 309). The NS3/4A protease can inhibit the innate 
immune response by reducing RIG-I, MDA5, MAVS and MyD88 expression. 
Thus, differences in NS3/4A activity could be related to viral pathogenicity. In 
this study, the inhibitory efficiency of NS3/4A from HCV genotypes 1b, 1a and 2a 
were analyzed. However this study the expression of the NS3 and NS3/4A 
proteins from genotypes 1a, 1b and 2a showed that was no significance difference 
in their ability to inhibit the transcription of RIG-I, MDA5, MAVS and MyD88. 
However, other studies have shown that the catalytic efficiency of NS3/4A 
protease is genotype dependent. The enzymatic activity of each variant protease 
were evaluated by engineering the HCV polyprotein NS5A/NS5B cleavage site 
into a bacteriophage λ,  and this demonstrated a six-fold difference between 
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different genotypes (310). NS3/4A proteases from genotype 1b displayed the 
highest catalytic efficiency (310). Another study also showed that MAVS is 
cleaved by all HCV NS3/4A  from all genotypes and that NS3/4A from genotypes 
2 and 3 were more efficient in proteolysis than those genotypes 1 and 4 (311). 
Potent inhibitors have been developed for both the viral NS3/4A protease and 
NS5B RNA-dependent RNA polymerase. Major in vivo antiviral responses have 
been demonstrated in early clinical trials with several protease inhibitors, 
including BILN 2061 and VX-950 (telaprevir). Some of these candidate antivirals 
are now advancing into larger phase III studies. To further confirm the role of 
NS3 protein in inhibition of type I IFN induction. BILN 2061 was used to study 
the effect of NS3 inhibition on dsRNA components expression restoration. The 
specific antiviral inhibitor BILN2061 blocked the NS3-mediated cleavage of 
MAVS and completely restored the dsRNA-activated antiviral response.  In this 
study, treatment of replicon cells with BILN 2061 reduced the expression levels of 
RIG-I, MDA5, MAVS and MyD88 to the level of naïve Huh7 cells and reversed 
the NS3/4A-mediated inhibition of RIG-I, MDA5 and MAVS signaling in 
response to transfection with poly (I:C). These results indicate a possible role of 
NS3 protein in the inhibition of IFN induction mediated by dsRNA stimulation. 
However BILN 2061 also inhibits the replication of HCV and this could also lead 
to upregulation of ISG sensors. However, since the role of HCV NS3/4A proteins 
have been identified in IFN inhibition by direct targeting both TRIF and MAVS 
adaptors proteolysis (270, 273, 292, 307). The mechanism of the NS3/4A in the 
inhibition of IFN components at the transcription level, as demonstrated clearly in 
this study, is still not fully understood. In agreement, a recent study showed 
similar effects on the innate responses to intracellular dsRNA. It showed that 
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transcription of several innate response genes is severely compromised upon 
ectopic expression of the HCV NS3/4A protease in normal human primary 
hepatocytes, and treating cell with protease inhibitor BILN2061 completely 
restored gene expression (312). 
Apoptosis and cell cycle regulation: 
In this study, HCV infection showed direct cytopathic effects which indicate that 
HCV has the potential to mediate apoptosis. This suggests a role for HCV in liver 
injury during chronic HCV infection, in addition to the immune-mediated liver 
injury. The appearance of cytopathic effects may be due to the induction of cell 
death-related genes. The results of the microarray study, showed a reduction in 
expression of genes related to the cell cycle e.g. cyclin B1, CDC25C and SKP2 
and related to growth arrest and DNA-damage e.g. GADD45-α and GADD45-β, 
were consistent with this. Furthermore this was confirmed by quantitation of sub-
G0 cells as appeared in the FACS analysis results. The highest cell death rate 
coincided with peak viral loads, suggesting that intra-hepatic HCV RNA levels 
play a role in hepatocyte cell death.  However, the role of viral load in HCV-liver 
disease remains controversial, Pal et al, demonstrated an association between the 
number of hepatocytes harboring replicating HCV and severity of fibrosis (313). 
Other studies have shown that HCV levels were associated with cholestatic 
fibrosis, a severe form of hepatitis (314) and accelerated HCV-induced allograft 
injury (315). In this study, we showed that, in vitro, the cell death rate is 
associated with viral replication.  
Also in this study, a comparison between the parental Huh7 cells and Huh7.5 
(which have a defective RIG-I) was performed. This comparison was necessary to 
explain the discrepancy in the level of hepatocyte cell death that occurred in vitro 
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and during chronic HCV infection. The levels of HCV replication in Huh7 cells 
are much lower than in Huh7.5 cells and there is an increase in the number of 
apoptotic cells in Huh7.5 cells. Additionally the level of HCV replication was 
associated with an increased expression of GADD45-β, as validated by qRT-PCR 
and at protein level as demonstrated by Western blotting.  It might therefore be 
concluded that the inactivation of dsRNA signaling through RIG-I has an 
important role in apoptosis induction. This indicates that the balance of IFN 
mediated suppression of HCV replication and HCV-mediated regulation of host 
innate antiviral pathways are key factors for HCV control over innate antiviral 
signaling and shape the outcome of infection.  
 
The ability of HCV to perturb the cell cycle and the consequent effects on virus 
replication are not well understood. Alteration of the host cell cycle by RNA 
viruses has not been described as extensively in the literature compared to DNA 
viruses or retroviruses. For example, human immunodeficiency virus type 1 (HIV-
1) Vpr arrests cells in the G2 phase (316-318). This arrest leads to an increase in 
RNA transcription and virus production (317, 319). Similar observations were 
found in Coronavirus infection, which induces a G2/M phase arrest in infected 
cells to promote viral replication (320). However, studies based on single protein 
expression have shown that HCV core protein has a role in impairment of G1 to S 
phase transition by induction of p21 expression, a decrease in cdk2 activity (321), 
and direct interaction and suppression of CAK activity, and stabilization of cell 
cycle inhibitor p27 (322).  In addition to microarray analysis and qRT-PCR (table 
5.1 and figure 5.6), this study and another recently published study (299) have 
shown that gene expression profiling and flow cytometry analysis suggest that 
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HCV mediated apoptosis of Huh7.5 cells is linked to perturbations in cell cycle 
progression. However, the current study has also shown effects on cell cycle 
regulation in both Huh7 and Huh7.5 cells. Additionally, it was shown that there 
was an increase in GADD45-β protein expression, which is consistent with the 
findings that HCV infection causes cell death by DNA fragmentation. The cell 
cycle arrest caused by HCV infection led to increased virus production, as 
demonstrated by the increased levels of HCV core protein. Furthermore, the 
current study also showed that key points in the cell cycle were perturbed by 
HCV. In addition to the increase in GADD45-β expression a reduction of cyclin 
B1 expression and its redistribution in cell cytoplasm was also observed. 
 
Perturbation of the cell cycle has been observed in other viral infections including 
HIV (vpr) (316-318), and HBV (x protein) (323). The role of the HCV proteins 
that are responsible for inducing the delay in cell cycle progression is not fully 
understood.  The role of the NS5A protein was tested to see whether it associates 
with cyclin B1 in JFH-1 infected cells. No association between these proteins was 
observed. However, these results indicate that it would be very interesting to 
investigate the role of other HCV proteins in cell cycle control since it is linked to 
the development of chronic HCV infection and viral pathogenesis.   
 
In conclusion, HCV infection controls IFN induction by reducing the 
transcription of the genes involved in the detection of dsRNA and ssRNA, RIG-I, 
MDA5, MAVS, TRIF and MyD88. However from the results of this study, it is 
not possible to distinguish whether this is due to direct and specific effects on 
expression of these genes or whether it is an indirect consequence of the 
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previously observed cleavage of MAVS, resulting in reduced expression of IFN-β 
and the ISGs, as the latter includes RIG-I, MDA5, MAVS, TRIF and MyD88. In 
agreement with other studies the work presented here also shows that HCV 
attenuates IFN signaling through the JAK-STAT pathway by the induction of 
SOCS3 protein. It was demonstrated that the HCV NS3 and NS3/4A protein 
inhibit the mRNA expression of dsRNA sensing components RIG-I, MDA5 and 
MAVS and also inhibit MyD88 mRNA expression.  This results in the inhibition 
of IFN-α and IFN-β production which may contribute to viral persistence. It was 
also shown by knockdown of gene expression that MDA5 and the signaling 
mediators MAVS and MyD88 play an important role in the host response to HCV 
replication. Gene expression data and flow cytometry analysis indicate that HCV 
infection is associated with perturbations of the cell cycle which may lead to 
apoptosis and cell death. An increase in the number of apoptotic cells was also 
shown to be associated with HCV replication levels. 
Further characterisation of the roles of MDA5, MAVS, TRIF and MyD88 during 
HCV infection would help in understanding if the RIG-I/MDA5 pathways work 
independently or in synergistic manner. Additional genes including members of 
the SOCS family, IRFs and other candidate genes identified by microarray 
analysis may also be involved in the IFN response to HCV infection. 
Systematically targeting these by siRNA knockout should indicate if IFN-β can be 
still induced by other mechanisms and might indicate novel therapeutic targets. 
Further work is also needed to understand the mechanisms by which NS3/4A can 
suppress IFN transcription.  
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Transduction of Huh7 cells with NS3 and NS3/4A recombinant adenoviruses and 
then treating them with BILN2061, should show whether the NS3/4A protease is 
essential for the suppression of transcription related to IFN expression.  
This study suggests a direct cytopathic effect of HCV through the induction of 
apoptosis and it investigated a number of candidate genes involved in ER stress. 
Future work will address the question of the role of the RIG-I/MDA5 pathways in 
linking innate immune responses and apoptosis. Furthermore, the effects of HCV 
infection on cell cycle modulation have not yet fully elucidated. However the 
transcription of several other genes (presented in table 5.1) involved in cell cycle 
regulation was also affected by HCV infection. It will be important to investigate 
their role in the regulation of the cell cycle and apoptosis during HCV infection.  
 
 
 
 
 
 
 
 
 
 
 
 220 
7.0. References: 
1. Mosley JW, Redeker AG, Feinstone SM, Purcell RH. 1977. Mutliple hepatitis 
viruses in multiple attacks of acute viral hepatitis. N Engl J Med 296: 75-8 
2. Booth JC. 1998. Chronic hepatitis C: the virus, its discovery and the natural 
history of the disease. J Viral Hepat 5: 213-22 
3. Alter HJ, Purcell RH, Holland PV, Popper H. 1978. Transmissible agent in 
non-A, non-B hepatitis. Lancet 1: 459-63 
4. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. 1989. 
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral 
hepatitis genome. Science 244: 359-62 
5. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo 
G. 1989. Detection of antibody to hepatitis C virus in prospectively followed 
transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J 
Med 321: 1494-500 
6. Alter HJ, Houghton M. 2000. Clinical Medical Research Award. Hepatitis C 
virus and eliminating post-transfusion hepatitis. Nat Med 6: 1082-6 
7. Brett D Lindenbach H-JT, Charles M. Rice, ed. 2007. Fields Virology, 
Chapter 33: Philadelphia: Lippincott Williams and Wilkins. 1101-51 pp. 
8. Polgreen PM, Xiang J, Chang Q, Stapleton JT. 2003. GB virus type 
C/hepatitis G virus: a non-pathogenic flavivirus associated with prolonged 
survival in HIV-infected individuals. Microbes Infect 5: 1255-61 
9. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, 
Kaslow RA, Margolis HS. 1999. The prevalence of hepatitis C virus infection 
in the United States, 1988 through 1994. N Engl J Med 341: 556-62 
10. Basu D. 2010. Overview of Substance Abuse and Hepatitis C Virus Infection 
and Co-infections in India. J Neuroimmune Pharmacol  
11. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, 
El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, Sallam I. 2000. The 
role of parenteral antischistosomal therapy in the spread of hepatitis C virus in 
Egypt. Lancet 355: 887-91 
12. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter 
MJ. 2006. The prevalence of hepatitis C virus infection in the United States, 
1999 through 2002. Ann Intern Med 144: 705-14 
 221 
13. Sy T, Jamal MM. 2006. Epidemiology of hepatitis C virus (HCV) infection. 
Int J Med Sci 3: 41-6 
14. Bevilacqua E, Fabris A, Floreano P, Pembrey L, Newell ML, Tovo PA, 
Amoroso A. 2009. Genetic factors in mother-to-child transmission of HCV 
infection. Virology 390: 64-70 
15. Roberts EA, Yeung L. 2002. Maternal-infant transmission of hepatitis C virus 
infection. Hepatology 36: S106-13 
16. Touzet S, Kraemer L, Colin C, Pradat P, Lanoir D, Bailly F, Coppola RC, 
Sauleda S, Thursz MR, Tillmann H, Alberti A, Braconier JH, Esteban JI, 
Hadziyannis SJ, Manns MP, Saracco G, Thomas HC, Trepo C. 2000. 
Epidemiology of hepatitis C virus infection in seven European Union 
countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C 
European Network for Co-operative Research. Eur J Gastroenterol Hepatol 
12: 667-78 
17. Thomson BJ, Finch RG. 2005. Hepatitis C virus infection. Clin Microbiol 
Infect 11: 86-94 
18. Urbanus AT, van de Laar TJ, Stolte IG, Schinkel J, Heijman T, Coutinho RA, 
Prins M. 2009. Hepatitis C virus infections among HIV-infected men who 
have sex with men: an expanding epidemic. AIDS 23: F1-7 
19. Scott C, Day S, Low E, Sullivan A, Atkins M, Asboe D. 2010. Unselected 
hepatitis C screening of men who have sex with men attending sexual health 
clinics. J Infect 60: 351-3 
20. Herrmann E, Neumann AU, Schmidt JM, Zeuzem S. 2000. Hepatitis C virus 
kinetics. Antivir Ther 5: 85-90 
21. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson 
AS. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of 
interferon-alpha therapy. Science 282: 103-7 
22. Bartenschlager R, Lohmann V. 2000. Replication of hepatitis C virus. J Gen 
Virol 81: 1631-48 
23. Eriksen MB, Jorgensen LB, Krarup H, Laursen AL, Christensen PB, Moller 
A, Schlichting P, Kuiken C, Bukh J, Weis N. 2010. Molecular and 
epidemiological profiles of hepatitis C virus genotype 4 in Denmark. J Med 
Virol 82: 1869-77 
 222 
24. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon 
P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto 
H, Pawlotsky JM, Penin F, Sablon E, Shin IT, Stuyver LJ, Thiel HJ, Viazov S, 
Weiner AJ, Widell A. 2005. Consensus proposals for a unified system of 
nomenclature of hepatitis C virus genotypes. Hepatology 42: 962-73 
25. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Beall E, 
Yap PL, Kolberg J, Urdea MS. 1993. Classification of hepatitis C virus into 
six major genotypes and a series of subtypes by phylogenetic analysis of the 
NS-5 region. J Gen Virol 74 ( Pt 11): 2391-9 
26. Jopling CL. 2008. Regulation of hepatitis C virus by microRNA-122. Biochem 
Soc Trans 36: 1220-3 
27. Fraser CS, Doudna JA. 2007. Structural and mechanistic insights into hepatitis 
C viral translation initiation. Nat Rev Microbiol 5: 29-38 
28. Boehringer D, Thermann R, Ostareck-Lederer A, Lewis JD, Stark H. 2005. 
Structure of the hepatitis C virus IRES bound to the human 80S ribosome: 
remodeling of the HCV IRES. Structure 13: 1695-706 
29. Wang C, Le SY, Ali N, Siddiqui A. 1995. An RNA pseudoknot is an essential 
structural element of the internal ribosome entry site located within the 
hepatitis C virus 5' noncoding region. RNA 1: 526-37 
30. Song Y, Friebe P, Tzima E, Junemann C, Bartenschlager R, Niepmann M. 
2006. The hepatitis C virus RNA 3'-untranslated region strongly enhances 
translation directed by the internal ribosome entry site. J Virol 80: 11579-88 
31. Rehermann B. 2009. Hepatitis C virus versus innate and adaptive immune 
responses: a tale of coevolution and coexistence. J Clin Invest 119: 1745-54 
32. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Shimotohno K. 1991. Gene 
mapping of the putative structural region of the hepatitis C virus genome by in 
vitro processing analysis. Proc Natl Acad Sci U S A 88: 5547-51 
33. McLauchlan J. 2000. Properties of the hepatitis C virus core protein: a 
structural protein that modulates cellular processes. J Viral Hepat 7: 2-14 
34. Boulant S, Vanbelle C, Ebel C, Penin F, Lavergne JP. 2005. Hepatitis C virus 
core protein is a dimeric alpha-helical protein exhibiting membrane protein 
features. J Virol 79: 11353-65 
 223 
35. Shavinskaya A, Boulant S, Penin F, McLauchlan J, Bartenschlager R. 2007. 
The lipid droplet binding domain of hepatitis C virus core protein is a major 
determinant for efficient virus assembly. J Biol Chem 282: 37158-69 
36. Santolini E, Migliaccio G, La Monica N. 1994. Biosynthesis and biochemical 
properties of the hepatitis C virus core protein. J Virol 68: 3631-41 
37. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Weinman 
SA. 2002. Mitochondrial injury, oxidative stress, and antioxidant gene 
expression are induced by hepatitis C virus core protein. Gastroenterology 
122: 366-75 
38. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, 
Schaff Z, Chapman MJ, Miyamura T, Brechot C. 1997. Hepatitis C virus core 
protein shows a cytoplasmic localization and associates to cellular lipid 
storage droplets. Proc Natl Acad Sci U S A 94: 1200-5 
39. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chretien Y, Koike K, 
Pessayre D, Chapman J, Barba G, Brechot C. 2002. Hepatitis C virus core 
protein inhibits microsomal triglyceride transfer protein activity and very low 
density lipoprotein secretion: a model of viral-related steatosis. FASEB J 16: 
185-94 
40. Matsumoto M, Hsieh TY, Zhu N, VanArsdale T, Hwang SB, Jeng KS, 
Gorbalenya AE, Lo SY, Ou JH, Ware CF, Lai MM. 1997. Hepatitis C virus 
core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor. J 
Virol 71: 1301-9 
41. Dubuisson J, Hsu HH, Cheung RC, Greenberg HB, Russell DG, Rice CM. 
1994. Formation and intracellular localization of hepatitis C virus envelope 
glycoprotein complexes expressed by recombinant vaccinia and Sindbis 
viruses. J Virol 68: 6147-60 
42. Zibert A, Meisel H, Kraas W, Schulz A, Jung G, Roggendorf M. 1997. Early 
antibody response against hypervariable region 1 is associated with acute self-
limiting infections of hepatitis C virus. Hepatology 25: 1245-9 
43. Zibert A, Schreier E, Roggendorf M. 1995. Antibodies in human sera specific 
to hypervariable region 1 of hepatitis C virus can block viral attachment. 
Virology 208: 653-61 
44. Shimizu YK, Igarashi H, Kiyohara T, Cabezon T, Farci P, Purcell RH, 
Yoshikura H. 1996. A hyperimmune serum against a synthetic peptide 
 224 
corresponding to the hypervariable region 1 of hepatitis C virus can prevent 
viral infection in cell cultures. Virology 223: 409-12 
45. Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, 
Shimizu Y, Shapiro M, Alter HJ, Purcell RH. 1996. Prevention of hepatitis C 
virus infection in chimpanzees by hyperimmune serum against the 
hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A 93: 
15394-9 
46. Kumar U, Monjardino J, Thomas HC. 1994. Hypervariable region of hepatitis 
C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. 
Gastroenterology 106: 1072-5 
47. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. 1999. Inhibition of the 
interferon-inducible protein kinase PKR by HCV E2 protein. Science 285: 
107-10 
48. Pavio N, Romano PR, Graczyk TM, Feinstone SM, Taylor DR. 2003. Protein 
synthesis and endoplasmic reticulum stress can be modulated by the hepatitis 
C virus envelope protein E2 through the eukaryotic initiation factor 2alpha 
kinase PERK. J Virol 77: 3578-85 
49. Allander T, Forns X, Emerson SU, Purcell RH, Bukh J. 2000. Hepatitis C 
virus envelope protein E2 binds to CD81 of tamarins. Virology 277: 358-67 
50. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, 
Houghton M, Rosa D, Grandi G, Abrignani S. 1998. Binding of hepatitis C 
virus to CD81. Science 282: 938-41 
51. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. 1999. Hepatitis C virus 
and other flaviviridae viruses enter cells via low density lipoprotein receptor. 
Proc Natl Acad Sci U S A 96: 12766-71 
52. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, 
Traboni C, Nicosia A, Cortese R, Vitelli A. 2002. The human scavenger 
receptor class B type I is a novel candidate receptor for the hepatitis C virus. 
EMBO J 21: 5017-25 
53. Lavillette D, Tarr AW, Voisset C, Donot P, Bartosch B, Bain C, Patel AH, 
Dubuisson J, Ball JK, Cosset FL. 2005. Characterization of host-range and cell 
entry properties of the major genotypes and subtypes of hepatitis C virus. 
Hepatology 41: 265-74 
 225 
54. Meunier JC, Engle RE, Faulk K, Zhao M, Bartosch B, Alter H, Emerson SU, 
Cosset FL, Purcell RH, Bukh J. 2005. Evidence for cross-genotype 
neutralization of hepatitis C virus pseudo-particles and enhancement of 
infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A 102: 4560-5 
55. Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, Pawlotsky JM, 
Lavillette D, Cosset FL. 2005. An interplay between hypervariable region 1 of 
the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-
density lipoprotein promotes both enhancement of infection and protection 
against neutralizing antibodies. J Virol 79: 8217-29 
56. Carrere-Kremer S, Montpellier-Pala C, Cocquerel L, Wychowski C, Penin F, 
Dubuisson J. 2002. Subcellular localization and topology of the p7 
polypeptide of hepatitis C virus. J Virol 76: 3720-30 
57. Griffin S, Clarke D, McCormick C, Rowlands D, Harris M. 2005. Signal 
peptide cleavage and internal targeting signals direct the hepatitis C virus p7 
protein to distinct intracellular membranes. J Virol 79: 15525-36 
58. Griffin SD, Beales LP, Clarke DS, Worsfold O, Evans SD, Jaeger J, Harris 
MP, Rowlands DJ. 2003. The p7 protein of hepatitis C virus forms an ion 
channel that is blocked by the antiviral drug, Amantadine. FEBS Lett 535: 34-
8 
59. Pavlovic D, Neville DC, Argaud O, Blumberg B, Dwek RA, Fischer WB, 
Zitzmann N. 2003. The hepatitis C virus p7 protein forms an ion channel that 
is inhibited by long-alkyl-chain iminosugar derivatives. Proc Natl Acad Sci U 
S A 100: 6104-8 
60. Harada T, Tautz N, Thiel HJ. 2000. E2-p7 region of the bovine viral diarrhea 
virus polyprotein: processing and functional studies. J Virol 74: 9498-506 
61. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM. 2007. Hepatitis C 
virus p7 and NS2 proteins are essential for production of infectious virus. J 
Virol 81: 8374-83 
62. Steinmann E, Penin F, Kallis S, Patel AH, Bartenschlager R, Pietschmann T. 
2007. Hepatitis C virus p7 protein is crucial for assembly and release of 
infectious virions. PLoS Pathog 3: e103 
63. Brohm C, Steinmann E, Friesland M, Lorenz IC, Patel A, Penin F, 
Bartenschlager R, Pietschmann T. 2009. Characterization of determinants 
 226 
important for hepatitis C virus p7 function in morphogenesis by using trans-
complementation. J Virol 83: 11682-93 
64. Hirowatari Y, Hijikata M, Tanji Y, Nyunoya H, Mizushima H, Kimura K, 
Tanaka T, Kato N, Shimotohno K. 1993. Two proteinase activities in HCV 
polypeptide expressed in insect cells using baculovirus vector. Arch Virol 133: 
349-56 
65. Hijikata M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, Tanaka T, 
Kimura K, Shimotohno K. 1993. Two distinct proteinase activities required 
for the processing of a putative nonstructural precursor protein of hepatitis C 
virus. J Virol 67: 4665-75 
66. Schregel V, Jacobi S, Penin F, Tautz N. 2009. Hepatitis C virus NS2 is a 
protease stimulated by cofactor domains in NS3. Proc Natl Acad Sci U S A 
106: 5342-7 
67. Pallaoro M, Lahm A, Biasiol G, Brunetti M, Nardella C, Orsatti L, Bonelli F, 
Orru S, Narjes F, Steinkuhler C. 2001. Characterization of the hepatitis C virus 
NS2/3 processing reaction by using a purified precursor protein. J Virol 75: 
9939-46 
68. Foster TL, Tedbury PR, Pearson AR, Harris M. 2010. A comparative analysis 
of the fluorescence properties of the wild-type and active site mutants of the 
hepatitis C virus autoprotease NS2-3. Biochim Biophys Acta 1804: 212-22 
69. Yi M, Ma Y, Yates J, Lemon SM. 2007. Compensatory mutations in E1, p7, 
NS2, and NS3 enhance yields of cell culture-infectious intergenotypic 
chimeric hepatitis C virus. J Virol 81: 629-38 
70. Jirasko V, Montserret R, Appel N, Janvier A, Eustachi L, Brohm C, 
Steinmann E, Pietschmann T, Penin F, Bartenschlager R. 2008. Structural and 
functional characterization of nonstructural protein 2 for its role in hepatitis C 
virus assembly. J Biol Chem 283: 28546-62 
71. Ciesek S, Steinmann E, Wedemeyer H, Manns MP, Neyts J, Tautz N, Madan 
V, Bartenschlager R, von Hahn T, Pietschmann T. 2009. Cyclosporine A 
inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. 
Hepatology 50: 1638-45 
72. Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. 1993. Nonstructural 
protein 3 of the hepatitis C virus encodes a serine-type proteinase required for 
cleavage at the NS3/4 and NS4/5 junctions. J Virol 67: 3835-44 
 227 
73. Bartenschlager R. 2002. Hepatitis C virus replicons: potential role for drug 
development. Nat Rev Drug Discov 1: 911-6 
74. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. 1993. 
Characterization of the hepatitis C virus-encoded serine proteinase: 
determination of proteinase-dependent polyprotein cleavage sites. J Virol 67: 
2832-43 
75. Tomei L, Failla C, Santolini E, De Francesco R, La Monica N. 1993. NS3 is a 
serine protease required for processing of hepatitis C virus polyprotein. J Virol 
67: 4017-26 
76. Hijikata M, Mizushima H, Tanji Y, Komoda Y, Hirowatari Y, Akagi T, Kato 
N, Kimura K, Shimotohno K. 1993. Proteolytic processing and membrane 
association of putative nonstructural proteins of hepatitis C virus. Proc Natl 
Acad Sci U S A 90: 10773-7 
77. Kang LW, Cho HS, Cha SS, Chung KM, Back SH, Jang SK, Oh BH. 1998. 
Crystallization and preliminary X-ray crystallographic analysis of the helicase 
domain of hepatitis C virus NS3 protein. Acta Crystallogr D Biol Crystallogr 
54: 121-3 
78. Kwong AD, Kim JL, Rao G, Lipovsek D, Raybuck SA. 1998. Hepatitis C 
virus NS3/4A protease. Antiviral Res 40: 1-18 
79. Silverman E, Edwalds-Gilbert G, Lin RJ. 2003. DExD/H-box proteins and 
their partners: helping RNA helicases unwind. Gene 312: 1-16 
80. Frick DN. 2006. Step-by-step progress toward understanding the hepatitis C 
virus RNA helicase. Hepatology 43: 1392-5 
81. Frick DN, Banik S, Rypma RS. 2007. Role of divalent metal cations in ATP 
hydrolysis catalyzed by the hepatitis C virus NS3 helicase: magnesium 
provides a bridge for ATP to fuel unwinding. J Mol Biol 365: 1017-32 
82. Frick DN, Rypma RS, Lam AM, Gu B. 2004. The nonstructural protein 3 
protease/helicase requires an intact protease domain to unwind duplex RNA 
efficiently. J Biol Chem 279: 1269-80 
83. Lam AM, Rypma RS, Frick DN. 2004. Enhanced nucleic acid binding to 
ATP-bound hepatitis C virus NS3 helicase at low pH activates RNA 
unwinding. Nucleic Acids Res 32: 4060-70 
 228 
84. Pang PS, Jankowsky E, Planet PJ, Pyle AM. 2002. The hepatitis C viral NS3 
protein is a processive DNA helicase with cofactor enhanced RNA unwinding. 
EMBO J 21: 1168-76 
85. Heilek GM, Peterson MG. 1997. A point mutation abolishes the helicase but 
not the nucleoside triphosphatase activity of hepatitis C virus NS3 protein. J 
Virol 71: 6264-6 
86. Kim DW, Gwack Y, Han JH, Choe J. 1997. Towards defining a minimal 
functional domain for NTPase and RNA helicase activities of the hepatitis C 
virus NS3 protein. Virus Res 49: 17-25 
87. Kim DW, Kim J, Gwack Y, Han JH, Choe J. 1997. Mutational analysis of the 
hepatitis C virus RNA helicase. J Virol 71: 9400-9 
88. Wardell AD, Errington W, Ciaramella G, Merson J, McGarvey MJ. 1999. 
Characterization and mutational analysis of the helicase and NTPase activities 
of hepatitis C virus full-length NS3 protein. J Gen Virol 80 ( Pt 3): 701-9 
89. Kim JL, Morgenstern KA, Griffith JP, Dwyer MD, Thomson JA, Murcko MA, 
Lin C, Caron PR. 1998. Hepatitis C virus NS3 RNA helicase domain with a 
bound oligonucleotide: the crystal structure provides insights into the mode of 
unwinding. Structure 6: 89-100 
90. Pijlman GP, Kondratieva N, Khromykh AA. 2006. Translation of the 
flavivirus kunjin NS3 gene in cis but not its RNA sequence or secondary 
structure is essential for efficient RNA packaging. J Virol 80: 11255-64 
91. Kummerer BM, Rice CM. 2002. Mutations in the yellow fever virus 
nonstructural protein NS2A selectively block production of infectious 
particles. J Virol 76: 4773-84 
92. Patkar CG, Kuhn RJ. 2008. Yellow Fever virus NS3 plays an essential role in 
virus assembly independent of its known enzymatic functions. J Virol 82: 
3342-52 
93. Welsch C, Albrecht M, Maydt J, Herrmann E, Welker MW, Sarrazin C, 
Scheidig A, Lengauer T, Zeuzem S. 2007. Structural and functional 
comparison of the non-structural protein 4B in flaviviridae. J Mol Graph 
Model 26: 546-57 
94. Lemon SM, McKeating JA, Pietschmann T, Frick DN, Glenn JS, 
Tellinghuisen TL, Symons J, Furman PA. 2010. Development of novel 
therapies for hepatitis C. Antiviral Res 86: 79-92 
 229 
95. Yu GY, Lee KJ, Gao L, Lai MM. 2006. Palmitoylation and polymerization of 
hepatitis C virus NS4B protein. J Virol 80: 6013-23 
96. Egger D, Wolk B, Gosert R, Bianchi L, Blum HE, Moradpour D, Bienz K. 
2002. Expression of hepatitis C virus proteins induces distinct membrane 
alterations including a candidate viral replication complex. J Virol 76: 5974-
84 
97. Gosert R, Kanjanahaluethai A, Egger D, Bienz K, Baker SC. 2002. RNA 
replication of mouse hepatitis virus takes place at double-membrane vesicles. 
J Virol 76: 3697-708 
98. Gao L, Aizaki H, He JW, Lai MM. 2004. Interactions between viral 
nonstructural proteins and host protein hVAP-33 mediate the formation of 
hepatitis C virus RNA replication complex on lipid raft. J Virol 78: 3480-8 
99. Einav S, Gerber D, Bryson PD, Sklan EH, Elazar M, Maerkl SJ, Glenn JS, 
Quake SR. 2008. Discovery of a hepatitis C target and its pharmacological 
inhibitors by microfluidic affinity analysis. Nat Biotechnol 26: 1019-27 
100. Einav S, Sklan EH, Moon HM, Gehrig E, Liu P, Hao Y, Lowe AW, Glenn JS. 
2008. The nucleotide binding motif of hepatitis C virus NS4B can mediate 
cellular transformation and tumor formation without Ha-ras co-transfection. 
Hepatology 47: 827-35 
101. Tellinghuisen TL, Marcotrigiano J, Rice CM. 2005. Structure of the zinc-
binding domain of an essential component of the hepatitis C virus replicase. 
Nature 435: 374-9 
102. Gale M, Jr., Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM, 
Korth MJ, Polyak SJ, Gretch DR, Katze MG. 1998. Control of PKR protein 
kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of 
kinase regulation. Mol Cell Biol 18: 5208-18 
103. Gale M, Jr., Foy EM. 2005. Evasion of intracellular host defence by hepatitis 
C virus. Nature 436: 939-45 
104. Gale M, Jr., Kwieciszewski B, Dossett M, Nakao H, Katze MG. 1999. 
Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to 
interferon resistance by viral repression of the PKR protein kinase. J Virol 73: 
6506-16 
105. Appel N, Zayas M, Miller S, Krijnse-Locker J, Schaller T, Friebe P, Kallis S, 
Engel U, Bartenschlager R. 2008. Essential role of domain III of nonstructural 
 230 
protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog 4: 
e1000035 
106. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. 1999. 
Crystal structure of the RNA-dependent RNA polymerase from hepatitis C 
virus reveals a fully encircled active site. Nat Struct Biol 6: 937-43 
107. Leveque VJ, Johnson RB, Parsons S, Ren J, Xie C, Zhang F, Wang QM. 2003. 
Identification of a C-terminal regulatory motif in hepatitis C virus RNA-
dependent RNA polymerase: structural and biochemical analysis. J Virol 77: 
9020-8 
108. Lee H, Shin H, Wimmer E, Paul AV. 2004. cis-acting RNA signals in the 
NS5B C-terminal coding sequence of the hepatitis C virus genome. J Virol 78: 
10865-77 
109. Lerat H, Rumin S, Habersetzer F, Berby F, Trabaud MA, Trepo C, Inchauspe 
G. 1998. In vivo tropism of hepatitis C virus genomic sequences in 
hematopoietic cells: influence of viral load, viral genotype, and cell 
phenotype. Blood 91: 3841-9 
110. Navas MC, Fuchs A, Schvoerer E, Bohbot A, Aubertin AM, Stoll-Keller F. 
2002. Dendritic cell susceptibility to hepatitis C virus genotype 1 infection. J 
Med Virol 67: 152-61 
111. Radkowski M, Wilkinson J, Nowicki M, Adair D, Vargas H, Ingui C, Rakela 
J, Laskus T. 2002. Search for hepatitis C virus negative-strand RNA sequences 
and analysis of viral sequences in the central nervous system: evidence of 
replication. J Virol 76: 600-8 
112. Cai Z, Zhang C, Chang KS, Jiang J, Ahn BC, Wakita T, Liang TJ, Luo G. 
2005. Robust production of infectious hepatitis C virus (HCV) from stably 
HCV cDNA-transfected human hepatoma cells. J Virol 79: 13963-73 
113. Goffard A, Callens N, Bartosch B, Wychowski C, Cosset FL, Montpellier C, 
Dubuisson J. 2005. Role of N-linked glycans in the functions of hepatitis C 
virus envelope glycoproteins. J Virol 79: 8400-9 
114. Lavie M, Goffard A, Dubuisson J. 2007. Assembly of a functional HCV 
glycoprotein heterodimer. Curr Issues Mol Biol 9: 71-86 
115. Pietschmann T, Lohmann V, Rutter G, Kurpanek K, Bartenschlager R. 2001. 
Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. 
J Virol 75: 1252-64 
 231 
116. Bartenschlager R, Kaul A, Sparacio S. 2003. Replication of the hepatitis C 
virus in cell culture. Antiviral Res 60: 91-102 
117. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, 
Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. 2005. 
Complete replication of hepatitis C virus in cell culture. Science 309: 623-6 
118. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, 
Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ. 
2005. Production of infectious hepatitis C virus in tissue culture from a cloned 
viral genome. Nat Med 11: 791-6 
119. Tang H, Grise H. 2009. Cellular and molecular biology of HCV infection and 
hepatitis. Clin Sci (Lond) 117: 49-65 
120. Harris HJ, Farquhar MJ, Mee CJ, Davis C, Reynolds GM, Jennings A, Hu K, 
Yuan F, Deng H, Hubscher SG, Han JH, Balfe P, McKeating JA. 2008. CD81 
and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol 82: 
5007-20 
121. Benedicto I, Molina-Jimenez F, Barreiro O, Maldonado-Rodriguez A, Prieto J, 
Moreno-Otero R, Aldabe R, Lopez-Cabrera M, Majano PL. 2008. Hepatitis C 
virus envelope components alter localization of hepatocyte tight junction-
associated proteins and promote occludin retention in the endoplasmic 
reticulum. Hepatology 48: 1044-53 
122. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. 
2009. Human occludin is a hepatitis C virus entry factor required for infection 
of mouse cells. Nature 457: 882-6 
123. Meertens L, Bertaux C, Cukierman L, Cormier E, Lavillette D, Cosset FL, 
Dragic T. 2008. The tight junction proteins claudin-1, -6, and -9 are entry 
cofactors for hepatitis C virus. J Virol 82: 3555-60 
124. Andre P, Perlemuter G, Budkowska A, Brechot C, Lotteau V. 2005. Hepatitis 
C virus particles and lipoprotein metabolism. Semin Liver Dis 25: 93-104 
125. Cocquerel L, Voisset C, Dubuisson J. 2006. Hepatitis C virus entry: potential 
receptors and their biological functions. J Gen Virol 87: 1075-84 
126. Rosa D, Campagnoli S, Moretto C, Guenzi E, Cousens L, Chin M, Dong C, 
Weiner AJ, Lau JY, Choo QL, Chien D, Pileri P, Houghton M, Abrignani S. 
1996. A quantitative test to estimate neutralizing antibodies to the hepatitis C 
 232 
virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target 
cells. Proc Natl Acad Sci U S A 93: 1759-63 
127. Yu X, Qiao M, Atanasov I, Hu Z, Kato T, Liang TJ, Zhou ZH. 2007. Cryo-
electron microscopy and three-dimensional reconstructions of hepatitis C virus 
particles. Virology 367: 126-34 
128. Bressanelli S, Stiasny K, Allison SL, Stura EA, Duquerroy S, Lescar J, Heinz 
FX, Rey FA. 2004. Structure of a flavivirus envelope glycoprotein in its low-
pH-induced membrane fusion conformation. EMBO J 23: 728-38 
129. Yagnik AT, Lahm A, Meola A, Roccasecca RM, Ercole BB, Nicosia A, 
Tramontano A. 2000. A model for the hepatitis C virus envelope glycoprotein 
E2. Proteins 40: 355-66 
130. Bartosch B, Dubuisson J, Cosset FL. 2003. Infectious hepatitis C virus 
pseudo-particles containing functional E1-E2 envelope protein complexes. J 
Exp Med 197: 633-42 
131. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Scarselli 
E, Cortese R, Nicosia A, Cosset FL. 2003. Cell entry of hepatitis C virus 
requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 
scavenger receptor. J Biol Chem 278: 41624-30 
132. Wang C, Sarnow P, Siddiqui A. 1993. Translation of human hepatitis C virus 
RNA in cultured cells is mediated by an internal ribosome-binding 
mechanism. J Virol 67: 3338-44 
133. Reynolds JE, Kaminski A, Carroll AR, Clarke BE, Rowlands DJ, Jackson RJ. 
1996. Internal initiation of translation of hepatitis C virus RNA: the ribosome 
entry site is at the authentic initiation codon. RNA 2: 867-78 
134. Rijnbrand RC, Abbink TE, Haasnoot PC, Spaan WJ, Bredenbeek PJ. 1996. 
The influence of AUG codons in the hepatitis C virus 5' nontranslated region 
on translation and mapping of the translation initiation window. Virology 226: 
47-56 
135. Henke JI, Goergen D, Zheng J, Song Y, Schuttler CG, Fehr C, Junemann C, 
Niepmann M. 2008. microRNA-122 stimulates translation of hepatitis C virus 
RNA. EMBO J 27: 3300-10 
136. Jangra RK, Yi M, Lemon SM. 2010. Regulation of hepatitis C virus 
translation and infectious virus production by the microRNA miR-122. J Virol 
84: 6615-25 
 233 
137. Kruger M, Beger C, Welch PJ, Barber JR, Manns MP, Wong-Staal F. 2001. 
Involvement of proteasome alpha-subunit PSMA7 in hepatitis C virus internal 
ribosome entry site-mediated translation. Mol Cell Biol 21: 8357-64 
138. Pestova TV, Shatsky IN, Fletcher SP, Jackson RJ, Hellen CU. 1998. A 
prokaryotic-like mode of cytoplasmic eukaryotic ribosome binding to the 
initiation codon during internal translation initiation of hepatitis C and 
classical swine fever virus RNAs. Genes Dev 12: 67-83 
139. Vauloup-Fellous C, Pene V, Garaud-Aunis J, Harper F, Bardin S, Suire Y, 
Pichard E, Schmitt A, Sogni P, Pierron G, Briand P, Rosenberg AR. 2006. 
Signal peptide peptidase-catalyzed cleavage of hepatitis C virus core protein is 
dispensable for virus budding but destabilizes the viral capsid. J Biol Chem 
281: 27679-92 
140. Yasui K, Wakita T, Tsukiyama-Kohara K, Funahashi SI, Ichikawa M, Kajita 
T, Moradpour D, Wands JR, Kohara M. 1998. The native form and maturation 
process of hepatitis C virus core protein. J Virol 72: 6048-55 
141. Pawlotsky JM, Chevaliez S, McHutchison JG. 2007. The hepatitis C virus life 
cycle as a target for new antiviral therapies. Gastroenterology 132: 1979-98 
142. Konan KV, Giddings TH, Jr., Ikeda M, Li K, Lemon SM, Kirkegaard K. 2003. 
Nonstructural protein precursor NS4A/B from hepatitis C virus alters function 
and ultrastructure of host secretory apparatus. J Virol 77: 7843-55 
143. Gosert R, Egger D, Lohmann V, Bartenschlager R, Blum HE, Bienz K, 
Moradpour D. 2003. Identification of the hepatitis C virus RNA replication 
complex in Huh-7 cells harboring subgenomic replicons. J Virol 77: 5487-92 
144. Rouille Y, Helle F, Delgrange D, Roingeard P, Voisset C, Blanchard E, 
Belouzard S, McKeating J, Patel AH, Maertens G, Wakita T, Wychowski C, 
Dubuisson J. 2006. Subcellular localization of hepatitis C virus structural 
proteins in a cell culture system that efficiently replicates the virus. J Virol 80: 
2832-41 
145. Stone M, Jia S, Heo WD, Meyer T, Konan KV. 2007. Participation of rab5, an 
early endosome protein, in hepatitis C virus RNA replication machinery. J 
Virol 81: 4551-63 
146. Berger KL, Cooper JD, Heaton NS, Yoon R, Oakland TE, Jordan TX, Mateu 
G, Grakoui A, Randall G. 2009. Roles for endocytic trafficking and 
 234 
phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc 
Natl Acad Sci U S A 106: 7577-82 
147. Berger KL, Randall G. 2009. Potential roles for cellular cofactors in hepatitis 
C virus replication complex formation. Commun Integr Biol 2: 471-3 
148. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. 
1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell 
line. Science 285: 110-3 
149. You S, Stump DD, Branch AD, Rice CM. 2004. A cis-acting replication 
element in the sequence encoding the NS5B RNA-dependent RNA 
polymerase is required for hepatitis C virus RNA replication. J Virol 78: 1352-
66 
150. Astier-Gin T, Bellecave P, Litvak S, Ventura M. 2005. Template requirements 
and binding of hepatitis C virus NS5B polymerase during in vitro RNA 
synthesis from the 3'-end of virus minus-strand RNA. FEBS J 272: 3872-86 
151. Shirota Y, Luo H, Qin W, Kaneko S, Yamashita T, Kobayashi K, Murakami 
S. 2002. Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA 
polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase 
activity. J Biol Chem 277: 11149-55 
152. Quezada EM, Kane CM. 2009. The Hepatitis C Virus NS5A Stimulates NS5B 
During In Vitro RNA Synthesis in a Template Specific Manner. Open 
Biochem J 3: 39-48 
153. Chung RT, Kaplan LM. 1999. Heterogeneous nuclear ribonucleoprotein I 
(hnRNP-I/PTB) selectively binds the conserved 3' terminus of hepatitis C viral 
RNA. Biochem Biophys Res Commun 254: 351-62 
154. Tsuchihara K, Tanaka T, Hijikata M, Kuge S, Toyoda H, Nomoto A, 
Yamamoto N, Shimotohno K. 1997. Specific interaction of polypyrimidine 
tract-binding protein with the extreme 3'-terminal structure of the hepatitis C 
virus genome, the 3'X. J Virol 71: 6720-6 
155. Petrik J, Parker H, Alexander GJ. 1999. Human hepatic glyceraldehyde-3-
phosphate dehydrogenase binds to the poly(U) tract of the 3' non-coding 
region of hepatitis C virus genomic RNA. J Gen Virol 80 ( Pt 12): 3109-13 
156. Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, Shimotohno 
K. 2005. Cyclophilin B is a functional regulator of hepatitis C virus RNA 
polymerase. Mol Cell 19: 111-22 
 235 
157. Chatterji U, Bobardt M, Selvarajah S, Yang F, Tang H, Sakamoto N, 
Vuagniaux G, Parkinson T, Gallay P. 2009. The isomerase active site of 
cyclophilin A is critical for hepatitis C virus replication. J Biol Chem 284: 
16998-7005 
158. Boulant S, Douglas MW, Moody L, Budkowska A, Targett-Adams P, 
McLauchlan J. 2008. Hepatitis C virus core protein induces lipid droplet 
redistribution in a microtubule- and dynein-dependent manner. Traffic 9: 
1268-82 
159. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, 
Bartenschlager R, Wakita T, Hijikata M, Shimotohno K. 2007. The lipid 
droplet is an important organelle for hepatitis C virus production. Nat Cell 
Biol 9: 1089-97 
160. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M, Jr., Ye J. 2007. Hepatitis 
C virus production by human hepatocytes dependent on assembly and 
secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A 104: 
5848-53 
161. Chang KS, Jiang J, Cai Z, Luo G. 2007. Human apolipoprotein e is required 
for infectivity and production of hepatitis C virus in cell culture. J Virol 81: 
13783-93 
162. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann 
E, Abid K, Negro F, Dreux M, Cosset FL, Bartenschlager R. 2006. 
Construction and characterization of infectious intragenotypic and 
intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 103: 
7408-13 
163. Pietschmann T, Lohmann V, Kaul A, Krieger N, Rinck G, Rutter G, Strand D, 
Bartenschlager R. 2002. Persistent and transient replication of full-length 
hepatitis C virus genomes in cell culture. J Virol 76: 4008-21 
164. Murayama A, Date T, Morikawa K, Akazawa D, Miyamoto M, Kaga M, Ishii 
K, Suzuki T, Kato T, Mizokami M, Wakita T. 2007. The NS3 helicase and 
NS5B-to-3'X regions are important for efficient hepatitis C virus strain JFH-1 
replication in Huh7 cells. J Virol 81: 8030-40 
165. Ma Y, Yates J, Liang Y, Lemon SM, Yi M. 2008. NS3 helicase domains 
involved in infectious intracellular hepatitis C virus particle assembly. J Virol 
82: 7624-39 
 236 
166. Tellinghuisen TL, Foss KL, Treadaway J. 2008. Regulation of hepatitis C 
virion production via phosphorylation of the NS5A protein. PLoS Pathog 4: 
e1000032 
167. Benga WJ, Krieger SE, Dimitrova M, Zeisel MB, Parnot M, Lupberger J, 
Hildt E, Luo G, McLauchlan J, Baumert TF, Schuster C. 2010. Apolipoprotein 
E interacts with hepatitis C virus nonstructural protein 5A and determines 
assembly of infectious particles. Hepatology 51: 43-53 
168. Meier V, Mihm S, Braun Wietzke P, Ramadori G. 2001. HCV-RNA positivity 
in peripheral blood mononuclear cells of patients with chronic HCV infection: 
does it really mean viral replication? World J Gastroenterol 7: 228-34 
169. Blackard JT, Kemmer N, Sherman KE. 2006. Extrahepatic replication of 
HCV: insights into clinical manifestations and biological consequences. 
Hepatology 44: 15-22 
170. Hoofnagle JH. 2002. Course and outcome of hepatitis C. Hepatology 36: S21-
9 
171. Marcellin P, Asselah T, Boyer N. 2002. Fibrosis and disease progression in 
hepatitis C. Hepatology 36: S47-56 
172. Agnello V, De Rosa FG. 2004. Extrahepatic disease manifestations of HCV 
infection: some current issues. J Hepatol 40: 341-52 
173. Mayo MJ. 2003. Extrahepatic manifestations of hepatitis C infection. Am J 
Med Sci 325: 135-48 
174. Sharma SD. 2010. Hepatitis C virus: molecular biology & current therapeutic 
options. Indian J Med Res 131: 17-34 
175. Farci P, Alter HJ, Wong D, Miller RH, Shih JW, Jett B, Purcell RH. 1991. A 
long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N 
Engl J Med 325: 98-104 
176. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. 1993. Natural 
course of chronic hepatitis C. Am J Gastroenterol 88: 240-3 
177. Blackham S, Baillie A, Al-Hababi F, Remlinger K, You S, Hamatake R, 
McGarvey MJ. 2010. Gene expression profiling indicates the roles of host 
oxidative stress, apoptosis, lipid metabolism, and intracellular transport genes 
in the replication of hepatitis C virus. J Virol 84: 5404-14 
 237 
178. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. 2008. Hepatitis C 
virus-induced oxidative stress suppresses hepcidin expression through 
increased histone deacetylase activity. Hepatology 48: 1420-9 
179. Choi J, Ou JH. 2006. Mechanisms of liver injury. III. Oxidative stress in the 
pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol 
290: G847-51 
180. Poli G. 2000. Pathogenesis of liver fibrosis: role of oxidative stress. Mol 
Aspects Med 21: 49-98 
181. Diamond DL, Jacobs JM, Paeper B, Proll SC, Gritsenko MA, Carithers RL, 
Jr., Larson AM, Yeh MM, Camp DG, 2nd, Smith RD, Katze MG. 2007. 
Proteomic profiling of human liver biopsies: hepatitis C virus-induced fibrosis 
and mitochondrial dysfunction. Hepatology 46: 649-57 
182. Fischer HP, Willsch E, Bierhoff E, Pfeifer U. 1996. Histopathologic findings 
in chronic hepatitis C. J Hepatol 24: 35-42 
183. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, Spahr L, 
Zarski JP, Borisch B, Hadengue A, Negro F. 2000. Hepatocyte steatosis is a 
cytopathic effect of hepatitis C virus genotype 3. J Hepatol 33: 106-15 
184. Negro F. 2006. Mechanisms and significance of liver steatosis in hepatitis C 
virus infection. World J Gastroenterol 12: 6756-65 
185. Mirandola S, Bowman D, Hussain MM, Alberti A. 2010. Hepatic steatosis in 
hepatitis C is a storage disease due to HCV interaction with microsomal 
triglyceride transfer protein (MTP). Nutr Metab (Lond) 7: 13 
186. McPherson S, Jonsson JR, Barrie HD, O'Rourke P, Clouston AD, Powell EE. 
2008. Investigation of the role of SREBP-1c in the pathogenesis of HCV-
related steatosis. J Hepatol 49: 1046-54 
187. Mirandola S, Osterreicher CH, Marcolongo M, Datz C, Aigner E, 
Schlabrakowski A, Realdon S, Gerotto M, Alberti A, Stickel F. 2009. 
Microsomal triglyceride transfer protein polymorphism (-493G/T) is 
associated with hepatic steatosis in patients with chronic hepatitis C. Liver Int 
29: 557-65 
188. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, 
Chien DY, Munoz SJ, Balestrieri A, Purcell RH, Alter HJ. 2000. The outcome 
of acute hepatitis C predicted by the evolution of the viral quasispecies. 
Science 288: 339-44 
 238 
189. Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, Cosset FL, Patel 
AH, Meisel H, Baumert J, Viazov S, Rispeter K, Blum HE, Roggendorf M, 
Baumert TF. 2007. Rapid induction of virus-neutralizing antibodies and viral 
clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A 
104: 6025-30 
190. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, 
Manns MP, Rehermann B. 2000. Cellular immune responses persist and 
humoral responses decrease two decades after recovery from a single-source 
outbreak of hepatitis C. Nat Med 6: 578-82 
191. Neumann-Haefelin C, Blum HE, Chisari FV, Thimme R. 2005. T cell 
response in hepatitis C virus infection. J Clin Virol 32: 75-85 
192. Nascimbeni M, Mizukoshi E, Bosmann M, Major ME, Mihalik K, Rice CM, 
Feinstone SM, Rehermann B. 2003. Kinetics of CD4+ and CD8+ memory T-
cell responses during hepatitis C virus rechallenge of previously recovered 
chimpanzees. J Virol 77: 4781-93 
193. Urbani S, Amadei B, Fisicaro P, Tola D, Orlandini A, Sacchelli L, Mori C, 
Missale G, Ferrari C. 2006. Outcome of acute hepatitis C is related to virus-
specific CD4 function and maturation of antiviral memory CD8 responses. 
Hepatology 44: 126-39 
194. Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R, 
Hoffmann R, Schirren CA, Santantonio T, Pape GR. 1999. Recurrence of 
hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute 
hepatitis C. Gastroenterology 117: 933-41 
195. Lauer GM, Ouchi K, Chung RT, Nguyen TN, Day CL, Purkis DR, Reiser M, 
Kim AY, Lucas M, Klenerman P, Walker BD. 2002. Comprehensive analysis 
of CD8(+)-T-cell responses against hepatitis C virus reveals multiple 
unpredicted specificities. J Virol 76: 6104-13 
196. Wong DK, Dudley DD, Dohrenwend PB, Lauer GM, Chung RT, Thomas DL, 
Walker BD. 2001. Detection of diverse hepatitis C virus (HCV)-specific 
cytotoxic T lymphocytes in peripheral blood of infected persons by screening 
for responses to all translated proteins of HCV. J Virol 75: 1229-35 
197. Kasprowicz V, Schulze Zur Wiesch J, Kuntzen T, Nolan BE, Longworth S, 
Berical A, Blum J, McMahon C, Reyor LL, Elias N, Kwok WW, McGovern 
BG, Freeman G, Chung RT, Klenerman P, Lewis-Ximenez L, Walker BD, 
 239 
Allen TM, Kim AY, Lauer GM. 2008. High level of PD-1 expression on 
hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV 
infection, irrespective of clinical outcome. J Virol 82: 3154-60 
198. Zeuzem S. 2008. Interferon-based therapy for chronic hepatitis C: current and 
future perspectives. Nat Clin Pract Gastroenterol Hepatol 5: 610-22 
199. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, 
Jacobs S. 2000. Pegylated interferon-alpha2b: pharmacokinetics, 
pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C 
Intervention Therapy Group. Clin Pharmacol Ther 68: 556-67 
200. Bodenheimer HC, Jr., Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. 
1997. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: 
a multicenter trial. Hepatology 26: 473-7 
201. Crotty S, Cameron C, Andino R. 2002. Ribavirin's antiviral mechanism of 
action: lethal mutagenesis? J Mol Med 80: 86-95 
202. Crotty S, Cameron CE, Andino R. 2001. RNA virus error catastrophe: direct 
molecular test by using ribavirin. Proc Natl Acad Sci U S A 98: 6895-900 
203. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bos 
M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, 
Kawai SH, Kukolj G, Lagace L, LaPlante SR, Narjes H, Poupart MA, 
Rancourt J, Sentjens RE, St George R, Simoneau B, Steinmann G, Thibeault 
D, Tsantrizos YS, Weldon SM, Yong CL, Llinas-Brunet M. 2003. An NS3 
protease inhibitor with antiviral effects in humans infected with hepatitis C 
virus. Nature 426: 186-9 
204. Mo H, Lu L, Pilot-Matias T, Pithawalla R, Mondal R, Masse S, Dekhtyar T, 
Ng T, Koev G, Stoll V, Stewart KD, Pratt J, Donner P, Rockway T, Maring C, 
Molla A. 2005. Mutations conferring resistance to a hepatitis C virus (HCV) 
RNA-dependent RNA polymerase inhibitor alone or in combination with an 
HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother 49: 
4305-14 
205. Lu L, Pilot-Matias TJ, Stewart KD, Randolph JT, Pithawalla R, He W, Huang 
PP, Klein LL, Mo H, Molla A. 2004. Mutations conferring resistance to a 
potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents 
Chemother 48: 2260-6 
 240 
206. Perni RB, Almquist SJ, Byrn RA, Chandorkar G, Chaturvedi PR, Courtney 
LF, Decker CJ, Dinehart K, Gates CA, Harbeson SL, Heiser A, Kalkeri G, 
Kolaczkowski E, Lin K, Luong YP, Rao BG, Taylor WP, Thomson JA, Tung 
RD, Wei Y, Kwong AD, Lin C. 2006. Preclinical profile of VX-950, a potent, 
selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine 
protease. Antimicrob Agents Chemother 50: 899-909 
207. Lin C, Gates CA, Rao BG, Brennan DL, Fulghum JR, Luong YP, Frantz JD, 
Lin K, Ma S, Wei YY, Perni RB, Kwong AD. 2005. In vitro studies of cross-
resistance mutations against two hepatitis C virus serine protease inhibitors, 
VX-950 and BILN 2061. J Biol Chem 280: 36784-91 
208. Carroll SS, Tomassini JE, Bosserman M, Getty K, Stahlhut MW, Eldrup AB, 
Bhat B, Hall D, Simcoe AL, LaFemina R, Rutkowski CA, Wolanski B, Yang 
Z, Migliaccio G, De Francesco R, Kuo LC, MacCoss M, Olsen DB. 2003. 
Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside 
analogs. J Biol Chem 278: 11979-84 
209. Migliaccio G, Tomassini JE, Carroll SS, Tomei L, Altamura S, Bhat B, 
Bartholomew L, Bosserman MR, Ceccacci A, Colwell LF, Cortese R, De 
Francesco R, Eldrup AB, Getty KL, Hou XS, LaFemina RL, Ludmerer SW, 
MacCoss M, McMasters DR, Stahlhut MW, Olsen DB, Hazuda DJ, Flores 
OA. 2003. Characterization of resistance to non-obligate chain-terminating 
ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol 
Chem 278: 49164-70 
210. Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, Han J, Berger 
K, Thudium K, Kuo C, et al. 1994. Vaccination of chimpanzees against 
infection by the hepatitis C virus. Proc Natl Acad Sci U S A 91: 1294-8 
211. Ray R, Khanna A, Lagging LM, Meyer K, Choo QL, Ralston R, Houghton M, 
Becherer PR. 1994. Peptide immunogen mimicry of putative E1 glycoprotein-
specific epitopes in hepatitis C virus. J Virol 68: 4420-6 
212. Forns X, Payette PJ, Ma X, Satterfield W, Eder G, Mushahwar IK, 
Govindarajan S, Davis HL, Emerson SU, Purcell RH, Bukh J. 2000. 
Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus 
(HCV) envelope E2 protein modified the infection after challenge with 
homologous monoclonal HCV. Hepatology 32: 618-25 
 241 
213. Heile JM, Fong YL, Rosa D, Berger K, Saletti G, Campagnoli S, Bensi G, 
Capo S, Coates S, Crawford K, Dong C, Wininger M, Baker G, Cousens L, 
Chien D, Ng P, Archangel P, Grandi G, Houghton M, Abrignani S. 2000. 
Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an 
endoplasmic reticulum-retained recombinant protein is superior to secreted 
recombinant protein and DNA-based vaccine candidates. J Virol 74: 6885-92 
214. Habersetzer F, Baumert TF, Stoll-Keller F. 2009. GI-5005, a yeast vector 
vaccine expressing an NS3-core fusion protein for chronic HCV infection. 
Curr Opin Mol Ther 11: 456-62 
215. Shiina M, Rehermann B. 2006. Hepatitis C vaccines: Inducing and 
challenging memory T cells. Hepatology 43: 1395-8 
216. Randall RE, Goodbourn S. 2008. Interferons and viruses: an interplay between 
induction, signalling, antiviral responses and virus countermeasures. J Gen 
Virol 89: 1-47 
217. Sadler AJ, Williams BR. 2008. Interferon-inducible antiviral effectors. Nat 
Rev Immunol 8: 559-68 
218. Carpick BW, Graziano V, Schneider D, Maitra RK, Lee X, Williams BR. 
1997. Characterization of the solution complex between the interferon-
induced, double-stranded RNA-activated protein kinase and HIV-I trans-
activating region RNA. J Biol Chem 272: 9510-6 
219. Meurs E, Chong K, Galabru J, Thomas NS, Kerr IM, Williams BR, 
Hovanessian AG. 1990. Molecular cloning and characterization of the human 
double-stranded RNA-activated protein kinase induced by interferon. Cell 62: 
379-90 
220. Carroll SS, Chen E, Viscount T, Geib J, Sardana MK, Gehman J, Kuo LC. 
1996. Cleavage of oligoribonucleotides by the 2',5'-oligoadenylate- dependent 
ribonuclease L. J Biol Chem 271: 4988-92 
221. Weber F. 2007. Interaction of hepatitis C virus with the type I interferon 
system. World J Gastroenterol 13: 4818-23 
222. Bigger CB, Guerra B, Brasky KM, Hubbard G, Beard MR, Luxon BA, Lemon 
SM, Lanford RE. 2004. Intrahepatic gene expression during chronic hepatitis 
C virus infection in chimpanzees. J Virol 78: 13779-92 
 242 
223. Helbig KJ, Lau DT, Semendric L, Harley HA, Beard MR. 2005. Analysis of 
ISG expression in chronic hepatitis C identifies viperin as a potential antiviral 
effector. Hepatology 42: 702-10 
224. Jiang D, Guo H, Xu C, Chang J, Gu B, Wang L, Block TM, Guo JT. 2008. 
Identification of three interferon-inducible cellular enzymes that inhibit the 
replication of hepatitis C virus. J Virol 82: 1665-78 
225. Hinson ER, Cresswell P. 2009. The N-terminal amphipathic alpha-helix of 
viperin mediates localization to the cytosolic face of the endoplasmic 
reticulum and inhibits protein secretion. J Biol Chem 284: 4705-12 
226. Horner SM, Gale M, Jr. 2009. Intracellular innate immune cascades and 
interferon defenses that control hepatitis C virus. J Interferon Cytokine Res 29: 
489-98 
227. Murao K, Imachi H, Yu X, Cao WM, Nishiuchi T, Chen K, Li J, Ahmed RA, 
Wong NC, Ishida T. 2008. Interferon alpha decreases expression of human 
scavenger receptor class BI, a possible HCV receptor in hepatocytes. Gut 57: 
664-71 
228. Abid K, Quadri R, Negro F. 2000. Hepatitis C virus, the E2 envelope protein, 
and alpha-interferon resistance. Science 287: 1555 
229. Chang KS, Cai Z, Zhang C, Sen GC, Williams BR, Luo G. 2006. Replication 
of hepatitis C virus (HCV) RNA in mouse embryonic fibroblasts: protein 
kinase R (PKR)-dependent and PKR-independent mechanisms for controlling 
HCV RNA replication and mediating interferon activities. J Virol 80: 7364-74 
230. Ferreon JC, Ferreon AC, Li K, Lemon SM. 2005. Molecular determinants of 
TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease. J Biol 
Chem 280: 20483-92 
231. Fredericksen B, Akkaraju GR, Foy E, Wang C, Pflugheber J, Chen ZJ, Gale 
M, Jr. 2002. Activation of the interferon-beta promoter during hepatitis C 
virus RNA replication. Viral Immunol 15: 29-40 
232. Barton GM, Medzhitov R. 2002. Toll-like receptors and their ligands. Curr 
Top Microbiol Immunol 270: 81-92 
233. Honda K, Yanai H, Takaoka A, Taniguchi T. 2005. Regulation of the type I 
IFN induction: a current view. Int Immunol 17: 1367-78 
234. Akira S, Takeda K. 2004. Toll-like receptor signalling. Nat Rev Immunol 4: 
499-511 
 243 
235. Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, Alexopoulou L, 
Azuma YT, Flavell RA, Liljestrom P, Reis e Sousa C. 2005. Toll-like receptor 
3 promotes cross-priming to virus-infected cells. Nature 433: 887-92 
236. Seth RB, Sun L, Chen ZJ. 2006. Antiviral innate immunity pathways. Cell Res 
16: 141-7 
237. Edelmann KH, Richardson-Burns S, Alexopoulou L, Tyler KL, Flavell RA, 
Oldstone MB. 2004. Does Toll-like receptor 3 play a biological role in virus 
infections? Virology 322: 231-8 
238. Yoneyama M, Fujita T. 2007. Function of RIG-I-like receptors in antiviral 
innate immunity. J Biol Chem 282: 15315-8 
239. Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K, 
Foy E, Loo YM, Gale M, Jr., Akira S, Yonehara S, Kato A, Fujita T. 2005. 
Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and 
LGP2 in antiviral innate immunity. J Immunol 175: 2851-8 
240. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi 
M, Taira K, Akira S, Fujita T. 2004. The RNA helicase RIG-I has an essential 
function in double-stranded RNA-induced innate antiviral responses. Nat 
Immunol 5: 730-7 
241. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, 
Coyle AJ, Liao SM, Maniatis T. 2003. IKKepsilon and TBK1 are essential 
components of the IRF3 signaling pathway. Nat Immunol 4: 491-6 
242. Matsui K, Kumagai Y, Kato H, Sato S, Kawagoe T, Uematsu S, Takeuchi O, 
Akira S. 2006. Cutting edge: Role of TANK-binding kinase 1 and inducible 
IkappaB kinase in IFN responses against viruses in innate immune cells. J 
Immunol 177: 5785-9 
243. Miyahira AK, Shahangian A, Hwang S, Sun R, Cheng G. 2009. TANK-
binding kinase-1 plays an important role during in vitro and in vivo type I IFN 
responses to DNA virus infections. J Immunol 182: 2248-57 
244. Scheidereit C. 2006. IkappaB kinase complexes: gateways to NF-kappaB 
activation and transcription. Oncogene 25: 6685-705 
245. Salminen A, Paimela T, Suuronen T, Kaarniranta K. 2008. Innate immunity 
meets with cellular stress at the IKK complex: regulation of the IKK complex 
by HSP70 and HSP90. Immunol Lett 117: 9-15 
 244 
246. Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB. 2005. VISA is an adapter 
protein required for virus-triggered IFN-beta signaling. Mol Cell 19: 727-40 
247. Ishikawa H, Ma Z, Barber GN. 2009. STING regulates intracellular DNA-
mediated, type I interferon-dependent innate immunity. Nature 461: 788-92 
248. Zhong B, Yang Y, Li S, Wang YY, Li Y, Diao F, Lei C, He X, Zhang L, Tien 
P, Shu HB. 2008. The adaptor protein MITA links virus-sensing receptors to 
IRF3 transcription factor activation. Immunity 29: 538-50 
249. Bode JG, Brenndorfer ED, Haussinger D. 2007. Subversion of innate host 
antiviral strategies by the hepatitis C virus. Arch Biochem Biophys 462: 254-
65 
250. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu 
S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, 
Reis e Sousa C, Matsuura Y, Fujita T, Akira S. 2006. Differential roles of 
MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441: 
101-5 
251. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, Poeck H, Akira S, 
Conzelmann KK, Schlee M, Endres S, Hartmann G. 2006. 5'-Triphosphate 
RNA is the ligand for RIG-I. Science 314: 994-7 
252. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, Weber F, Reis e 
Sousa C. 2006. RIG-I-mediated antiviral responses to single-stranded RNA 
bearing 5'-phosphates. Science 314: 997-1001 
253. Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M, Jr. 2008. Innate 
immunity induced by composition-dependent RIG-I recognition of hepatitis C 
virus RNA. Nature 454: 523-7 
254. Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, Flavell RA, Diamond 
MS, Colonna M. 2006. Essential role of mda-5 in type I IFN responses to 
polyriboinosinic:polyribocytidylic acid and encephalomyocarditis 
picornavirus. Proc Natl Acad Sci U S A 103: 8459-64 
255. Liao S, Bao X, Liu T, Lai S, Li K, Garofalo RP, Casola A. 2008. Role of 
retinoic acid inducible gene-I in human metapneumovirus-induced cellular 
signalling. J Gen Virol 89: 1978-86 
256. Kubo M, Hanada T, Yoshimura A. 2003. Suppressors of cytokine signaling 
and immunity. Nat Immunol 4: 1169-76 
 245 
257. Song MM, Shuai K. 1998. The suppressor of cytokine signaling (SOCS) 1 and 
SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and 
antiproliferative activities. J Biol Chem 273: 35056-62 
258. Vlotides G, Sorensen AS, Kopp F, Zitzmann K, Cengic N, Brand S, Zachoval 
R, Auernhammer CJ. 2004. SOCS-1 and SOCS-3 inhibit IFN-alpha-induced 
expression of the antiviral proteins 2,5-OAS and MxA. Biochem Biophys Res 
Commun 320: 1007-14 
259. Stoiber D, Kovarik P, Cohney S, Johnston JA, Steinlein P, Decker T. 1999. 
Lipopolysaccharide induces in macrophages the synthesis of the suppressor of 
cytokine signaling 3 and suppresses signal transduction in response to the 
activating factor IFN-gamma. J Immunol 163: 2640-7 
260. Yao ZQ, Waggoner SN, Cruise MW, Hall C, Xie X, Oldach DW, Hahn YS. 
2006. SOCS1 and SOCS3 are targeted by hepatitis C virus core/gC1qR 
ligation to inhibit T-cell function. J Virol 80: 8287 
261. Huang Y, Feld JJ, Sapp RK, Nanda S, Lin JH, Blatt LM, Fried MW, Murthy 
K, Liang TJ. 2007. Defective hepatic response to interferon and activation of 
suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology 
132: 733-44 
262. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston 
AD, Powell EE. 2006. Non-response to antiviral therapy is associated with 
obesity and increased hepatic expression of suppressor of cytokine signalling 3 
(SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 55: 529-
35 
263. Friedman CS, O'Donnell MA, Legarda-Addison D, Ng A, Cardenas WB, 
Yount JS, Moran TM, Basler CF, Komuro A, Horvath CM, Xavier R, Ting 
AT. 2008. The tumour suppressor CYLD is a negative regulator of RIG-I-
mediated antiviral response. EMBO Rep 9: 930-6 
264. Arimoto K, Takahashi H, Hishiki T, Konishi H, Fujita T, Shimotohno K. 
2007. Negative regulation of the RIG-I signaling by the ubiquitin ligase 
RNF125. Proc Natl Acad Sci U S A 104: 7500-5 
265. Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, Takeuchi O, Akira S, 
Chen Z, Inoue S, Jung JU. 2007. TRIM25 RING-finger E3 ubiquitin ligase is 
essential for RIG-I-mediated antiviral activity. Nature 446: 916-20 
 246 
266. Saito T, Hirai R, Loo YM, Owen D, Johnson CL, Sinha SC, Akira S, Fujita T, 
Gale M, Jr. 2007. Regulation of innate antiviral defenses through a shared 
repressor domain in RIG-I and LGP2. Proc Natl Acad Sci U S A 104: 582-7 
267. Rothenfusser S, Goutagny N, DiPerna G, Gong M, Monks BG, Schoenemeyer 
A, Yamamoto M, Akira S, Fitzgerald KA. 2005. The RNA helicase Lgp2 
inhibits TLR-independent sensing of viral replication by retinoic acid-
inducible gene-I. J Immunol 175: 5260-8 
268. Venkataraman T, Valdes M, Elsby R, Kakuta S, Caceres G, Saijo S, Iwakura 
Y, Barber GN. 2007. Loss of DExD/H box RNA helicase LGP2 manifests 
disparate antiviral responses. J Immunol 178: 6444-55 
269. Foy E, Li K, Sumpter R, Jr., Loo YM, Johnson CL, Wang C, Fish PM, 
Yoneyama M, Fujita T, Lemon SM, Gale M, Jr. 2005. Control of antiviral 
defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I 
signaling. Proc Natl Acad Sci U S A 102: 2986-91 
270. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, Ray SC, Gale 
M, Jr., Lemon SM. 2005. Immune evasion by hepatitis C virus NS3/4A 
protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. 
Proc Natl Acad Sci U S A 102: 2992-7 
271. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. 2005. Hepatitis C virus protease 
NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria 
to evade innate immunity. Proc Natl Acad Sci U S A 102: 17717-22 
272. Otsuka M, Kato N, Moriyama M, Taniguchi H, Wang Y, Dharel N, Kawabe 
T, Omata M. 2005. Interaction between the HCV NS3 protein and the host 
TBK1 protein leads to inhibition of cellular antiviral responses. Hepatology 
41: 1004-12 
273. Loo YM, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM, Carney DS, 
Wang T, Ishida H, Yoneyama M, Fujita T, Saito T, Lee WM, Hagedorn CH, 
Lau DT, Weinman SA, Lemon SM, Gale M, Jr. 2006. Viral and therapeutic 
control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. 
Proc Natl Acad Sci U S A 103: 6001-6 
274. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, 
Tschopp J. 2005. Cardif is an adaptor protein in the RIG-I antiviral pathway 
and is targeted by hepatitis C virus. Nature 437: 1167-72 
 247 
275. Hino K, Sainokami S, Shimoda K, Iino S, Wang Y, Okamoto H, Miyakawa Y, 
Mayumi M. 1994. Genotypes and titers of hepatitis C virus for predicting 
response to interferon in patients with chronic hepatitis C. J Med Virol 42: 
299-305 
276. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. 1982. Growth of 
human hepatoma cells lines with differentiated functions in chemically 
defined medium. Cancer Res 42: 3858-63 
277. Kumar U, Cheng D, Thomas H, Monjardino J. 1992. Cloning and sequencing 
of the structural region and expression of putative core gene of hepatitis C 
virus from a British case of chronic sporadic hepatitis. J Gen Virol 73 ( Pt 6): 
1521-5 
278. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland 
SF, Uprichard SL, Wakita T, Chisari FV. 2005. Robust hepatitis C virus 
infection in vitro. Proc Natl Acad Sci U S A 102: 9294-9 
279. Graham FL, Smiley J, Russell WC, Nairn R. 1977. Characteristics of a human 
cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 
59-74 
280. Harrison T, Graham F, Williams J. 1977. Host-range mutants of adenovirus 
type 5 defective for growth in HeLa cells. Virology 77: 319-29 
281. Pfaffl MW. 2001. A new mathematical model for relative quantification in 
real-time RT-PCR. Nucleic Acids Res 29: e45 
282. Pfaffl MW, Horgan GW, Dempfle L. 2002. Relative expression software tool 
(REST) for group-wise comparison and statistical analysis of relative 
expression results in real-time PCR. Nucleic Acids Res 30: e36 
283. Kato T, Date T, Murayama A, Morikawa K, Akazawa D, Wakita T. 2006. Cell 
culture and infection system for hepatitis C virus. Nat Protoc 1: 2334-9 
284. Shuai K, Liu B. 2005. Regulation of gene-activation pathways by PIAS 
proteins in the immune system. Nat Rev Immunol 5: 593-605 
285. Pollack A, Ciancio G. 1990. Cell cycle phase-specific analysis of cell viability 
using Hoechst 33342 and propidium iodide after ethanol preservation. 
Methods Cell Biol 33: 19-24 
286. Nunez R. 2001. DNA measurement and cell cycle analysis by flow cytometry. 
Curr Issues Mol Biol 3: 67-70 
 248 
287. Lee J, Wu CC, Lee KJ, Chuang TH, Katakura K, Liu YT, Chan M, Tawatao 
R, Chung M, Shen C, Cottam HB, Lai MM, Raz E, Carson DA. 2006. 
Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc 
Natl Acad Sci U S A 103: 1828-33 
288. Abe T, Kaname Y, Hamamoto I, Tsuda Y, Wen X, Taguwa S, Moriishi K, 
Takeuchi O, Kawai T, Kanto T, Hayashi N, Akira S, Matsuura Y. 2007. 
Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-
MyD88-dependent signaling pathway in macrophage cell lines. J Virol 81: 
8953-66 
289. Arnaud N, Dabo S, Maillard P, Budkowska A, Kalliampakou KI, Mavromara 
P, Garcin D, Hugon J, Gatignol A, Akazawa D, Wakita T, Meurs EF. 2010. 
Hepatitis C virus controls interferon production through PKR activation. PLoS 
One 5: e10575 
290. Dansako H, Ikeda M, Kato N. 2007. Limited suppression of the interferon-
beta production by hepatitis C virus serine protease in cultured human 
hepatocytes. FEBS J 274: 4161-76 
291. Ikegame S, Takeda M, Ohno S, Nakatsu Y, Nakanishi Y, Yanagi Y. 2010. 
Both RIG-I and MDA5 RNA helicases contribute to the induction of 
alpha/beta interferon in measles virus-infected human cells. J Virol 84: 372-9 
292. Cheng G, Zhong J, Chung J, Chisari FV. 2007. Double-stranded DNA and 
double-stranded RNA induce a common antiviral signaling pathway in human 
cells. Proc Natl Acad Sci U S A 104: 9035-40 
293. Wang Q, Nagarkar DR, Bowman ER, Schneider D, Gosangi B, Lei J, Zhao Y, 
McHenry CL, Burgens RV, Miller DJ, Sajjan U, Hershenson MB. 2009. Role 
of double-stranded RNA pattern recognition receptors in rhinovirus-induced 
airway epithelial cell responses. J Immunol 183: 6989-97 
294. Chang TH, Liao CL, Lin YL. 2006. Flavivirus induces interferon-beta gene 
expression through a pathway involving RIG-I-dependent IRF-3 and PI3K-
dependent NF-kappaB activation. Microbes Infect 8: 157-71 
295. Loo YM, Fornek J, Crochet N, Bajwa G, Perwitasari O, Martinez-Sobrido L, 
Akira S, Gill MA, Garcia-Sastre A, Katze MG, Gale M, Jr. 2008. Distinct 
RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol 82: 
335-45 
 249 
296. Lanford RE, Guerra B, Bigger CB, Lee H, Chavez D, Brasky KM. 2007. Lack 
of response to exogenous interferon-alpha in the liver of chimpanzees 
chronically infected with hepatitis C virus. Hepatology 46: 999-1008 
297. Cheng G, Chen W, Li Z, Yan W, Zhao X, Xie J, Liu M, Zhang H, Zhong Y, 
Zheng Z. 2006. Characterization of the porcine alpha interferon multigene 
family. Gene 382: 28-38 
298. Garaigorta U, Chisari FV. 2009. Hepatitis C virus blocks interferon effector 
function by inducing protein kinase R phosphorylation. Cell Host Microbe 6: 
513-22 
299. Walters KA, Syder AJ, Lederer SL, Diamond DL, Paeper B, Rice CM, Katze 
MG. 2009. Genomic analysis reveals a potential role for cell cycle 
perturbation in HCV-mediated apoptosis of cultured hepatocytes. PLoS 
Pathog 5: e1000269 
300. Kobasa D, Jones SM, Shinya K, Kash JC, Copps J, Ebihara H, Hatta Y, Kim 
JH, Halfmann P, Hatta M, Feldmann F, Alimonti JB, Fernando L, Li Y, Katze 
MG, Feldmann H, Kawaoka Y. 2007. Aberrant innate immune response in 
lethal infection of macaques with the 1918 influenza virus. Nature 445: 319-
23 
301. Conceicao TM, El-Bacha T, Villas-Boas CS, Coello G, Ramirez J, Montero-
Lomeli M, Da Poian AT. 2010. Gene expression analysis during dengue virus 
infection in HepG2 cells reveals virus control of innate immune response. J 
Infect 60: 65-75 
302. Baskin CR, Garcia-Sastre A, Tumpey TM, Bielefeldt-Ohmann H, Carter VS, 
Nistal-Villan E, Katze MG. 2004. Integration of clinical data, pathology, and 
cDNA microarrays in influenza virus-infected pigtailed macaques (Macaca 
nemestrina). J Virol 78: 10420-32 
303. Kim KA, Lin W, Tai AW, Shao RX, Weinberg E, De Sa Borges CB, Bhan 
AK, Zheng H, Kamegaya Y, Chung RT. 2009. Hepatic SOCS3 expression is 
strongly associated with non-response to therapy and race in HCV and 
HCV/HIV infection. J Hepatol 50: 705-11 
304. Persico M, Capasso M, Persico E, Svelto M, Russo R, Spano D, Croce L, La 
Mura V, Moschella F, Masutti F, Torella R, Tiribelli C, Iolascon A. 2007. 
Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-
 250 
related chronic hepatitis: Insulin resistance and response to antiviral therapy. 
Hepatology 46: 1009-15 
305. Bode JG, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, Schaper F, Heinrich 
PC, Haussinger D. 2003. IFN-alpha antagonistic activity of HCV core protein 
involves induction of suppressor of cytokine signaling-3. FASEB J 17: 488-90 
306. Shao RX, Zhang L, Peng LF, Sun E, Chung WJ, Jang JY, Tsai WL, Hyppolite 
G, Chung RT. 2010. Suppressor of cytokine signaling 3 suppresses hepatitis C 
virus replication in an mTOR-dependent manner. J Virol 84: 6060-9 
307. Baril M, Racine ME, Penin F, Lamarre D. 2009. MAVS dimer is a crucial 
signaling component of innate immunity and the target of hepatitis C virus 
NS3/4A protease. J Virol 83: 1299-311 
308. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, 
Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Ceron D, Degott C, 
Cacoub P, Perronne C. 2004. Pegylated interferon alfa-2b vs standard 
interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected 
patients: a randomized controlled trial. JAMA 292: 2839-48 
309. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, 
Younossi Z, Albrecht J. 2003. Effect of treatment with peginterferon or 
interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis 
C. Hepatology 38: 75-85 
310. Franco S, Clotet B, Martinez MA. 2008. A wide range of NS3/4A protease 
catalytic efficiencies in HCV-infected individuals. Virus Res 131: 260-70 
311. Bellecave P, Sarasin-Filipowicz M, Donze O, Kennel A, Gouttenoire J, 
Meylan E, Terracciano L, Tschopp J, Sarrazin C, Berg T, Moradpour D, Heim 
MH. 2010. Cleavage of mitochondrial antiviral signaling protein in the liver of 
patients with chronic hepatitis C correlates with a reduced activation of the 
endogenous interferon system. Hepatology 51: 1127-36 
312. Jouan L, Melancon P, Rodrigue-Gervais IG, Raymond VA, Selliah S, Boucher 
G, Bilodeau M, Grandvaux N, Lamarre D. 2010. Distinct antiviral signaling 
pathways in primary human hepatocytes and their differential disruption by 
HCV NS3 protease. J Hepatol 52: 167-75 
313. Pal S, Shuhart MC, Thomassen L, Emerson SS, Su T, Feuerborn N, Kae J, 
Gretch DR. 2006. Intrahepatic hepatitis C virus replication correlates with 
chronic hepatitis C disease severity in vivo. J Virol 80: 2280-90 
 251 
314. Doughty AL, Spencer JD, Cossart YE, McCaughan GW. 1998. Cholestatic 
hepatitis after liver transplantation is associated with persistently high serum 
hepatitis C virus RNA levels. Liver Transpl Surg 4: 15-21 
315. Pelletier SJ, Raymond DP, Crabtree TD, Berg CL, Iezzoni JC, Hahn YS, 
Sawyer RG, Pruett TL. 2000. Hepatitis C-induced hepatic allograft injury is 
associated with a pretransplantation elevated viral replication rate. Hepatology 
32: 418-26 
316. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. 1995. Human 
immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 
phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 69: 6705-11 
317. Kashanchi F, Agbottah ET, Pise-Masison CA, Mahieux R, Duvall J, Kumar A, 
Brady JN. 2000. Cell cycle-regulated transcription by the human 
immunodeficiency virus type 1 Tat transactivator. J Virol 74: 652-60 
318. Re F, Braaten D, Franke EK, Luban J. 1995. Human immunodeficiency virus 
type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-
cyclin B. J Virol 69: 6859-64 
319. Goh WC, Rogel ME, Kinsey CM, Michael SF, Fultz PN, Nowak MA, Hahn 
BH, Emerman M. 1998. HIV-1 Vpr increases viral expression by 
manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat 
Med 4: 65-71 
320. Dove B, Brooks G, Bicknell K, Wurm T, Hiscox JA. 2006. Cell cycle 
perturbations induced by infection with the coronavirus infectious bronchitis 
virus and their effect on virus replication. J Virol 80: 4147-56 
321. Nguyen H, Mudryj M, Guadalupe M, Dandekar S. 2003. Hepatitis C virus 
core protein expression leads to biphasic regulation of the p21 cdk inhibitor 
and modulation of hepatocyte cell cycle. Virology 312: 245-53 
322. Ohkawa K, Ishida H, Nakanishi F, Hosui A, Ueda K, Takehara T, Hori M, 
Hayashi N. 2004. Hepatitis C virus core functions as a suppressor of cyclin-
dependent kinase-activating kinase and impairs cell cycle progression. J Biol 
Chem 279: 11719-26 
323. Park US, Park SK, Lee YI, Park JG. 2000. Hepatitis B virus-X protein 
upregulates the expression of p21waf1/cip1 and prolongs G1-->S transition 
via a p53-independent pathway in human hepatoma cells. Oncogene 19: 3384-
94 
 252 
8.0. Appendix 
 
8.1. Gel electrophoresis markers 
 
 Ambion Millennium RNA ladder 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Promega DNA 100bp ladder    Promega DNA 100bp ladder 
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SDS-PAGE prestained molecular weight marker (Invitrogen) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Orientation band (pink) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Band number Molecular 
weight 
1 180 kDa 
2 115 
3 82 
4 64 
5 49 
6 37 
7 26 
8 19 
9 15 
10 6 
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8.2. Plasmid maps 
  
I. pCR2.1 vector map: 
 
 
 
Features of pCR®2.1 
3929 nucleotides 
LacZ gene: bases 1-545 
M13 Reverse priming site: bases 205-221 
T7 promoter: bases 362-381 
M13 (-20) forward priming site: bases 389-404 
F1 origin: bases 546-983 
Kanamycin resistance ORF: bases 1317-2111 
Ampicillin resistance ORF: bases 2129-2989 
pUC origin: bases 3134-3807 
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II. pENTR/D-TOPO vector map: 
 
 
Features of pENTR/D-TOPO 
2580 nucleotides 
rrnB T2 transcription termination sequence: bases 268-295  
rrnB T2 transcription termination sequence: bases 427-470 
M13 forward (-20) priming site: bases 537-552 
attL1 site: bases 569-668 
TOPO recognition site 1: bases 680-684 
Overhang: bases 685-688 
TOPO recognition site 2: bases 689-693 
attL2 site: bases 705-804 
T7 promoter/priming site: bases 821-840 (c) 
M13 reverse priming site: bases 845-861  
Kanamycin resistance gene: bases 974-1783 
pUC origin: bases 1904-2577 
 
(C) = complementary strand 
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III. pAd/CMV/V5-DEST vector map: 
 
Features of pAd/CMV/V5-DEST™ 
36686 nucleotides 
Human Ad5 sequences (wt 1-458; includes 5‟ L-ITR and packaging signal): 1-
458pAd forward priming site: bases 361-384 
CMV promoter: bases 728-1315 
T7 promoter/priming site: bases 1359-1378 
attR1 site: bases 1407-1531 
ccdB gene: bases 1960-2265 (C) 
Chloramphenicol resistance gene (CmR): bases 2607-3266 (C) 
attR2 site: bases 3547-3671 
V5 epitope: bases 3697-3738 
TK polyadenylation signal: bases 3765-4036 
Human Ad5 sequences (wt 3513-35935; E3 region deleted, includes 3‟ R-ITR): bases 
4056-34604 
pAd reverse priming site: bases 4059-4082 
pUC origin: bases 34781-35442 (C) 
Ampicillin (bla) resistance gene: bases 35568-36428 (C) 
bla promoter: bases 36429-36527 (C) 
Pac I restrictions sites: bases 34610 and 36684 
 
(C) = complementary strand 
T7 attR1  
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8.3. Quantifying of gene expression levels using real-time RT-PCR 
method: 
 
I. Relative quantification 
 
 
 
 
Figure 8.1: Example of real-time PCR using LightCycler 2.0 (Roche): the figure 
shows a linear plot of the amount of DNA (y axis) and the cycle number (x axis). 
Folds changes were calculated as detailed in section 2.2.2.11. The relative Ct method 
(or ΔCt) was used to assess relative changes in mRNA levels between two samples. 
Amplification of the example housekeeping gene (GAPDH) and the example target 
gene (SOCS3) was carried out in triplicate. 
 
 
 
 
 
Base line 
Log linear phase 
Threshold 
Housekeeping 
gene (GAPDH) 
Target gene 
(SOCS3)  
Ct Ct 
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An example of employing the comparative Ct method: 
 
 
 
 
 
 
 
 
 
 
 
 
HCV JFH-1 
Mock  
A 
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Figure 8.2: An example of employing the comparative Ct method by the 
comparison of the expression of innate immune responses target gene in mock 
infected vs. HCV JFH-1 infected Huh7 cells. (A). Amplification plots showing 
increases in fluorescence from target gene (HCV JFH-1 infected cells, in 
triplicate) and unknown samples (Mock infected cells, triplicate). (B) For 
controlling error in qRT-PCR, second PCR was performed for normalizing to 
an endogenous reference (GAPDH) gene. 
 
 
 
 
 
 
 
B 
 260 
II. Absolute quantification 
 
 
 
 
 
 
 
 
A 
B 
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Figure 8.3: Example of an amplification plot obtained using a SYBR Green I 
assay (A) the standard curve method is used to assess the quantity of the 
transcript (JFH-1 genomic RNA). This requires that a template dilution series 
of an RNA standard is included (i.e. the same mRNA as the target RNA). 
Quantities interpolated from the resulting standard curve are used to calculate 
relative mRNA levels in each unknown sample. (B) The amplification plots 
were generated by ten-fold serial dilutions of an RNA sample containing 4ng 
of RNA. The standard curve generated from these amplification plots is linear, 
over 5 logs, with a slope = -3.613 and an r = -1. (C) Examination for non-
specific amplicons e.g. primer dimers, and genomic DNA contamination 
identified by melting curve analysis, including shows only one peak 
corresponding to target amplicon.   
 
 
 
 
 
 
 
C 
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8.4. Analysis of cell cycle using FACS by double staining for PI and HCV core 
protein: 
                                      
                                        
                                                              
                                                              
                                      
Huh7 mock Huh7 JFH-1 
A 
B 
C 
D 
E 
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Figure 8.4: HCV infection mediated G2 cell cycle arrest results in higher levels of 
viral replication: Huh7 cells were either mock infected or infected with HCV JFH-1 
(MOI = 3).  Histogram of cell cycle phase analysis in mock and JFH-1 HCV infected 
cells (A), dot-plot analysis, of the selected population of gated cells is within the area 
bounded to eliminate the debris of necrotic cells. (B), doublet discrimination by a 
density plot of forward scatter versus DNA content, selected population of gated cells 
is within the area bounded. (C), cells were stained with PI and the cell cycle profiles 
at 72 hours post infection were shown. (D) cells were stained with anti-core 
antibodies and thus the infection efficiency was evaluated by percentage of core 
positive cells compared to the gated cells from B (E) The histograms were analyzed 
to determine the percentage of HCV core protein in each phase of the cell cycle. 
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Huh7.5 mock Huh7.5 JFH-1 
A 
B 
C 
D 
E 
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Figure 8.5: HCV infection mediated G2 cell cycle arrest results in higher levels of 
viral replication: Huh7.5 cells were either mock infected or infected with HCV JFH-1 
(MOI = 3).  Histogram of cell cycle phase analysis in mock and JFH-1 HCV infected 
cells (A), dot-plot analysis, of the selected population of gated cells is within the area 
bounded to eliminate the debris of necrotic cells. (B), doublet discrimination by a 
density plot of forward scatter versus DNA content, selected population of gated cells 
is within the area bounded. (C), cells were stained with PI and the cell cycle profiles 
at 72 hours post infection were shown. (D) cells were stained with anti-core 
antibodies and thus the infection efficiency was evaluated by percentage of core 
positive cells compared to the gated cells from B (E) The histograms were analyzed 
to determine the percentage of HCV core protein in each phase of the cell cycle. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
